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ABSTRACT 
This study describes the immunological and pathophysiological features of 
a diabetic syndrome induced in inbred rats by a combination of 
thymectomy and irradiation (Tx-X), a procedure known to alter immune 
function and regulation. 
The syndrome was characterized clinically by hyperglycaemia, 
insulinopaenia, ketoacidosis and polyuria. Onset of the disease was rapid 
and fatal unless daily insulin therapy was initiated immediately. Acutely 
diabetic animals had pancreatic lesions largely confined to the islets of 
Langerhans, where atrophy was typically observed. lmmunohistochemical 
studies clearly demonstrated that the atrophic change was due to 
selective destruction of the B cells of the islets, leading to collapse of 
these structures. lnsulitis was also observed in some diabetic rats, 
particularly those with less acute disease and also occasionally in non­
diabetic Tx-X animals, indicating that a sub-clinical form of the disease 
may occur. Acute diabetic animals developed autoantibodies to islet cells 
as detected by immunofluorescence, and to a 64kDa islet protein as 
detected by immunoprecipitation. A large proportion of Tx-X animals also 
developed a lymphocytic infiltration of thyroid glands and autoantibodies to 
thyroid components. 
The incidence of diabetes ranged from 11 to 62 percent (mean 34 
percent). Incidence levels were slightly elevated in males and induction of 
disease was strain related, but did not depend upon the RT1 u MHC 
haplotype as does the spontaneous diabetes of BB rats. Incidence and 
onset of the disease were variable between groups of animals and could 
be modulated by altering the hygienic background of the animal, 
implicating a role for environmental factor(s) in disease pathogenesis. 
Inhibition of disease by reconstituting Tx-X rats with normal lymphocytes, 
transfer of disease to naive recipients using diabetic lymphoid cells and 
demonstration of abnormalities in cell mediated and humeral immunity 
provided strong evidence supporting an autoimmune pathogenesis for this 
syndrome. 
In conclusion, the Tx-X-induced diabetic syndrome in rats has been shown 
to bear many features of the human diabetic condition (IDDM) and thus 
provides further evidence supporting a role for autoimmune mechanisms 
in the pathogenesis of this major human disease. Finally, it is proposed 
that this model should provide a valuable adjunct to existing animal 
models for studying factors influencing the development of this disease 
and in assessing potential prophylactic or therapeutic regimes. 
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The term diabetes mellitus does not refer to a single disease, but rather 
encompasses a heterogeneous group of diseases that have in common a 
systemic disorder of carbohydrate metabolism. Although diabetic 
syndromes may be classified into a number of subclasses, each with a 
distinct pathogenesis and clinical symptoms, two major forms of the 
disease are generally recognized based on their dependency for insulin, a 
peptide hormone central to the regulation of carbohydrate metabolism 
synthesized by the B cells of the pancreatic islets of Langerhans. 
Insulin-dependent diabetes mellitus (/DOM), considered the classical form 
of diabetes, is often observed at a young age and has as its underlying 
pathogenesis an inability to synthesize insulin, thought to be due to the 
immunological destruction of islet B cells. The precise nature of the 
factors involved in the aetiology of this immunological attack, however, still 
remain unclear. Onset of this syndrome is acute, and IDDM patients have 
an absolute requirement for exogenous insulin therapy for survival. 
Non-insulin dependent diabetes mellitus (NIDDM), a milder form of 
diabetes, is generally observed at an older age and is thought to result 
from a relative insulin deficiency or a resistance to the biological activity of 
the hormone. NIDDM has a more chronic progression than IDDM and can 
often be controlled by diet and exercise or oral hypoglycaemic agents. 
During the history of diabetes research, much attention has focused on 
identifying and describing animal models of the disease that simulate the 
human syndrome. Animal models allow opportunities to study many 
aspects of disease initiation and pathogenesis that are not possible in 
humans, and to date have provided much of our knowledge of the 
pathogenesis of a wide variety of human disorders, enabling the 
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development of strategies for disease development and control in several 
cases. While NIDDM has been found to occur naturally in a number of 
animal species, spontaneous IDDM is less common and there has been 
difficulty in finding a model that effectively simulates the human syndrome. 
For this reason a number of chemical, hormonal or infectious agents have 
been used to induce diabetes in animals not usually prone to the disease, 
and these have provided a valuable adjunct to the few available 
spontaneous models for the study of IDDM pathogenesis. To date 
however, no induced model has been available that avoids the possible 
adverse secondary effects of the chemical or infectious agents used for 
disease expression. 
The following work describes the features of a newly-described diabetic 
syndrome induced in rats by manipulation of the immune system using a 
combination of thymectomy and irradiation (Tx-X), and examines the 
validity of using this model to simulate human IDDM. Detailed clinical, 
histopathological and immunological features of the syndrome are thus 
presented, and it is argued that this syndrome closely resembles human 
IDDM in many respects. Studies on the immunopathogenesis of Tx-X­
induced IDDM suggest an autoimmune pathogenesis for the disease, 
while the consequences of Tx-X could be profoundly modulated by 
altering the hygienic background of the animals used. It is thus proposed 
that the Tx-X model is a relevant model of human IDDM and has potential 
for the study of diabetes initiation and pathogenesis. 
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2.1 INTRODUCTION 
2.1.1 Historical Perspective 
Diabetes research has a history dating back to the late 17th century, when 
patients were noted to have polyuria ('diabetes' meaning literally to 
'siphon-through') and their urine was observed to have a sweet taste. 
Thus, the classification diabetes mellitus ('honey' diabetes) was adopted 
and due to the associated polyuria the kidney was originally proposed as 
the causative organ. It was not until 1795, when the pancreas of a 
diabetic patient at autopsy was noticed to be atrophied and granular, that 
the first association of the pancreas with diabetes was made (Levine, 
1979). 
The course of diabetes research was changed in 1889 by Minkowski and 
van Mering, who performed the first effective total removal of the pancreas 
of a dog which led to raised blood glucose, glycosuria, polyuria, loss of 
weight and acetone in the urine, thus demonstrating a relationship 
between pancreatic function and diabetes mellitus (Minkowski, 1929). As 
no defects of the nervous system could be found in the pancreatectomized 
animal, the diabetic syndrome was attributed directly to removal of the 
pancreas. Although at the time these findings were considered contrary to 
popular belief (as several highly respected workers had apparently shown 
that pancreatectomy did not lead to a diabetic state), Minkowski and von 
Mering's results were repeated and ultimately accepted. 
As a result of the above work and that of pathologists such as Paul 
Langerhans, who first described 'little heaps of cells' in rabbit pancreas, 
later termed the 'islets of Langerhans', it gradually became evident that the 
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pancreas must produce an internal secretion capable of controlling blood 
glucose levels, and that this secretion probably originated in the islets. 
From 1898 onwards attempts were made to isolate and purify this 
hypoglycaemic factor, but initial pancreatic extracts were so toxic they 
could not be used in live animals. In 1921, however, Banting and Best 
prepared a dog pancreatic extract that could lower the glycosuria of 
diabetic dogs. This extract, initially called isletin, later became known as 
insulin and was purified and successfully used to control hyperglycaemia 
in humans (Wrenshall, 1962). Insulin is now known to be a polypeptide 
hormone consisting of 51 amino acids in 2 polypeptide chains linked by 
disulphide bonds synthesized by the B cell of the pancreatic islets of 
Langerhans (Smith et al, 1983). 
2.1.2 Types of Diabetic Syndromes 
Today diabetes mellitus is classified into a number of subclasses 
depending on the severity of the disease and requirement for insulin 
therapy. The common theme for all subclasses, however, is the inability 
to control blood glucose levels as a result of a systemic disorder in 
carbohydrate metabolism. Type 1 or insulin-dependent diabetes mellitus 
(IDDM) is characterized by weight loss, proneness to ketosis and an 
absolute requirement for exogenous insulin therapy. This form of diabetes 
may be diagnosed at any age but is more common in the 17 years or 
younger age group (hence the previous "juvenile-onset" classification). 
Non-insulin-dependent diabetes mellitus (NIDDM), also known as mature­
onset diabetes mellitus, is usually associated with obesity, but not insulin 
deficiency, and can often be controlled by oral hypoglycaemic agents or 
diet. This syndrome may also be diagnosed at any age, but tends to be 
more common in the 40 years and above age group (National Diabetes 
------------ ---
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Data Group, 1979). Other forms of diabetes mellitus include gestational 
diabetes associated with pregnancy and glucose intolerance associated 
with certain conditions or syndromes. 
This review will focus on the current state of research relating to the 
aetiology and pathogenesis of IDDM, both in humans and in animal 
models of the human syndrome. 
2.2 THE HUMAN IDDM SYNDROME 
2.2.1 Clinical Features 
IDDM is characterized clinically by an abrupt decline in circulating insulin 
levels and associated rapid onset of glucosuria and severe 
hyperglycaemia. At this stage patients are prone to ketosis as indicated 
by raised levels of circulating B--hydroxybutyrate and acetoacetate 
(ketotic-stage). Exogenous, parenteral insulin therapy initiated at this 
point is effective in controlling hyperglycaemia and ketosis and daily 
therapy is required for survival. A pre-ketotic stage may also be identified 
up to several months prior to the onset of ketosis based on a fasting 
euglycaemia but an inability to control blood glucose levels after oral 
administration of glucose (National Diabetes Data Group, 1979). 
Polydipsia, polyuria, polyphagia, hypercholesterolaemia and 
hypertriglyceridaemia are also characteristic features which may be 
present 1-2 months prior to the onset of the ketotic stage (Drash and 
Becker, 1978; Cahill and McDavitt, 1981 ). Long-term complications of 
IDDM include neuropathy, nephropathy, retinopathy, coronary heart 
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disease and peripheral vascular disease as a result of impaired 
neurological function and microcirculation (Taylor and Agius, 1988). 
2.2.2 Incidence 
Incidence levels of IDDM are difficult to ascertain precisely due to age, 
sex, seasonal and geographical variations and accuracy of disease 
diagnoses and record keeping. Thus, records of Western countries tend 
to be more readily available and accurately interpreted than those of less 
developed countries. Nevertheless, the available data suggests that 
incidence levels of IDDM world-wide, particularly in Northern Europe and 
North America, appear to be rising at a steady rate, with an estimated 
doubling rate of 20 to 30 years in some countries (Bingley and Gale, 
1989a). A common feature of incidence rates of IDDM in most regions of 
the world is the geographical variation between, and even within, 
countries. This trend is particularly evident in Scandinavian countries, 
which have relatively stable populations and some of the highest 
incidence rates of IDDM in the world, ranging from 38 cases per 100 000 
per year in Finland, to 25 cases per 100 000 per year in Sweden 
(Akerblom and Reunanen, 1985; Dahlquist et al., 1985). Similar figures 
have also been reported for Denmark, Norway and other European 
countries (Green and Anderson, 1983; Joner and Sovik, 1989; Bingley 
and Gale, 1989b). In Scotland, the figure drops to around 18 cases per 
100 000 per year, to 10 in the Netherlands, England and Luxembourg and 
to 4 in France (Patterson et al., 1983; DeBeaufort et al., 1988; Bingley and 
Gale, 1989a). 
In North America the figures range from 20 cases per 100 000 per year in 
Minnesota to 9 in California, while in Japan the figure is as low as 0.6 
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(Diabetes Epidemiology International Research Group, 1988). In 
Australia, a figure of 14 cases per 100 000 per year has been estimated, 
indicating a frequency of around 2 000 newly diagnosed cases of IDDM in 
this country every year (Karvonen et al., 1993). 
A number of studies have also reported seasonal variations in the 
incidence levels of IDDM, with the number of reported cases reaching a 
peak during winter and declining dramatically during summer months 
(Fishbein et al., 1982; Dahlquist et al., 1985; Joner and Sovik, 1989). 
Incidence levels also tend to peak in certain age groups, particularly 
between the ages of 5 to 9 and 10 to 14 years (Fishbein et al., 1982; 
Jon er and Sovik, 1989). 
Generally there is little difference in incidence levels of IDDM between 
males and females world-wide, although a number of studies show a 
definite trend towards an increased incidence in males (Fishbein et al., 
1982; Dahlquist et al., 1985; deBeaufort et al, 1988; Diabetes 




The most significant pancreatic lesions of recent-onset IDDM patients are 
confined to the islets of Langerhans - clusters of cells dispersed 
throughout the pancreas which constitute the endocrine component of 
pancreatic function. Islets consist of 4 different cell types .. a, B, 8 and PP 
cells. These cells synthesize glucagon, insulin, somatostatin and 
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polypeptide (PP) hormones respectively and are responsible for the 
correct regulation of carbohydrate metabolism. 
Early morphological studies of pancreas sections taken from children who 
died at the onset of IDDM revealed a mononuclear-cell infiltration confined 
to the islets termed insulitis (Gepts, 1965). Later studies characterized 
this infiltration as consisting of activated (MHC class II and interleukin-2 
receptor (IL-2r) positive) T lymphocytes, predominantly of the 
cytotoxic/suppressor (CDS+) and to a lesser extent helper/inducer (CD4+) 
and natural killer (NK) cell sub-populations (Bottazzo et al., 1985). 
Pancreatic isograft biopsies have tended to support these findings (Sibley 
et al., 1985), although one such study failed to detect any sign of insulitis 
in 7 pancreatic biopsies taken 2-4 months after the onset of disease 
(Hanafusa et al., 1990). When insulitis is present, however, most (but not 
usually all) islets are affected and this is accompanied by a B cell loss of 
up to 90 percent (Gepts, 1984; Gepts and Lecompte, 1985). This loss of 
B cell mass prior to the onset of diabetes indicates that there is an 
extended preclinical phase, and this is supported by clinical data showing 
a progressive loss of glucose-stimulated insulin secretion prior to disease 
onset (Eisenbarth, 1986). 
In long-term IDDM patients a reduction in islet size (atrophy) results from 
the almost exclusive destruction of B cells. In severe cases (end-stage 
atrophy), such islets show no signs of cellular infiltration and consist 
entirely of normal or elevated numbers of a, 8 and PP cells, with an almost 
complete absence of B cells (Gepts, 1977; Hanafusa et al., 1990). 
Consequently a severe reduction in insulin-producing capacity results, 
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hyperglycaemia. Chronic IDDM can eventually lead to reduction in size 
and weight of the pancreas and fibrosis. 
ii) Extrapancreatic
In addition to lesions of the pancreas, other pathological changes include 
glomeruloscleroses and other kidney changes, retinopathy, neuropathy, 
cardiovascular diseases such as atherosclerosis and microangiopathy, 
various endocrine defects and abnormal pituitary function (Legg and 
Harawi, 1985). 
2.2.4 lmmunopathology 
The histopathological picture described above strongly suggests a role for 
the ;immune system in the destruction of B cells and development of 
\ 
IDDM. In addition, the association of IDDM with other autoimmune 
diseases such as thyroid disorders (Grave•s disease, Hashimoto•s 
thyroiditis), Addison•s disease, rheumatoid arthritis and myasthenia gravis 
provides circumstantial evidence for an autoimmune pathogenesis 
(Rossini et al., 1991 ). To support this hypothesis, there is evidence for 
both humoral and cell-mediated autoimmunity in IDDM patients. 
i) Humoral Immunity
Islet-cell Cytoplasmic Antibodies (ICA) 
Circulating autoantibodies to islet-cell cytoplasmic components were first 
described in 197 4 as detected by indirect immunofluorescence of human 
serum on frozen sections of human type O pancreas (Bottazzo et al., 
1974). These antibodies produced a uniform staining pattern across all 
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cell types of the islet, were shown to be of the immunoglobulin G (lgG) 
class and a proportion, but not all, were complement-fixing (Bottazzo et 
al., 1974; Bottazzo et al., 1980). Subsequently it has been shown that ICA 
can be detected in 60 to 90 percent of newly diagnosed IDDM patients 
and in 0.1 to 3 percent of the community (Timsit et al., 1992; Genovese et 
al., 1992; Irvine et al., 1977). The presence of ICA, however, seemed to 
be dependent upon the time elapsed since diagnosis, being detected in 20 
percent of patients 2 to 5 years after diagnosis and dropping to 5 percent 
after 1 Oto 20 years, presumably due to a loss of sustaining antigen (Irvine 
et al., 1977). 
Since the detection of ICA, attention has focused on their ability to predict 
the onset of IDDM and today they have become the best serological 
marker of disease onset. Studies have shown that high titres of ICA (>40 
Juvenile Diabetes Foundation [JDF] units) of the complement-fixing, lgG 
class have a high predictive value within families of IDDM patients and 
that lower levels (<20 JDF units) are predictive in non-familial IDDM 
(Bonifacio et al., 1990a; Landin-Olsen et al., 1989). In addition, loss of B 
cell function in IDDM patients, as assessed by B cell C-peptide release, 
has been shown to be more rapid and complete in ICA positive than in 
ICA negative patients (Peig et al., 1989). 
Despite the high predictive value of ICA, a high proportion of ICA positive 
patients do not progress to overt diabetes (Landin-Olsen et al., 1989; Bosi 
et al., 1991 ). The predictive value of ICA may be enhanced when 
considered in conjunction with insulin autoantibodies (IAA), however this 
remains controversial (Dean et al., 1986; Betterle et al., 1987; Wilkin, 
1990). Recent improvements in the immunofluorescent techniques have 
enabled the detection of a heterogeneous population of ICA in IDDM 
! I 
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patients. Thus, in addition to the classical 11whole islet" staining, ICA from 
a proportion of recent-onset IDDM patients showed a 11granular11 pattern 
where staining was B cell-specific, or a 11mixed 11 pattern in which both a 
and B cells were stained, although the B cells more intensely (Genovese 
et al., 1992; Timsit et al., 1992). Ninety percent of sera from newly 
diagnosed IDDM patients and 70 percent of sera from endocrine 
autoimmune patients who. developed IDDM showed the 11whole islef' 
pattern, while both the granular or mixed patterns were rarely seen 
(Genovese et al., 1992). Therefore, this heterogeneity in ICA staining may 
allow a greater degree of prediction for development of IDDM. 
64 Kilodalton (64kDa) Autoantibodies 
Despite the widespread use of immunofluorescence to detect ICA in IDDM 
patients, problems are associated with standardization, sensitivity and 
reproducibility of the technique (Bonifacio et al., 1990b) and this has lead 
workers to adopt alternative approaches to detect autoantibodies to islet 
cytoplasmic components. One such approach has been to metabolically 
label islet cell proteins in vitro with a radioactively-labelled amino acid, 
such as 35S-methionine, and then search for immunoprecipitating 
antibodies to the resulting radiolabelled antigens of islet cell extracts. By 
using this technique, Baekkeskov and associates were able to detect 
autoantibodies in recent-onset IDDM patients to an islet cell component of 
Mr 64 000 daltons (64kDa), as determined by SDS-polyacrylamide gel 
electrophoresis (SOS-PAGE) and autoradiography of isolated 
antibody/antigen complexes (Baekkeskov et al., 1982). 
A subsequent study identified 64kDa autoantibodies in 80 percent of 
newly diagnosed IDDM patients and only 3 percent of healthy controls 
(Sigurdsson and Baekkeskov, 1990). In another study using canine islets, 
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Barmeier et al., identified 64kDa antibodies in 89 percent of recent-onset 
patients (Barmeier et al., 1992). Similar to ICA, levels of 64kDa antibodies 
tend to decline with time from disease onset, reaching low or undetectable 
levels after 18 months (Sigurdsson and Baekkeskov, 1990). To assess 
the value of 64kDa antibodies in predicting future onset of IDDM, these 
workers also examined sera from pre-diabetic individuals at 11high-risk 11 for 
IDDM (monozygotic twins or siblings to IDDM patients) who subsequently 
went on to develop disease (Baekkeskov et al., 1987). Sixty four kDa 
antibodies were detected in 78 percent of serum samples taken from 
IDDM patients 4 to 91 months prior to disease onset, and in 100 percent 
of first degree relatives. In addition, 64 percent of 64kDa positive patients 
were concordant for ICA. 
Other studies have shown that the combined measurement of 64kDa 
antibodies and ICA have an increased ability to predict IDDM onset when 
compared to ICA alone (Seibler et al., 1992). Christie and associates 
have shown that the predictive value of 64kDa antibodies may be 
improved even further if tryptic fragments of the antigen are used (Christie 
et al., 1990a). Thus, 93 percent of IDDM patients immunoprecipitated one 
of three fragments of the 64kDa antigen obtained by tryptic digestion, and 
some previously 64kDa antibody negative patients had antibodies to one 
of these fragments. 
The immunoprecipitation assay, although providing high sensitivity and 
specificity, is costly, time consuming and not suitable for screening large 
numbers of samples. An alternative approach is to subject islet�cell 
extracts to electrophoretic separation and transfer the separated proteins 
to a solid membrane matrix. Serum samples are then immunoblotted 
against the membrane-bound antigens and bound antibodies detected by 
------------,-- � � .  C •·------ •--------•• 
14 
means of a secondary, enzyme-conjugated antiserum in conjunction with 
a coloured or luminescent enzyme substrate. Unfortunately, there are few 
reports of success with this technique in relation to IDDM, but in the two 
reports of immunoblotting of human IDDM sera against islet cell 
preparations, 71 percent of sera from recent-onset IDDM patients showed 
high titre antibodies to human islet cell antigens, while 29 percent of cases 
were positive when the RINm5 rat insulinoma cell line was used as 
antigen (Karounos et al., 1990; Karounos and Thomas, 1990). Although a 
dominant protein band of 52kDa was identified in RINm5 extracts, the 
pattern of reactivity was heterogeneous when human islets were used, 
with proteins in the range of 52 to 150kDa being detected and no single 
band being bound in more than 50 percent of cases. These results are 
contradicted by those of Tuck and associates, however, who failed to 
detect autoantibody reactivity to RINm5 extracts by this method (Tuck et 
al., 1992). 
Islet Cell Surface Antibodies (ICSA) 
In addition to ICA, antibodies directed towards cell surface components of 
viable islets have also been demonstrated in IDDM sera. Indirect 
immunofluorescence, complement-mediated cytotoxicity assays and 
radioimmunoassays have been used to detect antibodies to viable rat or 
mouse islet cells in 35 to 45 percent of IDDM patients (Lernmark et al., 
1978; Lernmark et al., 1980; Huen et al., 1983; Toguchi et al., 1985). As 
seen with ICA, levels of ICSA seem to decline with duration of disease 
and in addition, appear to be preferentially lytic to B cells, indicating an 
active role for this type of antibody in B -cell destruction (Lernmark et al., 
1980; Toguchi et al., 1985). The value of this type of antibody in 
predicting the onset of IDDM, however, remains to be determined. 
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Insulin Autoantibodies (IAA) 
For many years autoantibodies to insulin have been known to develop 
following the initiation of insulin therapy (Berson et al., 1956). More 
recently, however, IAA have been detected in the serum of patients at the 
onset of IDDM but before the commencement of insulin therapy (Palmer et 
al., 1983) and consequently, interest in the value of IAA as predictive 
markers of IDDM has been renewed. 
IAA have been detected by radioimmunoassay in 30 to 50 percent of 
newly diagnosed IDDM patients and in 30 to 50 percent of subjects at 
11high-risk11 for the development of IDDM - that is, ICA positive monozygotic 
twins and first degree relatives of IDDM patients (Srikanta et al., 1986; 
Ludwig et al., 1987; Vardi et al., 1987). In one study, the detection of IAA 
in conjunction with ICA appeared to have a greater predictive value tor 
progression to IDDM than for either marker alone (Srikanta et al., 1986). 
In contrast, other studies have not shown this association, but rather have 
shown that IAA are prevalent in patients with on-going organ or non-organ 
specific autoimmune diseases such as autoimmune thyroid disease, 
Addison's disease, pernicious anaemia and systemic lupus erythematosis 
(Wilkin et al., 1985a; Ludvigsson et al., 1988; DiMario et al., 1990). An 
inherent problem with the use of IAA as predictors of IDDM appears to be 
the specificity and sensitivity of the radioimmunoassay (Wilkin et al., 
1985b; Sodoyez-Goffaux et al., 1988). This fact, in conjunction with the 
apparent lack of disease specificity of IAA restricts the use of these 
antibodies, whether alone or in conjunction with ICA, as predictive 
markers of IDDM. 
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Other Antibody Specificities 
In addition to antibodies to islet cell components and insulin, serum 
samples from IDDM patients have been shown to contain antibody 
reactivity to a number of other self and non-self antigens. A high 
proportion contain antibodies to thyroid components, parietal cells, adrenal 
gland cells, anterior pituitary cells, tubulin, single-stranded DNA and 
insulin receptor (Nerup and Lernmark, 1981; Drell and Notkins, 1987; 
Ludwig et al., 1987; Johnston et al., 1990). Antibody reactivity has also 
been detected to immunoglobulin, lymphocyte cell surface antigens, 
human albumin, bovine albumin and viruses such as Coxsackievirus B 
and Reovirus (Drell and Notkins, 1987; DiMario et al., 1988; Mang iii et al., 
1988; Segers et al., 1989; Karjalainen et al., 1992a). 
ii) Cell-mediated Immunity
The first evidence for abnormalities in cell-mediated immunity in IDDM 
patients was provided in 1971 by Nerup and associates using leukocyte 
migration studies (Nerup et al., 1971). This study demonstrated that in
vitro migration of peripheral blood mononuclear cells (PBMNC) could be 
significantly inhibited by a porcine pancreatic extract in 55 percent of 
patients (regardless of disease duration) when compared to normal 
controls. The inhibition was organ specific in that liver or kidney extract 
caused no inhibition, and was not a result of insulin in the preparation as 
neither porcine or bovine insulin caused inhibition. The authors concluded 
that an anti-pancreatic cellular hypersensitivity could be demonstrated in 
IDDM patients, but due to the nature of the study antigenic activity could 
only be ascribed to the pancreas as a whole and not to islet or B cell 
components. 
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Evidence for an anti-B cell, cell-mediated immune response was 
subsequently provided by in vitro studies showing strong adherence (but 
not cytotoxicity) of PBMNCs from IDDM patients to human or rat 
insulinoma cell lines (Huang and Maclaren, 1976; Lang et al., 1987). The 
adherent cell population was shown to consist predominantly of la+
(activated), CD4+ T lymphocytes (Lang et al., 1987; Segain et al., 1988). 
More significantly, other studies have demonstrated that PBMNC are 
actually cytotoxic to B cells in vitro. Using either human, mouse or rat B 
cells as targets, it has been shown that PBMNC isolated from IDDM 
patients can inhibit B cell function in vitro, as assessed by insulin release 
of co-cultured islets, and immunochemical analysis has shown that CD8+
lymphocytes are responsible (Lohmann et al., 1986; Lampeter et al., 
1987). Cytolytic activity has also been shown, as assessed by 
radioisotope release from lyzed 51-Cr-labelled B cells, either directly or via
antibody mediated mechanisms (Charles et al., 1983). In addition, 
PBMNC from healthy subjects are able to inhibit the B cell cytotoxic effects 
of PBMNC from IDDM patients, and this suppressive effect is mediated by 
CD8+ T lymphocytes (Lohmann et al., 1986; Krug et al., 1991). 
Additional evidence for lymphocyte hypersensitivity towards islet cells in 
IDDM is provided by recent lymphocyte proliferation studies. By 
measuring DNA synthesis as an indicator of lymphocyte activation and 
proliferation, 68 percent of preclinical IDDM and 41 percent of recent­
onset IDDM patients showed significant PBMNC proliferative responses to 
sonicated foetal porcine pro-islets when compared to normal control 
subjects (Harrison et al., 1992a). An additional study has shown that 
PBMNC from 100 percent of preclinical and 64 percent of clinical IDDM 
patients respond to intact human or porcine islets, as measured by DNA 




(Harrison et al., 1991 a; Morse et al., 1992). The response was tissue 
specific, in that there was no response to thyroid, liver or kidney antigens 
and was shown to be greater than the response to insulin alone. 
In addition to cytotoxicity and proliferation assay studies, studies of 
peripheral blood T lymphocyte subsets from IDDM patients tend to support 
the concept of an irregularity in T cell function or immunoregulation. An 
increased number of activated peripheral T cells seems to be a consistent 
feature of IDDM (Jackson et al., 1982; Pozzilli et al., 1983; Hayward and 
Herberger, 1984) and abn(?rmalities of CD4+ and cos+ ·T cell subsets 
have been reported, but tend to be somewhat conflicting. Thus, Pozilli 
and associates reported levels of total peripheral T lymphocytes in newly­
diagnosed IDDM patients equivalent to those of normal controls, but the 
proportion of these cells declined significantly as the disease progressed. 
The proportion of CD4 + helper/inducer T cells followed the same trend as 
total T cells, but a relative increase in cytotoxic and decrease in 
"suppressive" cos+ T cells was observed in both newly diagnosed and 
long-standing IDDM patients (Pozzilli et al., 1983). 
These observations are supported by the work of Herold and co-workers 
who also showed alterations of the CD4+/CD8+ cell ratio in the initial 
stages of disease (Herold et al., 1984), but are in contrast to the work of 
Hayward and Herberger, who demonstrated a marked increase in the total 
number of peripheral T lymphocytes at IDDM onset which decreased to 
near-normal levels as disease progressed (Hayward and Herberger, 
1984). This study also reported no alterations in the· CD4+/CDs+ ratio, 
both in newly diagnosed and long-term patients. Faustman and 
associates also noted a normal CD4+/CDS+ ratio in newly diagnosed 




diabetic patients (Faustman et al., 1989). These workers also noted 
elevated levels of CD4+ T cells expressing the CD45R antigen , a marker 
of suppressor-inducer cells, when compared to cells expressing the 
CDw29 antigen (helper-inducer cells) in pre-diabetic patients, but this ratio 
tended to approach normal levels in recent-onset and long-term diabetic 
patients. 
Together these studies suggest that the relative proportions of lymphocyte 
sub-populations in diabetic patients are in a dynamic state during the 
course of the disease, and it is possible that identification of a particular 
lymphocyte abnormality or imbalance at an early stage of the disease may 
allow prediction of disease onset. 
In addition to alterations in the T lymphocyte subset, irregularities in the 
non-T cell subset of PBMNC from IDDM patients have been reported. In 
particular, natural killer (NK) cell numbers are decreased in newly 
diagnosed IDDM patients as compared to NIDDM and normal controls 
(Negishi et al., 1986; Hussain et al., 1987). NK cells of IDDM patients also 
show a decrease in cytolytic activity as assessed by the 51 Cr release 
assay using human myeloid (K562) cells as targets, but increased cytolytic 
activity when islet cells are used as targets (Negishi et al., 1986). This 
effect is only seen at the onset of IDDM, however, and is not 
demonstrable in long-term patients. 
Increased numbers of activated cells of the monocyte-macrophage sub­
populations of PBMNC have also been demonstrated in recent-onset 
IDDM patients. Thus, the number of cells positive for the Leu M3 
(monocyte/macrophage) marker, in conjunction with the CD25 (IL-2 
receptor) or DR (MHC class II) markers, were significantly higher in newly-
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diagnosed IDDM patients when compared to normal controls and again, 
this effect was not seen in long-term IDDM patients (Nicoletti et al., 1991 ). 
2.2.5 Genetics 
It has long been recognized that IDDM occurs in families more frequently 
than in the general population, and numerous family studies have 
attempted to confirm this. Despite the possible inconsistencies in the 
diagnosis of different categories of diabetes when tracing the history of the 
disease within a family, these studies indicate a recurrence risk among 
first degree relatives of IDDM probands of between 3 and 6 percent, as 
compared to 0.4 percent for the general population (Kobberling and 
Bruggeboes, 1980; Tillil and Kobberling, 1987; Green, 1990). In addition, 
this risk is significantly greater if the father is the affected parent (Dahlquist 
et al., 1985; Tillil and Kobberling, 1987). An increased risk is also seen in 
second degree relatives (1.5 percent), but this is somewhat less than first 
degree relatives (Green, 1990). 
Of particular interest is a study examining concordance rates for IDDM in 
identical (monozygotic) twins (Barnett et al., 1981 ). Although biased in the 
favour of concordant pairs, this study showed a concordance rate of 
around 55 percent, indicating that although susceptibility to I DOM is 
determined genetically, non-genetically determined factors are as equally 
important in the aetiology of the disease. 
More recently, effort has focused on identifying genetic markers that 
indicate susceptibility to disease, and these will be discussed later in this 
review. 
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2.3 ANIMAL MODELS OF DIABETES 
For the study of IDDM or any human disease at the pathological or 
therapeutic level, human experimentation is often not feasible for both 
ethical and practical reasons. Experimental animal models that closely 
resemble the human disease are therefore essential in order to 
characterize and understand the complex aetiological mechanisms that 
are often involved. An excellent example of the value of animal models in 
the study of human disease is provided by the discovery of pancreatic 
diabetes (see section 2.1.1) where studies on the dog were essential for 
establishing the role of the pancreas in disease induction and also for 
isolating and testing the first preparations of insulin that would later lead to 
its therapeutic use in man. The search for alternative animal models of 
IDDM has identified a number of spontaneously occurring and 
experimentally induced syndromes, predominantly in rodents, that have 
provided an extremely valuable source of experimental data. 
2.3.1 Spontaneous Models 
It has long been recognized that spontaneous diabetes in animals is a 
common event, having been first observed in monkeys in the mid-19th 
century, although the majority of these syndromes resemble the non­
insulin form of human diabetes (NIDDM) in that they display obesity, 
hypoinsulinaemia and resistance to insulin. Nevertheless, syndromes 
equivalent to human IDDM (that is, non-obese, hypoinsulinaemic, 
ketoacidotic syndromes) do occur spontaneously in rodents (reviewed in 
Mordes and Rossini, 1981) and of these, the Bio-Breeding (BB) rat and 
non-obese diabetic (NOD) mouse are now the most commonly used and 
thus have been extensively characterized. 
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i) The BB Rat
The IDDM syndrome of the BB rat was first discovered as a spontaneous 
mutation of the Wistar-derived rat at the Bio-Breeding Laboratories of 
Canada and at the University of Massachusetts, Worcester, 
Massachusetts (Nakhooda et al., 1977). This original colony was 
designated BB/W as referring to the Worcester colony, but colonies 
established in different centres are now given designations relating to that 
centre, for example, BB/E for the Edinburgh colony (Marliss, 1983). In 
addition, a second line of BB rats resistant to diabetes (DR-BB) was also 
established in parallel to the original diabetes-prone (DP-BB) line, and this 
line now provides a valuable source of control animals (Joseph et al., 
1993). The acute syndrome described in the DP-BB rat is metabolically 
and pathophysiologically similar to IDDM of man and has been extensively 
reviewed (Nakhooda et al., 1978; Seem ayer et al., 1980; Crisa et al., 
1992). 
Clinical Features 
The diabetic syndrome of the DP-BB rat is characterized by 
hyperglycaemia ranging from 14 to 40 mM, hypoinsulinaemia in the range 
of 0 to 1 ng/ml and hyperketonaemia of up to 13 mM (Nakhooda et al., 
1978; Seem ayer et al., 1982). A spectrum of disease severity is 
observed depending on the degree of ketoacidosis. Severely ketoacidotic 
rats (blood ketone levels between 6 and 13mM) show dehydration and 
rapid weight loss, while moderately ketoacidotic rats (1 to 5mM) lose 
weight gradually. A third (stable) group, with ketonaemia of less than 
1 mM, maintains weight for over 40 days (Nakhooda et al., 1977). 
Severely ketotic rats die within two weeks unless treated with insulin and 
all rats show polyuria and glycosuria of varying degrees. 
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Time of Onset and Incidence of Disease 
Onset of disease in DP-BB rats is usually between 48 and 120 days of 
age (mean 67 days) and is extremely rapid. Eighty to 90 percent of 
animals become affected and similar incidence rates are seen for males 
and females (Nakhooda et al., 1978). The cumulative frequency of 
diabetes in the DR subline is less than 1 percent (Crisa et al., 1992). 
Histopathology 
Histological examination of the pancreas shows an intense insulitis with an 
associated reduction in islet size (atrophy) and B cell number (Nakhooda 
et al., 1977; Seemayer et al., 1982). Simultaneous insulitis and islet 
atrophy are unique to the BB rat model and show similarity to the human 
situation. Islets of recent-onset diabetic rats show extensive infiltration by 
activated lymphocytes and macrophages, with B cell necrosis and 
degranulation. After a few days of overt diabetes, insulitis cannot be 
observed, islets decrease in number and size and B cells are absent 
(
11end stage 11 islet atrophy) (Seemayer et al., 1982; Marliss et al., 1983). 
Evidence also suggests that in overtly diabetic rats there is a reduction in 
a and 8 cell numbers and a decrease in glucagon and somatostatin 
concentrations (Seemayer et al., 1982). 
Examination of the onset and progression of disease by pancreatic biopsy 
revealed that in the pre-diabetic phase, islet lesions develop rapidly about 
2 to 3 weeks before onset of overt disease (Logothetopoulos et al., 1984). 
Lesions start focally in a small number of islets and most are infiltrated 
within a few days. lmmunofluorescent analysis of sequential pancreas 
sections taken from DP-BB rats between 30 and 110 days of age 
identified macrophages (ED1 +, MHC Class 11+) as being the first cells to 
infiltrate the islet, approximately 3 weeks before IDDM onset (Walker et 
- ----�-----.- , --- .-.-..... , .. , 
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al., 1988; Hanenberg et al., 1989). Significant numbers of activated C04+ 
T-lymphocytes and NK cells are the next to infiltrate, followed by a
massive number of B-lymphocytes approximately 1 O to 14 days before the 
onset of disease (Dean et al., 1985; Walker et al., 1988; Hanenberg et al., 
1989). 
Lymphocytic thyroiditis is also a common feature of the BB rat strain in 
general, and of diabetic rats in particular. One study has demonstrated 
lymphocytic thyroiditis in 60 percent of diabetic BB/W rats and 11 percent 
of non-diabetic cohorts (Sternthal et al., 1981 ), and others have reported 
incidence levels of 30 to 60 percent by 90 days of age for the BB/W colony 
as a whole (McKeever et al., 1990). Within sublines of the BB/W colony, 
there appears to be a variation in the incidence of thyroiditis, ranging from 
100 percent in NB to only 5 percent in BE sublines (Rajatanavin et al., 
1991 ). 
In addition to endocrine lesions, BB rats are more susceptible to 
pulmonary infections, sterile lymph node granulomata, kidney and 
pancreas granulomas, lymphomas and prostatic atrophy (Wright et al., 
1983). B-cell lymphomas of mesenteric lymph nodes are particularly 
prevalent in long term diabetic rats (Crisa et al., 1992). 
Humoral Immunity 
Evidence for a role for humeral autoimmunity in the pathogenesis of IDDM 
in BB rats is provided by the ability to detect antibodies to islet cell surface 
components (ICSA) in these rats before and after disease onset. 
Increased levels of ICSA can be detected in approximately 25 percent of 
animals at 60 days of age, and the incidence levels steadily increase until 
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reaching a peak of around 75 to 85 percent at 100 days of age (Dyrberg et 
al., 1982; Dean et al., 1987). A higher incidence of ICSA is also observed 
in rats becoming diabetic at a younger age (less than 85 days) than those 
developing the disease at a later age (Pipeleers et al., 1987). These 
antibodies have been shown to fix complement and mediate cytolytic 
activity against islet cells in vitro (Martin and Logothetopoulos, 1984). 
Islet cytolytic activity can be detected in the sera of prediabetic rats from 
40 days and peaks at around 95 days of age - a few days before disease 
onset in most cases (Laborie et al., 1985). A pathogenic role for ICSA in 
BB rats has not been described in vivo, however, and thus they may 
possibly be generated in response to prior islet-cell damage. 
Of particular interest is that a number of studies have failed to detect ICA 
in BB rats (Like et al., 1982a; Elder et al., 1982; Maclaren et al., 1983; 
Dyrberg et al., 1983). In contrast, antibodies to the human 64kDa islet cell 
antigen (see section 2.2.4 (i)) have been detected in a high proportion of 
sera from diabetic and prediabetic BB rats by immunoprecipitation 
(Baekkeskov et al., 1984). These antibodies are detectable from a very 
early age and seem to have a high predictive value for disease onset. In 
addition, Cole and associates have reported a low frequency of antibodies 
to a 64kDa islet protein as detected by immunoblotting (Cole et al., 1992). 
Circulating antibodies to insulin (IAA) have been demonstrated, but these 
findings are controversial. Low levels of IAA's have been reported as 
occurring in 30 to 70 percent of diabetic BB rats by enzyme-linked 
immunosorbent assay (ELISA), depending on the type of insulin used as 
antigen (rat or human), but seem to be poor predictors of disease onset 
and do not correlate with insulitis (Dean et al., 1987; Diaz et al., 1989; 
Diaz et al., 1991 ). This is in contrast to the work of Markholst and 
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associates, who failed to detect significant levels of IAA1s in the sera of 
prediabetic rats using both ELISA and the more sensitive RIA techniques 
(Markholst et al., 1990). 
Similar to human IDDM, circulating antibodies reactive to lymphocytes, 
thymocytes, thyroid colloid antigens, smooth muscle and gastric parietal 
cells have been detected in BB rats, providing evidence for a generalized 
dysfunction of immunoregulation in these animals (Like et al., 1982a; 
Dyrberg et al., 1982; Dyrberg et al., 1983; Maclaren et al., 1983). 
Cellular Immunity 
The primary perturbance of cell-mediated immunity in the DP-BB rat is a 
profound lymphopaenia. In the periphery, the lymphopaenia is confined 
primarily to T cells (W3/13+), and is most striking in the T helper (W3/25+) 
subpopulation, which shows a tenfold reduction in cell numbers compared 
to the control rat strain (Jackson et al., 1981; Jackson et al., 1983). 
Although OX8+ cells are present, the cytotoxic/suppressor (OX8+/QX19+) 
subpopulation is almost completely absent, while there is an increase in 
NK (OX8+ /QX19-) cell numbers (Woda et al., 1986) and there is an 
inversion of the W3/25 to OX8 ratio to a value of 0.7 compared to 1.2 in 
controls (Elder and Maclaren, 1983). B cell numbers appear normal, but 
the number of activated (ta+) cell numbers are increased (Jackson et al., 
1981 ). In the spleen, increased numbers of NK cells, macrophages and 
activated T cells are observed and also increased percentages of co4-
CD8-TCR+ (double negative) T cells, suggesting abnormal thymic
maturation in BB-DP rats (Hosszufalusi et al., 1992). Studies of the onset 
of lymphopaenia in DP-BB rats show that total lymphocyte and T cell 
numbers are reduced at birth, both in the W3/25 and OX8 subsets, and 




Greiner and associates have shown that the lymphopaenia of DP-BB rats 
is due almost entirely to the absence of T cells expressing the RT6 
differentiation alloantigen (Greiner et al., 1986). The RT6 alloantigenic 
system consists of nonglycosylated or variably glycosylated 24-26 kDa 
peptides expressed only on the surface of mature peripheral T cells and 
not on thymocytes or bone marrow cells, and expression is restricted to 
the final stages of post-thymic T cell development (Koch et al., 1990; Crisa 
et al., 1990). The RT6 antigenic system consists of two allelic forms, 
termed RT6.1 and RT6.2, covalently linked to cell membranes by a 
phosphatidylinositol moiety (Koch et al., 1988). RT6+ lymphocytes 
constitute around 60 percent of peripheral T cells, identifying 
approximately 50 percent of W3/25+ and 70 percent of OX8+ cells, and 
have been shown to participate in graft versus host responses, mitogenic 
responses and in allogeneic stimulation in mixed lymphocyte reactions 
(Greiner et al., 1987). 
Evidence for a regulatory role for RT6+ T cells in determining susceptibility 
or resistance to diabetes in BB rats was initially provided by the fact that 
diabetes could be prevented in DP rats by the transfusion of DR lymphoid 
cells, which contain normal levels of RT6+ cells (Rossini et al., 1984). 
More convincing evidence was provided by Greiner and associates in 
1987, who were able to show that in vivo depletion of RT6.1 + T cells in 
young DR-BB rats induced overt IDDM in 50 percent of animals, and 
insulitis in 40 percent of treated animals that did not become diabetic 
(Greiner et al., 1987). Spleen cells isolated from non-diabetic, RT6.1 
depleted DR-BB rats were also shown to transfer disease to DR and 
young DP rats. RT6 depletion of DR-BB rats has subsequently proved to 
be useful animal model of IDDM, providing an adjunct to the spontaneous 
syndrome of DP rats. 
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In addition to lymphopaenia, DP-BB rats have been shown to have poor 
splenic lymphocyte proliferative response to both mitogens and 
alloantigens. Removal of adherent cells from cultures or purification of T 
cells, however, restores this proliferative capacity, suggesting the 
presence of an inhibitory cell population (probably a macrophage) capable 
of suppressing lymphocyte activity in vitro (Prud'homme et al., 1984; 
Woda and Padden, 1986). Additional functional studies have 
demonstrated defective cytotoxic activity to alloantigens (Prud'homme et 
al., 1988; Woda and Padden, 1987), however in vitro cytotoxic activity of 
splenic lymphoid cells towards islet B cells has been described (MacKay 
et al., 1985). 
ii) The NOD Mouse
Another extensively characterized spontaneous IDDM syndrome occurring 
in animals is that of the non-obese diabetic (NOD) mouse. The progenitor 
mouse of this strain was discovered in a non-cataract prone, euglycaemic 
subline of a line of mice (CTL) that develop cataracts, and selective 
inbreeding of diabetic mice that showed good reproductivity produced the 
NOD strain (Makino et al., 1980). At the same time, however, a slightly 
hyperglycaemic subline of CTL mice was being established, from which a 
"control" strain for NOD mice termed nonobese nondiabetic (NON) mice 
was developed. 
Clinical Features 
Diabetic NOD mice display the classic features of human IDDM in that 
they develop hyperglycaemia (>16mM), hypoinsulinaemia (<1.0µU/ml), 
glycosuria, hypercholesterolaemia, ketonuria, polydipsia, polyuria and 
polyphagia (Makino et al., 1980). The disease process in NOD mice, 
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however, appears to be more chronic than that of humans or BB rats. In 
this regard, although the onset of disease appears abrupt, prospective 
analysis of changes in blood glucose levels shows a gradual rise, starting 
from 3 to 4 weeks before disease onset (Leiter et al., 1987). In contrast to 
humans and BB rats, NOD mice can survive without insulin therapy at 
onset of hyperglycaemia and for 1 to 2 months after disease onset before 
becoming insulin dependent (Leiter et al., 1987; Kikutani and Makino, 
1992). 
Time of Onset and Incidence of Disease 
Marked sex differences are observed in both the pattern of disease onset 
and incidence levels of the disease. In females, onset of diabetes is 
observed at around 10 weeks of age and the number of affected animals 
increases steadily until reaching a peak at 30 weeks of age. In males, 
disease onset does not occur until around 20 weeks of age and far fewer 
animals are affected by 30 weeks of age when compared to females 
(Makino et al., 1980). As for BB rats, incidence levels of disease vary 
between the various colonies of animals. Thus, in the original NOD/Shi 
colony maintained in Japan, 70 to 80 percent of females and 20 percent of 
males develop disease (Kikutani and Makino, 1992). In the NOD/Wehi 
colony maintained in Australia, incidence of diabetes is 40 to 50 percent in 
females and less than 1 O percent in males, while in the NOD/Lt strain 
originating from the USA but maintained in the same environment, 90 
percent of females and 20 percent of males develop the disease (Baxter 
et al., 1991 ). 
Histopathology 
Histopathological examination of the pancreas of NOD mice reveals 




is first observed at around 3 weeks of age with high frequency in both 
male and female mice by 6 weeks of age and reaches a cumulative 
incidence of 80 to 90 percent by 13 weeks of age (Miyazaki et al., 1985). 
Time course analysis of cells infiltrating the islet indicate that from the 
earliest stages the predominant cell type is of the Thy1 .2+ (T 
lymphocytes) / L3T4+(helper/inducer) phenotype, with lower numbers of 
Lyt 2+ (cytotoxic) subpopulations. The majority of cells are MHC class II 
positive, and a lower percentage express IL-2 receptor (Signore et al., 
1989). These findings are in concordance with those of Miyazaki et al., 
who also found lower numbers of NK cells and B lymphocytes in the lesion 
(Miyazaki et al., 1985) and Formby and associates (Formby et al., 1992a) 
but are in contrast to those of Kanazawa and associates, who identified 
lgM+ B lymphocytes as the predominant infiltrating cell type (Kanazawa et 
al., 1984). Pancreatic sections from chronically diabetic mice generally 
show no sign of insulitis and islets consist mainly of functional non-B cell 
types (Ohneda et al., 1984; Leiter et al., 1987) consistent with the 
conclusion that the cytotoxic activity of infiltrating lymphoid cells is B cell 
specific. 
Extrapancreatic lesions of NOD mice include mononuclear cell infiltration 
of the submandibular and lacrimal glands in mice older than 9 weeks 
(Kikutani and Makino, 1992) and lymphocytic thyroiditis in diabetic animals 
(Bernard et al., 1992a). 
Humeral Immunity 
NOD mice have been shown to produce circulating antibodies to both islet 
cell surface and cytoplasmic components. Approximately 50 percent of 
animals develop ICA by 2 weeks of age, and this proportion only 
increases slightly to a peak of 60 percent by 4 weeks of age (Reddy et al., 
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1988). The majority of these antibodies show a "whole islet" staining 
pattern by immunofluorescence similar to that seen with human sera 
(Reddy et al., 1988; Reddy et al., 1990). ICSA reactivity is also common 
in NOD mice, being detectable by 6 weeks of age and reaching a 
maximum incidence of 50 percent by 12 to 18 weeks of age (Kanazawa et 
al., 1984). These antibodies appear to be able to fix complement and are 
cytotoxic to islet cells in vitro (Hari et al., 1986). 
An interesting feature of anti-islet cell antibodies produced by NOD mice is 
their ability to be readily detected by immunoblotting using islet cells as 
antigen, a phenomenon not easily observed humans and not at all in BB 
rats (see sections 2.2.4(i) and 2.3.1 (i)). Karounos and Thomas were able 
to identify antibodies to a 52 kDa component of RINm5F cells using this 
method, and these antibodies appeared to be present in all sera tested, 
whether from diabetic or non-diabetic NOD animals (Karounos and 
Thomas, 1990). These antibodies were tissue specific in that they did not 
react with kidney, liver or adipose cells, were not observed in NON control 
animals and appeared to have a high predictive value for disease onset. 
A similar study using both RINm5F and mouse islets as antigen identified 
reactivity to a 58 kDa islet cell component in all NOD sera tested, but not 
in control mice and not to non-islet tissues (Villa et al., 1992). These 
antibodies were present from 6 weeks of age and seemed to correlate 
with the onset of insulitis. 
lmmunoprecipitation analysis also revealed antibody reactivity in NOD 
sera to a 64 kDa islet cell component similar to that detected by human 
and BB rat sera (Atkinson and Maclaren, 1988). Such antibodies were 
present in 60 to 80 percent of NOD mice from an early age, but their 
prevalence declined rapidly after onset of disease. 
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IAA also appear to be present in NOD mice, but reported incidence levels 
are conflicting. In one study, IAA were readily detected in a large 
proportion of young mice (2 to 5 weeks old) and their frequency increased 
to 100 percent in older mice (Reddy et al., 1988; Michel et al., 1989). 
Maruyama and associates also reported a high frequency of IAAs in 12 to 
14 week old mice correlating with the onset of insulitis (Maruyama et al., 
1989). In contrast, Bernard and associates reported only 5 percent 
positivity in 4 week old animals and maximum incidence levels of 14 to 20 
percent in animals 8 weeks or older (Bernard et al., 1992b). As for human 
IDDM, detection of IAA in NOD mice appears to poorly predict the onset of 
clinical diabetes but their predictive value may be increased when 
considered in conjunction with ICA (Reddy et al., 1990), however Ziegler 
and associates, using a sensitive fluid-phase radioimmunoassay, showed 
the presence of IAA alone to have a predictive value of up to 70 percent 
(Ziegler et al., 1989). 
In addition to reactivity towards islet cell antigens and insulin, antibody 
reactivity has also been detected towards thyroid membrane components 
(Bernard et al., 1992a; Bernard et al., 1992b) and lymphocyte surface 
components (Kanazawa et al., 1984) in NOD mice. 
Cellular Immunity 
Although adult NOD mice are not lymphopaenic, abnormalities in 
peripheral, splenic and thymic lymphocyte populations have been 
reported. Reduced numbers of peripheral T cells have been 
demonstrated in young NOD mice (less than 12 weeks old), but these 
increase to normal or raised levels in older mice (Kataoka et al., 1983). 
Increased levels of the helper/inducer (L3T 4 +) and cytotoxic (Lyt 2+) 
phenotypes (but no alteration in the L3T4/Lyt2 ratio) have also been 
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demonstrated in mice of all ages (Kataoka et al., 1983; Pontesilli et al., 
1987). In contrast, analysis of peripheral lymph node cell populations at 
disease onset revealed a significant reduction in the number of CD4 + cells 
and cells expressing the CD4+VB 8.1+ phenotype (Zipris et al., 1991). 
In the spleen, diabetic NOD mice have been shown to have dramatically 
increased numbers of co4-8-Thy1 .2+ cells and CD4 +v B 8.1, 8.2 and 8.3 
positive T cells when compared to non-diabetic and non-NOD controls 
(Formby et al., 1992a). In the thymus, decreased CD4+CD8+ (double 
positive) and correspondingly increased CD4-CD8- ( double negative) T 
cell numbers are observed prior to and after disease onset (Zipris et al., 
1991 ). 
Other cellular abnormalities include decreased NK cell activity, increased 
B lymphocyte activity and enhanced in vitro cell-mediated cytotoxicity to 
isolated islet cells (Kataoka et al., 1983; Maruyama et al., 1984), although 
this has been found to be a general feature of non-diabetes prone mouse 
strains (Burtles et al., 1992). 
A comparison of the major features of human, BB rat and NOD mouse 
diabetic syndromes is shown in Table 2.1. 
iii) Other Spontaneous Models
Other spontaneous-onset, non-obese diabetic syndromes of animals have 
been described that present interesting variations from the above models. 
These include such diverse species as the Chinese Hamster (Gerritsen 
and Dulin, 1967; Gerritsen et al., 197 4; Like et al., 197 4; Schmidt et al., 
1970), Celebese Ape (Howard, 1978; Howard, 1986; Howard and van 
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Table 2.1. Comparison of the human, BB rat and NOD mouse diabetic 
syndromes. 
Human BB Rat NOD Mouse 
Age of Onset Any age 
* 
50 - 120 days 70 - 210 days 
Incidence z0.2% 80-90% t 70-80% t
Sex Susceptibility Male � Female Male > Female Female >> Male 
Hyperglycaemia +++ +++ +++ 
lnsulinopaenia +++ +++ ++ 
Ketoacidosis +++ +++ +++ 
lnsulitis + +++ +++ 
Islet Atrophy Detectable Detectable Detectable 
ICA Detectable Not Detectable Detectable 
ICSA Detectable Detectable Detectable 
IAA Detectable Detectable? Detectable 
64kDa Antibodies Detectable Detectable Detectable 
Lymphopaenia ± +++ ± 
CD4+ T cells Decreased Decreased Normal-Increased 
CDS+ T cells Increased Decreased Normal-Increased 
CD4:CD8 ratio Abnormal? Abnormal Normal 
la Expression Increased Increased Increased 
Anti-B cell CTL Present Present Present 
Thyroiditis Present Present Present 
* 
Most common before 20 years of age 
t Varies according to subline or colony
35 
Bueren, 1986), Keeshond Dog (Kramer et al., 1980), South African 
Hamster (Stuhlman et al., 1974) and Guinea Pig (Maxlang and Munger, 
1976). These models, however, tend to have limited value in the study of 
human diabetes. 
2.3.2 Induced Models 
An alternative to searching for spontaneous diabetic syndromes in animals 
is to induce the disease experimentally. Chemical treatment or viral 
infection are the two predominant methods for inducing diabetes and have 
been used in a variety of animal species to provide models that are a 
useful adjunct to the spontaneous models. Although disease induced in 
this manner may not be as close to the human situation as disease arising 
spontaneously, these models have the advantage of not being constrained 
by numbers or availability of animals and are able to be introduced onto a 
range of genetic background by use of inbred animal strains. 
i) Chemically Induced
Streptozotoci n 
Streptozotocin (STZ) is a broad range antibiotic and anti-tumour agent 
isolated from the bacterium Streptomyces achromogenes. Since the 
discovery of the diabetogenic properties of this chemical, STZ has 
become the most widely used agent for chemical induction of diabetes in 
animals. 
The usual method of diabetes induction by STZ is to administer a single 
diabetogenic dose intraperitoneally (Paik et al., 1980) or multiple sub­
diabetogenic doses administered intravenously or intraperitoneally on a 
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daily basis (Like and Rossini, 1976). Severe hyperglycaemia (greater 
than 40mM) is induced within 2 days of a single STZ injection, with B cell 
necrosis being detected microscopically 24 hours after treatment, but the 
islets remain virtually inflammation free (Brosky and Logothetopoulos, 
1969). Hyperglycaemia develops more slowly after multi-dose STZ 
treatment (1 week or longer), and a mononuclear cell infiltration of the 
islets is present, the severity of which increases until reaching a peak 3 
days after treatment (Bonnevie-Nielsen et al., 1981 ). The infiltration is 
characterized by infiltrating lymphocytes and macrophages in an 
environment of reduced B cell numbers and B cell necrosis. 
Although an immunological pathogenesis for STZ-induced diabetes has 
been postulated, STZ has been shown to be toxic to lymphoid cells and 
islet cells in vitro (Gaulton et al., 1985; Charlton and Mandel, 1989). Thus 
it is possible that STZ is directly toxic to B cells in vivo or alters the 
antigenic structure of the B cell, making it a target for immune destruction. 
Other Chemically-Induced Models 
Other chemicals used to induce diabetes in animals include alloxan 
(2,4,5,6-tetra-oxo-hexa-hydro-pyrimidine}, which acts to decrease B cell 
mass (McEvoy and Hegre, 1977; Chang and Diani, 1985), and various 
hormones such as glucagon, growth hormone, epinepherine, 
glucocorticoids, catecholamines and sex hormones which antagonize the 
actions of insulin (Mordes and Rossini, 1981; Chang and Diani, 1985). In 
addition, immunosuppressive drugs such as cyclophosphamide have been 
used to enhance the onset of diabetes in NOD mice (Harada and Makino, 
1984; Charlton and Mandel, 1989). 
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ii) Virally Induced
Although a role for viruses in the aetiology of diabetes has long been 
postulated, it has never been established. Convincing evidence in favour 
of a link between viral infection and diabetes, however, is provided by the 
ability of certain viruses to induce diabetes in various animals. 
Encephalomyocarditis (EMC) virus, an RNA virus isolated from the heart 
of a myocarditic pig, induces a diabetic syndrome similar to human IDDM 
in infected mice (Craighead and Steinke, 1971; Craighead, 1985). B cell 
degranulation and decrease in islet I RI is associated with the detection of 
viral antigens in the pancreas of infected mice 3 days after inoculation 
(Craighead and Steinke, 1971; Notkins, 1977). Also seen at this stage is 
a mononuclear infiltration of islets, and this may suggest that disease 
onset is immune-mediated. Studies on immunosuppressed mice, 
however, have shown that this is not the case, but rather that the B cell 
destruction is a result of viral aggression (Vialettes et al., 1980; Gould et 
al., 1985). 
A diabetic syndrome can also be produced in mice by infection with 
Reovirus Types 1 and 3. These virus particles are able to infect B cells 
and induce hyperglycaemia, abnormal glucose tolerance and 
hypoinsulinaemia (Onodera et al., 1978; Onodera et al., 1981 ). In 
addition, viral particles can be demonstrated in a and o cells of mice 
infected with the type 1 strain. Both viruses induce polyendocrinopathy 
and autoantibodies to insulin (Onodera et al., 1981 ). 
Other viruses capable of inducing diabetes include the Group B Coxsackie 
Virus, Venezuelan Encephalitis Virus (VEV), Cytomegalovirus (CMV), 
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Rubella Virus and Foot and Mouth Disease Virus (FMDV) (Steinke and 
Taylor, 197 4; Notkins, 1977; Mordes and Rossini, 1981; Craighead, 1985). 
All are highly species specific RNA viruses and generally replicate in the B 
cell, causing functional alterations with eventual necrosis. 
2.3.3 Transgenic Models 
During recent years the use of transgenic animal models in the study of 
diabetes has become increasingly prevalent. Tissue-specific expression 
of foreign genes in islet B cells has become possible since the 
identification of the promoter/enhancer sequence for the insulin gene. 
Genes of interest linked to the insulin promoter can be expressed in high 
quantities in B cells only and a number of groups have used this approach 
to hyperexpress MHC class I or class II molecules on B cells of transgenic 
mice not usually prone to autoimmune disease. Allison et al. used this 
approach to hyperexpress mouse class I products (H-2K) on B cells. 
These mice did develop an insulin-dependent diabetic syndrome, although 
this was not associated with insulitis and was not inhibited by thymectomy, 
suggesting a non-immune mediated pathogenesis (Allison et al., 1988). 
This was later confirmed by experiments demonstrating an in vitro
reduction in insulin production of excised H-2K transgenic pancreatic 
tissue (Mandel et al., 1991 ). Similarly, transgenic expression of class II (I­
A) products on B cells in a normal strain of mouse and class 11 (1-E) 
products in mice deficient in 1-E expression also produced a diabetic 
syndrome with no evidence of immune involvement (Sarvetnick et al., 
1988; Lo et al., 1988). These experiments demonstrate that the extreme 
hyperexpression of MHC transgenic products under the insulin promoter is 
cytotoxic to B cells in vivo.
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In contrast, transgenic expression of the lymphocyte activating cytokines 
interferon-y (IFN-y) or interleukin-2 (IL-2) on B cells produced an immune-
mediated I DOM syndrome in all mice expressing the transgenes 
(Sarvetnick et al., 1990; Heath et al., 1992). Two groups have also 
examined transgenic expression of lymphocytic choriomeningitis virus 
(LMCV) glycoprotein on the surface of B cells (Oldstone et al., 1991; 
Ohashi et al., 1991 ). Both studies showed that mice were tolerant to the 
transgenic product during ontogeny, but this tolerance could be broken in 
adult animals by LCMV infection leading to an immune-mediated IDDM 
syndrome. 
2.4 FACTORS INFLUENCING THE PATHOGENESIS OF IDDM 
2.4.1 Genetic Factors 
Since the observation that susceptibility to IDDM tends to be higher in 
families of IDDM patients than in the general population (see section 
2.2.5) , attention has focused on identifying genetic markers that may be 
implicated in the pathogenesis of the disease. The major 
histocompatibility complex (MHC) is a highly polymorphic cluster of genes 
that code for class I, II and Ill transplantation (histocompatibility) and 
immune response antigens\ Numerous studies have provided evidence 
f 
for a strong association between IDDM susceptibility and certain MHC 





The MHC of humans is known as human leukocyte antigen (HLA) system 
and is found on the short arm of chromosome 6. Class I determinants of 
the HLA system are coded for by three separate regions termed HLA-A, B 
and C, while class II antigens are coded for by the HLA-O region, which is 
subdivided into 3 loci - DR, DQ and DP. As mentioned, molecules coded 
for by this region are highly polymorphic and these polymorphisms can be 
detected using alloantisera, monoclonal antibodies or alloreactive 
lymphocytes to allow identification, or typing, of allelic variants of HLA 
antigens within a population. More recently, molecular techniques such as 
restriction fragment length polymorphism (RFLP) or polymerase chain 
reaction (PCR) analysis have allowed polymorphisms at the genetic level 
to be identified (Baisch and Capra, 1992; Patel et al., 1992). Thus, for 
each individual, these alloantigenic variations can be identified and are 
given an identification code, for example HLA-A 1, DR2, DQ12, DP3 etc. 
Polymorphisms at each locus identified by RFLP analysis or PCR are 
classified further as A or B to designate a or B chain and given a further 
set of numbers to identify the polymorphism, for example HLA­
DQA 1*0101 . 
Initial studies identified an association between the HLA-8 antigens AB 
and w15 and susceptibility to I DOM (Nerup et al., 197 4; Cudworth and 
Woodrow, 1974). More recently it has become clear that MHC class I 
associations are not as strong as those of class 11 antigens, although a 
recent study has identified a decreased expression of class I proteins on 
peripheral cells from IDDM patients (Faustman et al., 1991 ). In particular, 
HLA-DR3 and DR4 have consistently shown a positive association with 
IDDM (Platz et al., 1981; Green, 1990). The presence of either DR3 or 
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DR4 confers an increased risk of developing IDDM, although this risk is 
greatly increased if both DR3 and DR4 are present (Platz et al., 1981 ). 
Strong associations have also been found for DQ, but not DP, haplotypes 
(Baisch and Capra, 1992). An interesting association has been made 
between the DQB1 allele and IDDM (Todd et al., 1987; Baisch et al., 
1992; Patel et al., 1992). Taking this further, Baisch and associates 
identified DQB 1 *0302 as conferring "dominant susceptibility" while 
DQB1 *0602 provides protection (Baisch et al., 1990). Sequence analysis 
of the DQ class 11 B chain showed that DQB 1 encodes a non-charged 
amino acid at position 57, whereas non-diabetogenic alleles at this locus 
encode a negatively charged aspartate (Asp) at this position (Todd, 1990). 
Position 57 of the DQ B chain has been predicted to have a position on 
the surface of the molecule where it is accessible to peptide and the T-cell 
antigen receptor (Brown et al., 1988). If the amino acid at position 57 is 
charged, such as Asp, this may allow an interaction with a neighbouring 
amino acid that inhibits peptide presentation by the MHC molecule and 
subsequent recognition by the T cell receptor, thus providing a protective 
effect. IDDM susceptibility cannot be entirely explained by the Asp57 
relationship, however, and further work is needed to establish the 
molecular basis of associations with other markers such as DQa or other 
M HC haplotypes (Todd, 1990; Baisch et al., 1992). 
In addition to MHC genes, polymorphisms in genes outside the MHC have 
been described. Millward and associates have identified a significant 
increase in the frequency of the 10.0;9.2 kb heterozygous phenotype of 
the CB chain of the T cell receptor in IDDM patients (Millward et al., 1987) 




chain that also appear linked to IDDM susceptibility (Todd and Bain, 
1992). 
ii) BB Rat
An association between IDDM susceptibility and the BB rat MHC complex 
has been well established. The rat MHC is termed RTI, the class I region 
being made up of RT1 A, C and E loci and the class 11 region the RT1 B 
and D loci (Gill et al., 1987). The BB rat expresses the RT1 u haplotype,
and diabetes expression is independent of class I alleles but is dependent 
upon expression of at least one class 11 RT1 u allele (Colle et al., 1981) In
vivo anti-RT1 D, but not RT1 B, monoclonal antibody treatment reduces 
the incidence of diabetes, indicating that RT1 ou confers susceptibility to
diabetes (Boitard et al., 1985). Molecular characterization of the RT1 D B
chains of BB rats and non-diabetes prone rat strains show that a serine 
residue is at position 57 in all strains, suggesting that Asp57 is not 
involved in resistance to IDDM in non-BB strain rats (Chao et al., 1989). 
Cross-breeding studies between diabetes-prone and -resistant sublines of 
BB rats, both u/u homozygous at the MHC, consistently show that F1 
generation hybrids are not susceptible to diabetes (Howard, 1983). This 
suggests that the original mutation that produced the DP subline of the BB 
strain occurred in a gene(s) outside the MHC, which in conjunction with 
the RT1 u background, predisposes to disease susceptibility. The role of





The MHC region of the mouse is termed H-2 and contains three loci 
encoding class I antigens termed H-2K, D and L and two loci encoding 
class II antigens termed I-A and I-E. NOD mice are H-2Kd and ob, but 
differ from other mouse strains in that they do not express I-E antigens 
and have a unique I-A molecule, termed I-ANOD, in which the B chain Pro 
56 and Asp57 are replaced by histidine and serine respectively (Hattori et 
al., 1986; Acha-Orbea and McDevitt, 1987). The development of 
transgenic technology has provided an ideal means by which to examine 
the role of I-ANOD and lack of I-E expression in diabetes susceptibility. 
Expression of I-E in transgenic NOD mice prevents the development of 
insulitis and diabetes in all mice (Nishimoto et al., 1987; Lund et al., 1990). 
It has been suggested that I-E expression during ontogeny deletes T cells 
expressing certain TCR VB chains (Reich et al., 1989), although the 
protective effect of this molecule remains unclear (Bohme et al., 1990). 
In a second set of experiments, transgenic expression of 1-Ak in NOD 
mice, which is Asp 57, markedly reduced insulitis and prevented onset of 
diabetes (Slattery et al., 1990) and a similar effect was seen if 1-Ak Asp 57 
was replaced by Ser 57 (Miyazaki et al., 1990). Transgenic expression of 
I-Ak with a praline at position 56 also inhibited disease onset (Lund et al.,
1990). These experiments indicate that both lack of I-E expression and 
expression of the altered I-ANOD molecule contribute to diabetes 
susceptibility in NOD mice. 
Backcross studies of NOD mice with the diabetes resistant NON strain 
have identified at least three additional genes, termed ldd-1, ldd-2 and 
ldd-3, that control the development of diabetes, two of which (/dd-2 and-
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3) are not associated with the MHC (Prochazka et al., 1987). Wicker and
associates, using NODxB10 backcrosses, also identified three 
independent genes controlling the onset of diabetes, only one of which 
was linked to the MHC, and also identified a single non-MHC linked gene 
controlling the initiation of insulitis (Wicker et al., 1987). In addition, as for 
human diabetes, defective cellular expression of class I molecules is also 
associated with NOD diabetes (Faustman et al., 1991 ). 
2.4.2 Immunological Factors 
The data outlined in the above sections provides strong evidence that the 
pathogenesis of IDDM, 13otn.in.humansc.andthe,two major-animal models, 
has an autoimmune aetiology based on the disruption of immunological 
tolerance to islet cell components. This evidence includes the detection of 
circulating antibodies to islet cell components, the presence of insulitis, in
vitro reactivity of lymphoid cells to islet cell antigens and the association of 
IDDM with other endocrinopathies of autoimmune origin. A major focus of 
diabetes research has been to define the autoantigen(s) responsible for 
targeting the immune system to B cells and to characterize the events 
that allow this response to be initiated. 
i) Autoantigens of IDDM
One of the remarkable features of the autoimmune response seen in 
IDDM is that it is highly B -cell specific. This implies that an autoantigenic 
molecule unique to B cells targets the immune system to these cells, 
whilst sparing other cell types within the islet. Of paramount importance 
for the development of any preventative strategy for IDDM is the 
identification and characterization of this B cell autoantigen(s). As 
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-- . - -
1 
45 
described in previous chapters, insulin itself has been the subject of 
interest for many years and although autoantibodies can be demonstrated, 
the role of these in disease induction is unclear and there have been no 
reports of T-cell reactivity. A number of other candidate molecules, 
including the 64kDa antigen, have been identified but as yet their 
pathogenicity has not been defined. 
Glutamic Acid Decarboxylase (GAD) 
As previously described, circulating antibodies of human patients and 
animal models immunoprecipitate a 64kDa islet specific molecule which 
seems to be a marker of disease onset. Identification of the target 
molecule of these antibodies may provide a starting point for identifying 
eventual T cell epitopes and consequently attention has focused on 
characterizing the 64kDa molecule. 
Until 1990, the 64kDa antigen was known to consist of two subunits (a 
and B ) of identical charge whose expression was restricted to the plasma 
membrane of islet B cells (Christie et al., 1990b; Baekkeskov et al., 1989). 
12s1 surface labelling of islets followed by immunoprecipitation showed 
that the molecule was not a cell-surface component, and high glucose 
concentrations could stimulate increased expression of the molecule in
vitro (Colman et al., 1987; Kampe et al., 1989). 
The identity of the 64kDa molecule, however, was not established until 
late in 1990 when Baekkeskov and associates published a report showing 
immunoprecipitation of the 64kDa islet antigen by sera from patients with 
stiff man syndrome (SMS), a rare neurological disorder in which patients 
often have antibodies to islet cell cytoplasmic components and a high 




principal autoantigen of SMS is the enzyme glutamic acid decarboxylase 
(GAD), which is involved in the synthesis of the inhibitory neurotransmitter 
y-amino butyric acid (GABA) in the brain and also known to be present in
small quantities in the islet. The fact that antibodies to GAD could 
immunoprecipitate an islet 64 kDa protein, and that anti-64kDa antibodies 
could precipitate GAD enzymic activity from islets and brain provided 
strong evidence that the 64kDa islet autoantigen is GAD. As a 
consequence of this finding many studies have attempted to characterize 
the structure and function of GAD in the islet and ascertain a role for this 
enzyme in the pathogenesis of IDDM. 
Structure and Function of GAD 
Prior to its association with IDDM, GAD was known to exist in bacteria and 
plants, with crystallized GAD from Escherichia coli being used to identify 
pyridoxal phosphate (vitamin 86) as a cofactor for enzyme activity 
(Strausbauch and Fischer, 1970; Sabo and Fischer, 1974). A role for 
GAD in the generation of GABA in the brain was postulated as early as 
1950 (Roberts and Frankel, 1950). In 1973 mammalian GAD was purified 
from mouse brain and was recognized at this stage to be a dimeric 
molecule of 120 kDa, consisting of two subunits of 59 to 70 kDa (Wu et al., 
1973). Using SOS-PAGE and immunoblotting, several groups reported 
that two different sized subunits of the GAD dimer could be identified - a 
smaller polypeptide of 59 to 60kDa and a larger polypeptide of 62 to 
66kDa (Legay et al., 1986; Kaufman et al., 1986; Gottlieb et al., 1986; 
Chang and Gottlieb, 1988) and further evidence suggested that native 
brain GAD is a homodimer (Legay et al., 1987). 
Thus, the conclusion was drawn that the two different polypeptides 
identified by SOS-PAGE and immunoblotting of GAD form two different 
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homodimeric GAD molecules in the brain. It was subsequently 
demonstrated that the small and large GAD polypeptides are encoded by 
two separate genes, and based on the calculated amino acid sequences it 
was recommended that they be designated GAD-65 and GAD-67 
respectively (Erlander and Tobin, 1991; Bu et al., 1992). Multiple isoforms 
of brain GAD-67 have also been reported, differing in isoelectric points 
and hydrophobicities (Spink et al., 1987). 
Apart from the brain, GAD activity has been detected in sites such as 
fallopian tubes, spermatozoa, kidney, liver, pituitary gland, thyroid gland, 
adrenal gland and notably in islets (Solimena and DeCamilli, 1991; 
Christie et al., 1992a). lsoforms of GAD expressed in sites other than 
brain or islets may be antigenically distinct and not targets for 
autoantibodies developing during the course of IDDM (Christie et al., 
1992a). In the islet, GAD activity is confined to B - cells, and is 
concentrated at the surface of microvesicles (Reetz et al., 1991 ). Further 
analysis has shown that these vesicles are distinct from insulin secretory 
granules and GAD activity is also found in unique tubular cysternal 
complexes (Sorenson et al., 1991) GABAergic nerve cells have been 
found at the periphery of islets with intra-islet processes, and receptors for 
GABA have been detected on islet a - and 8- cells (Sorenson et al., 1991; 
Michalik and Erecinska, 1992). This data, in conjunction with evidence 
that the expression of GAD in islets is increased with an increased rate of 
insulin release (Bjork et al., 1992), suggests that GABA and GAD activity 
in the islet are involved with regulation of islet endocrine function. 
Although both GAD-65 and GAD-67 have been reported to be expressed 
in islets, these reports tend to be somewhat conflicting and seem to 
depend on the species studied. Karlsen et al., identified two types of 
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cDNA coding for human GAD termed GAD-1 and GAD-2, and these 
encode GAD-67 and GAD-65 respectively (Karlsen et al., 1991). Northern 
blot analysis of mRNA from human and dog islets detected only a GAD-2 
(GAD-65) transcript, while in brain tissue from a number of species both 
GAD-1 (GAD-67) and GAD-2 transcripts were detected. In contrast, 
Giorda et al. found expression of both GAD-65 and -67 in human islets, 
although GAD-65 seemed to be expressed at much higher levels (Giorda 
et al., 1991 ). In the rat, however, there seems to be general agreement 
that both isoforms of GAD are expressed at varying levels (Christgau et 
al., 1991; Michelsen et al., 1991; Karlsen et al., 1992). A possible 
explanation for the heterogeneity of islet GAD expression may relate to 
the handling and culture conditions of the islets prior to extraction, a point 
that needs to be addressed in further comparative studies. 
Sequence analysis of GAD-65 and GAD-67 reveals that the brain and islet 
forms are identical, and there is a high degree of homology between GAD 
sequences of different mammalian species (Michelsen et al., 1991; Bu et 
al., 1992; Yamashita et al., 1992). In rat islets, GAD-67 seems to be 
hydrophilic and soluble with a pi of 6.9 to 7.1, while GAD-65 is a more 
abundant, amphiphilic protein of pi 6.7 (Christgau et al., 1991; Michelsen 
et al., 1991 ). In addition, GAD-65 appears to exist in 3 forms -
hydrophobic and membrane bound, hydrophobic and soluble or 
hydrophilic and soluble - all of which can be separated into an a or B 
subunit by SOS-PAGE (Christgau et al., 1991 ). This heterogeneity in the 
structure of GAD may reflect the level of activity or function of GAD within 
the cell and has implications for the autoantigenic properties of this 
molecule in relation to IDDM. 
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1992). As yet there have been no reports of GAD autoantibodies in NOD 
mice or BB rats, presumably due to insufficient quantities of the antigen. 
Since the identification of GAD as an autoantigen, its value as a predictive 
marker of IDDM onset has been of interest, but as yet is unclear. The 
association between anti-GAD antibodies and ICA is yet to be confirmed 
as Rowley et al., reported a weak association between the two, finding a 
higher proportion of GAD+ICA- than GAD+ICA+ individuals among short
and long term IDDM patients, whereas both Christie et al. and Martino et 
al. report a strong association between ICA, anti-GAD antibodies and the 
development of IDDM (Martino et al., 1991; Christie et al., 1992b). The 
11granular11 pattern described for ICA staining (see section 2.2.4(i)) has 
been shown to be specific for GAD, but this pattern has a poor predictive 
value for disease onset, and studies have shown that it is not possible to 
remove ICA or decrease their titre when sera are pre-adsorbed with 
recombinant forms of the enzyme (Genovese et al., 1992; Timsit et al., 
1992; DeAizpurua and Harrison, 1992). 
As shown for the 64 kDa antigen, certain tryptic fragments of GAD 
increase the predictive value when compared to the intact molecule. In 
particular, a study of identical twins showed that the 37 and 40 kDa tryptic 
fragments had high predictive values, while antibodies to native GAD were 
present in genetically susceptible individuals who did not develop disease 
(Christie et al., 1992b). This study also identified a number of pre-diabetic 
individuals discordant for GAD and 37 kDa antibodies, raising the question 
of whether GAD accounts for all anti-64kDa reactivity. The prevalence of 
antibodies to GAD, however, is increased amongst individuals of the 
11high-risk 11 HLA-DR3 or DR4 genotypes (Serjeanston et al., 1992). 
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51 
In contrast to antibody reactivity, there have been few reports describing 
T-cell reactivity to GAD. The first of these reports described the
generation of T-cell lines specific for GAD from immunized DR-BB rats, 
which was not convincing as the authors failed to adequately define the 
purity of their antigen, which was then used to immunize animals and 
screen for positive T-cell clones (Diaz et al., 1992). In humans, PBL 
responses to GAD have been detected in 50 to 70 percent of newly 
diagnosed patients and a high percentage of ICA+ first degree relatives 
(Atkinson et al., 1992; Harrison et al., 1992b; DeAizpurua and Harrison, 
1992). The most convincing evidence of a role for GAD in IDDM 
pathogenesis has come from two recent studies on tolerance induction in 
NOD mice (Kaufman et al., 1993; Tisch et al., 1993). Both studies 
showed that tolerization of GAD-reactive T cells by intravenous or 
intrathymic administration of GAD at an early age prevented the onset of 
IDDM in these mice. Furthermore, T-cell responses to GAD were 
detected during the normal course of disease at an early age, initially 
confined to a small region of the GAD molecule, but spreading to other 
GAD epitopes and eventually other B cell antigens with time. 
Although there is strong evidence to show that GAD is an autoantigen in 
IDDM, it is still not clear whether this molecule is the primary target of B 
cell destruction, or whether the autoimmune response to this antigen is a 
result of prior B cell damage. The equivocal value of GAD as a predictor 
of disease onset, the difficulty in demonstrating T-cell reactivity to the 
molecule, the apparent lack of tissue specificity and the lack of data from 
animal models, particularly in relation to autoantibodies to GAD and 
disease induction by immunization, are some of the questions that need to 




Insulin: Although other candidate autoantigens for IDDM have been 
suggested, none have been as extensively characterized as GAD and 
their aetiological role is far from clear. Insulin itself has been implicated as 
IAAs have been detected prior to the onset of disease in humans and 
animal models. With regard to T-cell reactivity, a low magnitude and 
frequency of PBL responses in preclinical or clinical IDDM patients 
(Harrison et al., 199-1 b) have been reported, while a study in NOD mice 
failed to demonstrate any insulin-specific T-cell reactivity (Hurtenbach and 
Maurer, 1989). More recent studies, however, have shown T cell 
reactivity to a variety of islet antigens including insulin in NOD mice 
(Kaufman et al., 1993; Tisch et al., 1993). Thus, insulin remains a 
potentially attractive autoantigen, although its role in disease pathogenesis 
remains unclear. 
38 kDa Autoantigen: A 38 kDa insulin secretory granule antigen of the 
RINm5 insulinoma cell line cells has been shown to be the target of a T­
eel! clone generated from a recent-onset IDDM patient to crude RINm5 
membranes (Roep et al., 1990). The clone responded strongly to 35-41 
kDa RINm5 secretory granule membrane proteins, but also to 
neuroblastoma, pituitary and adrenal cell membranes preparations, raising 
questions about the tissue specificity of the antigen or the clone. This 
group also claimed to be able to generate T cell lines to this antigen from 
80 percent of recent-onset patients (Roep et al., 1991 ). Pak et al. 
immunized Balb/c mice with human cytomegalovirus (CMV), a virus 
implicated in the pathogenesis of IDDM (Pak et al., 1988), and generated 
a panel of monoclonal antibodies, one of which reacted with islet cells 
(Pak et al., 1990). By immunoblotting, this antibody was shown to react 
with an islet cell protein of Mr 38kDa, suggesting that this may be a target 
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islet antigen of CMV-induced IDDM. In addition, a 38kDa band was 
observed in the initial human immunoprecipitation studies that identified 
the 64kDa antigen of islets (Baekkeskov et al., 1982) and Harrison and co­
workers claim to have identified a 64kDa-antibody reactive clone from a 
human islet cDNA library producing a 38kDa protein that stimulates PBLs 
from preclinical IDDM subjects (Harrison, 1992). 
58 kDa Autoantigen: lmmunoblotting of NOD mouse sera against 
RINm5 extracts identified a 58kDa protein in 100 percent of diabetic NOD 
mice and in none of the controls (Boitard et al., 1992). Antibodies to this 
protein were also shown to cross-react with a 58kDa intermediate filament 
protein of neuroblastoma cells previously identified as peripherin. The 
58kDa protein was also shown to share cross-reactive epitopes with MHC 
class 11 molecules, thus providing a means whereby islet 58kDa reactive 
T-cell clones may escape thymic deletion during ontogeny. Nevertheless,
it remains to be determined whether peripherin of purified islet cells, as 
opposed to RINm5 insulinoma cells, is also autoantigenic. 
Carboxypeptidase H: This is an enzyme of Mr 50 to 53kDa found within 
islet insulin secretory granules and involved in the conversion of proinsulin 
to insulin. It was identified by Castano et al., who screened a rat islet 
cDNA library with serum from a prediabetic IDDM subject and identified a 
positive clone whose DNA sequence corresponded to a fragment of the 
membrane form of carboxypeptidase H (Castano et al., 1991 ). Five of 20 
ICA+ relatives and none of 14 controls reacted with a 52kDa protein of 
RINm5 extracts by immunoblotting, however, this study suffered from a 
lack of appropriate non-islet tissue controls, and only a positive reaction of 
one patient was shown. 
I I 
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Heat Shock Protein (HSP): Of considerable debate at present is the role 
of HSP's in the pathogenesis of diabetes in particular, and autoimmune 
disease in general. The interest in HSPs as autoantigens stemmed from 
the identification of a microbacterial HSP as an autoantigen in adjuvant 
arthritis (Feige and Cohen, 1991; Yang and Feige, 1991 ). Elias and co­
workers first described an islet B cell antigen that was cross reactive with 
a 65 kDa HSP of Mycobacterium tuberculosis in NOD mice (Elias et al., 
1990). These workers were able to show that at the onset of IDDM in 
NOD mice T lymphocytes reactive with HSP65 are detectable. With time, 
HSP65 antibodies and indeed the HSP65 antigen itself are demonstrable 
in the sera and as disease progresses, levels of antibodies, T-cell 
reactivity and antigen decline. Moreover, HSP65 could be used to either 
induce or vaccinate against diabetes depending on the mode of 
administration, and T cell clones raised against recombinant HSP65 could 
induce disease in recipient mice. 
In a subsequent study, this group also reported that T-cell clones 
recognizing a peptide of HSP65 can transfer disease and can be used to 
immunize against disease (Elias et al., 1991 ). Jones et al. also described 
cross-reactivity between monoclonal antibodies to Mycobacterium 
tuberculosis HSP65, but not HSP from other sources, and the 64 kDa 
islet cell antigen by western blotting (Jones et al., 1990). Both these 
reports are refuted, however, by other studies showing no evidence for 
serological cross-reactivity between HSP65 and islet cell antigens (Kampe 
et al., 1990; Atkinson et al., 1991 ). Two reports have also suggested that 
an HSP60-like molecule is an islet cell antigen in IDDM. Brudzynski et al. 
demonstrated the presence of a mammalian HSP60 cross-reactive protein 
in the secretory granules and mitochondria of islet B cells, and a 
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subsequent study identified anti-HSP60 antibodies in the sera of diabetic 
and prediabetic mice (Brudzynski et al., 1992a; Brudzynski et al., 1992b). 
ii) Cellular Mechanisms
Although abnormalities of peripheral lymphocyte populations and the 
association of IDDM with insulitis and cell-mediated autoimmune 
endocrinopathies provide circumstantial evidence for a role of cellular 
immune-mechanisms in the aetiology of IDDM, studies in animal models 
of the disease have been valuable in establishing a direct role for an 
autoimmune, cell-mediated pathogenesis for IDDM. 
Direct evidence for the involvement of the immune system in the 
pathogenesis of IDDM comes from the following observations in both NOD 
mice and BB rats: 1) Treatment with anti-lymphocyte serum inhibits the 
onset of disease (Like et al., 1979; Maki et al., 1992); 2) Neonatal 
thymectomy inhibits disease onset and nude (athymic) animals do not 
develop disease (Like et al., 1982b; Ogawa et al., 1985); 3) 
lmmunosuppressive agents such as cyclosporin are protective (Laupacis 
et al., 1983; Mori et al., 1986; Makino et al., 1986); 4) Disease can be 
transferred to naive recipients using lymphoid cells from diabetic donors 
(Koevary et al., 1983; Like et al., 1985; Wicker et al., 1986a and b) and; 5) 
The course of the disease can be inhibited by reconstituting susceptible 
animals with lymphoid cells derived from resistant donors (Burstein et al., 
1989; Hutchings and Cooke, 1990). 
Identification of the cell types involved in IDDM pathogenesis has also 
been facilitated by studies in animal models. Studies of adoptive transfer 
of disease in NOD mice generally show that in vitro deletion of either 
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CD4+ or CD8+ T cells inhibits the induction of disease, indicating a 
requirement for both of these cell types for the initiation of B cell 
destruction in this experimental system (Bendelac et al., 1987; 
Christianson et al., 1993). A number of studies have shown that in vivo
depletion of CD4+ T cells in NOD mice prevents disease (Wang et al., 
1987; Koike et al., 1987; Charlton and Mandel, 1988; Hutchings et al., 
1992), however Charlton et al. also demonstrated an in vivo requirement 
for cos+ T cells (Charlton et al., 1988). Analysis of cloned T cells isolated 
from infiltrated islets of NOD mice of different ages showed that the 
majority of clones isolated from young mice were CD4 + , while CD8+
clones were readily isolated from older mice (Nagata and Yoon, 1992). In 
the BB rat, CD4 + T cells alone appear capable of transferring disease 
(Mordes et al., 1987; Metroz-Dayer et al., 1990) although in these studies 
the authors could not rule out interaction of these cells with other cell 
types. Other studies have shown that in vivo depletion of C08+ T-cells 
(Like et al., 1986) or NK cells (Like et al., 1986; Jacobsen et al., 1988) 
inhibit the onset of diabetes in the BB rat. 
Examination of the role of macrophages in the pathogenesis of IDDM in 
animal models has provided some interesting but apparently paradoxical 
observations. Macrophages have been shown to be present in islet 
infiltrations from a very early stage - even before the arrival of 
lymphocytes (Walker et al., 1988; Hanenberg et al., 1989). In addition, in
vivo treatment of both BB rats and NOD mice with silica, a macrophage 
toxin, prevented the onset of diabetes (Charlton et al., 1988; Amano and 
Yoon, 1990). In vitro macrophage - mediated islet cell cytotoxicity is 
raised in BB rats at the onset of diabetes (Nagy et al., 1989) and the 
inhibition of macrophage migration into islets using a monoclonal 
I I 
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antibody to adhesion-promoting complement receptors inhibits 
development of disease in NOD mice (Hutchings and Cooke, 1990). 
These observations imply that macrophages are essential for the 
development of insulitis and subsequent disease, possibly by mediating 
the initial B cell damage and/or recruiting lymphocytes into the islet. In 
contrast, the findings of several studies suggest that macrophages are 
capable of in vitro suppressive activity. Thus, two studies report dramatic 
improvement in the in vitro mitogen-induced proliferative responses and 
IL-2 production of spleen cells isolated from BB rats when depleted of 
adherent macrophage populations (Prud'homme et al., 1984; Woda and 
Padden, 1986) and a similar effect has been seen in the NOD mouse 
(Y okono et al., 1989). 
In addition, studies have shown that vaccine-induced inhibition of insulitis 
and diabetes in NOD mice is mediated by activated macrophages. BCG 
(bacille Calmette-Guerin), a tuberculosis vaccine derived from attenuated 
Mycobacterium bovis and a nonspecific stimulator of cell mediated 
immunity, is capable of inhibiting diabetes onset in vaccinated NOD mice 
(Yagi et al., 1991 a). Mice show reduced in vitro spleen-cell 
responsiveness to mitogens and alloantigens. Removal of adherent 
macrophages restores responsiveness and re-adding adherent cells 
restores suppression. In a subsequent study it was also shown that 
transfer of spleen-cell fractions enriched for macrophages from BCG­
vaccinated mice to young female NOD mice inhibited the occurrence of 
diabetes (Yagi et al., 1991 b). Metroz-Dayer et al. also reported improved 
in vitro mitogen activation and subsequent adoptive transfer of diabetes to 
young DP-BB rats by using macrophage-depleted spleen cells from 
diabetic donors (Metroz-Dayer et al., 1990). 
- ------ ---------------- ------ �  
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Considered together, the above results suggest that the initial event in the 
pathogenesis of IDDM in these models is the infiltration of macrophages 
into the islet. CD4+ T cells follow, either as a result of B cell damage or 
recruitment by macrophages and then, in conjunction with cos+ T cells, 
mediate B cell destruction. The role of suppressive macrophages is 
uncertain, but they may act to regulate this process either towards disease 
induction or suppression. 
iii) Cytokines
More recently there has been an increase in interest in the role of soluble 
mediators of immune function in the B cell destructive process. Cytokines 
are soluble immunoregulatory molecules produced by activated 
lymphocytes or monocytes that act as stimulatory or regulatory signals for 
both immune and non-immune cells. Although a wide variety of these 
molecules have been described that may act in the pathogenesis of IDDM, 
attention has focused on those shown to act directly or indirectly on the 
inflammatory response to B cells in humans and experimental systems. 
The interleukin 1 (IL-1) family consists of three polypeptide signal 
molecules {IL-1 a, IL-1 B and IL-1 receptor antagonist) produced by 
activated mononuclear cells (Dinarello and Wolff, 1993). A number of 
studies have shown that IL-1, and in particular IL-1 B, is able to inhibit 
islet-cell function and viability in vitro and in vivo, and is cytotoxic to B 
cells in vitro (Sandler et al., 1991; Welsh et al., 1991; Helqvist et al., 
1991; Ling et al., 1993). This has led to the hypothesis that IL-1 may 
mediate B cell destruction in infiltrated islets (Mandrup-Poulsen et al., 
1990). In contrast, long-term administration (5 times per week for 22 
weeks) of IL-1 a was able to inhibit spontaneous insulitis and diabetes in 
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NOD mice and IL-1a treatment of recipients inhibited the adoptive transfer 
of disease by CD4 + cells isolated from diabetic donors to young NOD 
mice (Formby et al., 1992b). In BB rats, short term administration (twice 
daily for 3 weeks) of IL-1 receptor antagonist delayed the onset of 
diabetes (Dinarello and Wolff, 1993). 
Tumour necrosis factor alpha (TNFa) is another macrophage derived 
cytokine that has been implicated in the pathogenesis of IDDM. Long­
term administration of TNFa to NOD mice or BB rats prevents the onset of 
diabetes (Jacob et al., 1990; Satoh et al., 1990) while diabetic and pre­
diabetic NOD mice have been shown to have increased circulating levels 
of this cytokine (Barel et al., 1992). Interferon gamma (IFNy), produced by 
activated T cells, has also been implicated as BB rats treated with poly 
i:C, a stimulator of IFNy production, accelerates diabetes in BB rats (Ewel 
et al., 1992) while in vivo treatment with IFNy monoclonal antibodies 
prevents disease onset (Nicoletti et al., 1990). In human patients, a defect 
in the synthesis of another activated lymphocyte-derived cytokine, 
interleukin-2 (IL-2), has been observed (Zier et al., 1984; Kaye et al., 
1986). 
It is evident from the above results that although there appears to be a 
role for cytokines in the pathogenesis of IDDM, the mechanism is far from 
clear and will probably involve a network of complex interactions. 
Nevertheless, an understanding of these interactions will ultimately be 
essential for eventually determining the pathogenic mechanisms of this 
disease. 
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2.4.3 Environmental Factors 
Although a strong genetic influence has been established for susceptibility 
to IDDM, genetics alone cannot account for a number of observations in 
humans and animal models. The observations that 1) a number of 
individuals with susceptible MHC haplotypes do not develop disease 2) 
the concordance rate for IDDM in identical twins is less than 50 percent 3) 
incidence rates vary according to season and geographical location and 4) 
the variable incidence rates seen between colonies of inbred BB rats and 
NOD mice, together strongly suggest a role for non-genetically determined 
environmental factors in the pathogenesis of IDDM. 
i) Infectious Agents
A role for viruses in the aetiology of diabetes has long been suspected, 
but not confirmed. Association between diabetes and mumps, Rubella, 
hepatitis, coxsackie and influenza viruses, cytomegalovirus and 
enterovirus have been proposed, but little epidemiological evidence has 
been provided in support of the association (Maugh, 1975). A Coxsackie 
B4-like virus has been isolated from the pancreas of a patient with diabetic 
ketoacidosis (Yoon et al., 1979). Anti-viral antibodies were present in the 
serum and viral antigens were demonstrated in B -cells. 
As previously described (2.3.2), viral infection has been associated with 
diabetes in the BB rat and NOD mouse, and experimental viral infection 
can induce diabetes in normal animals. In contrast, however, are studies 
showing that infection of NOD mice with mouse hepatitis virus or 
lymphocytic choriomeningitis virus reduced the incidence of disease 
(Oldstone, 1988; Wilberz et al., 1991 ). 
I I 
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Further evidence of a role for infectious agents comes from studies in the 
BB rat. Like et al. reported that DP rats raised under viral antibody-free 
(VAF) conditions showed increased frequency and accelerated onset of 
diabetes (Like et al., 1991) and an outbreak of spontaneous diabetes in 
the DR-BB subline was associated with the onset of viral infection in these 
animals (Thomas et al., 1991 ). This is in contrast to a study by Rossini 
and associates, who showed no difference in the incidence levels of 
disease between DP-BB rats reared under conventional or gnotobiotic 
conditions (Rossini et al., 1979). Ellerman and Like examined the 
possibility that T-cell stimulatory properties of Staphylococcal enterotoxin 
(SE), produced during Staphylococcal aureus infections, may be involved 
in the activation of quiescent self reactive T-cells (Ellerman and Like, 
1992). In vitro SE activation of spleen cells from diabetic BB was 
effective in stimulating diabetogenic effector cells capable of transferring 
disease to young DP animals. This raises the possibility that T-cell 
stimulatory microorganisms may play a role in IDDM pathogenesis. 
ii) Diet
The relationship between IDDM and diet in humans is difficult to study due 
to the highly varied nature of the human diet. Studies in both BB rats and 
NOD mice, however, suggest that modifications of one or more 
components of the diet - for example protein, carbohydrate or fat content -
are able to modify the incidence of disease (Helgason et al., 1982; Elliott 
and Martin, 1984; Scott et al., 1985; Atkinson et al., 1988; Elliott et al., 
1988). In contrast, other studies in the BB rat have indicated that neither 
the incidence nor severity of the diabetes is influenced by dietary 
modification (Rossini et al., 1981 ). The subject, therefore, still remains 
controversial, but in the numerous studies in favour of a dietary 
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component, protein content and composition appear to be the most 
influential factors in disease induction. 
Recently attention has focused on cow's milk proteins as being potential 
triggers of IDDM. Breast-feeding has been observed to have a protective 
effect (Mayer et al., 1988; Kostraba et al., 1992) and a number of recent 
studies have reported a high incidence of antibodies to cow's milk proteins 
in patients with diabetes mellitus. Dahlquist et al. found a positive 
correlation between antibodies to B--lactoglobulin and risk for developing 
early-age onset IDDM (Dahlquist et al., 1992). Similarly, Karjalainen and 
associates identified elevated levels of antibodies to bovine serum 
albumin (BSA) in 100 percent of newly-diagnosed patients (Karjalainen et 
al., 1992a). Furthermore, these workers identified a peptide sequence of 
BSA that differed from the amino acid sequence of human, rat and mouse 
albumins and showed that BSA antibodies from diabetic patients were 
specific for this peptide (Karjalainen et al., 1992b). Antibodies to BSA 
have also been demonstrated in BB rats and NOD mice, and these 
antibodies have been shown to cross react with a 69 kDa islet-cell protein 
termed p69 (Glerum et al., 1989; Beppu et al., 1987). Thus the authors 
argue that the triggering event of IDDM could be the cross-reaction of 
antibodies to a peptide of BSA with an islet-cell protein in genetically 
susceptible individuals. 
2.5 CONCLUSIONS 
From the above studies it is clear that IDDM is a disease characterized by 
profound disregulation of carbohydrate metabolism resulting from the 
immune-mediated destruction of insulin-secreting B -cells. The destructive 
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phase of the disease is a cell-mediated event, although the disease 
appears to have a long prodromal period during which autoantibodies to a 
variety of islet and non-islet components are generated. Of these, ICA 
and 64kDa antibodies are the best-characterized and together provide the 
best predictive markers of disease progression. 
Several animal models of IDDM are available and of these, the 88 rat and 
the NOD mouse have been extensively characterized. In both these 
models, disease arises spontaneously and while closely approximating the 
human condition, they are not identical. While several models of IDDM 
are available in which the disease is actively induced, they all require 
some form of chemical treatment or viral infection, often making 
interpretation of the results difficult. 
Studies in both humans and animals suggest an important role for genetic 
factors in the pathogenesis of the disease, particularly in relation to 
products of the class II region of the MHC. Nevertheless, susceptibility to 
I DOM appears to be a multi-factorial process, involving both genetic and 
environmental factors. Identification of these environmental factors and 
the way they influence the pathogenesis of IDDM, in conjunction with 
genetic studies, could ultimately allow development of effective 
preventative regimes. 
CHAPTER 3.0 
CLINICAL AND DYNAMIC FEATURES OF THE Tx-X 
INDUCED DIABETIC SYNDROME 
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3.1 INTRODUCTION 
Experimental animal models of human disease allow approaches to the 
investigation of factors that contribute to disease initiation and 
pathogenesis that are often not possible in humans. Animal models of 
human IDDM have provided much useful information, particularly with 
regard to the role of the immune system in disease pathogenesis. 
IDDM may develop in animals of particular genetic background 
spontaneously (that is, genetically determined) or may be induced by 
various chemical or viral induction protocols that disrupt immunological 
tolerance to islet-cell antigens (reviewed in the previous chapter). 
Although it can be argued that animal models of I DOM in which disease 
develops spontaneously more closely resemble the disease of humans, 
artificially induced models have the advantage of being more amenable to 
experimental manipulation, particularly with regard to the absence of 
genetic constraints and the availability of genetically identical, normal 
animals for control purposes. To date however, no well-characterized 
induced model of human IDDM has been available that does not rely on 
chemical or infectious agents for disease expression. The availability of 
such a model would offer an adjunct to the currently available 
spontaneous models for the study of disease pathogenesis, while 
avoiding the complications arising from the directly pathogenic effects of 
these agents. 
A combination of thymectomy and irradiation (Tx-X), a procedure known 
to alter immune function and regulation, was first described by Penhale 
and associates as a means of inducing lymphocytic thyroiditis in rats 
(Penhale et al., 1973). The induced thyroiditis was characterized by 
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infiltration of lymphocytes and macrophages into the thyroid gland, and 
studies by this group suggested that the disease was immune-mediated 
and not the result of direct thyroid tissue damage per se (Penhale et al., 
1973; Penhale et al., 1976). 
The Tx-X model has subsequently proven readily amenable to procedures 
capable of modifying expression of disease, with previous studies 
showing that treatment with anti-lymphocyte serum or reconstitution with 
normal syngeneic lymphoid cells inhibited thyroiditis onset (Pen hale et al., 
1975; Penhale et al., 1976), while thyroiditis could be transferred to naive 
recipients using activated spleen cells from thyroiditic donors (Penhale 
and Stumbles, unpublished observations). These observations indicated 
a causative role for the immune system in the pathogenesis of the 
disease and argued strongly in favour of autoimmune origin for Tx-X­
induced thyroiditis. 
Originally, the Tx-X model was developed in Wistar strain rats of 
conventional hygienic background. More recently, however, it was 
observed that changing to PVG strain rats of specific pathogen free (SPF) 
background induced an acute-onset and rapidly fatal wasting syndrome in 
addition to the previously observed thyroiditis. The ability to control this 
wasting syndrome by exogenous insulin therapy suggested that this 
disease was analogous to human IDDM 
This chapter describes the clinical and pathological features of this 
diabetic syndrome consistently observed in SPF PVG rats following the 
Tx-X procedure. The syndrome appeared closely analogous to clinical 
IDDM in man and the model thus has potential value for studies of 
diabetes initiation and pathogenesis. 
! I 
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3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Unless otherwise stated, all experiments utilized female PVG (RT1 C) rats 
reared under SPF conditions obtained from the Animal Resources Centre, 
Murdoch, Western Australia and housed under non-barrier conditions in 
the University animal house. Rats were maintained in groups of 3-5 per 
cage and fed on standard pelleted rat feed with water provided ad libitum.
Female WAG (RT1 LI), Lou/m (RT1 LI), SHR (RT1 k), DA (RT1 a) and F344 
(RT1 I) strain rats were obtained form the same source and housed under 
the same conditions. To examine the influence of environmental 
background on disease inducement, inbred PVG rats were bred under 
non-SPF conditions (conventional) and maintained in a separate room. 
All PVG animals, whether SPF or conventional, were derived from the 
same parental stock. Twenty-one day old F1 generation RT1 c/u hybrid 
rats were derived from SPF PVG (RT1 c) female/WF (RT1 u) male matings. 
3.2.2 Tx-X Protocol 
This was performed basically as described by Pen hale et al., 1973. Rats 
were thymectomized on arrival from the SPF unit under sodium 
pentobarbitone anaesthesia then given 4 fortnightly doses of low-dose 
(2.5 Gray) whole-body gamma irradiation using a Cobalt-60 source. Rats 
were treated in groups of 20 to 30 at one time, housed in groups of 3 to 5 
and maintained for 8 to 1 0 weeks after final irradiation, during which time 
diabetes developed spontaneously (Figure 3.1 ). All Tx-X rats were 
retrospectively checked at necropsy for the efficacy of thymectomy and 
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Figure 3.1. Protocol for the induction of diabetes by thymectomy and irradiation. 
PVG rats were weaned at 3 weeks of age, thymectomized (Tx) during the 
following week then given four fortnightly doses of whole-body gamma 
irradiation (X). During the following 10 weeks, disease developed 
spontaneously. 
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data from any animal with thymic remnants excluded from the study (less 
than 1 percent of all animals used in this study). 
3.2.3 Disease Monitoring 
During the 8 to 10 week development period following final irradiation 
animals were examined daily for early signs of diabetes, detectable by a 
rapid loss of weight and behavioural changes. Affected animals were 
then tested for hyperglycaemia by Glucostix® and a Glucometer®
analysis (Bayer Diagnostics, Mulgrave, Australia) using caudal vein blood 
samples taken under ether anaesthesia, and classified as diabetic on the 
basis of a blood glucose reading equal to or greater than 13.5 mM. 
Clinically diabetic animals were treated daily with subcutaneous doses of 
human insulin (1.5 units each of Protaphane® and Actrapid® ; CSL Novo, 
Melbourne, Australia). Animals were necropsied shortly after onset of 
clinical signs, or at the end of the 8 to 10 week period if clinical disease 
did not develop, and plasma samples prepared for enzymatic glucose 
determination (Cobas Mira biochemical analyzer) and pancreata and 
thyroids taken for histopathology. 
In some cases glucose tolerance tests were performed to establish 
irregularities in glucose metabolism. Blood samples for glucose 
determination were taken from non-fasted animals prior to the 
intraperitoneal (IP) injection of 2 mg per gram body weight of glucose 
dissolved in 0.15 M phosphate buffered saline, pH 7.3 (PBS). Blood 
glucose levels were then determined at 30, 60 and 120 minutes intervals. 
70 
3.2.4 Histopathology 
Histopathological change was assessed on formalin-fixed, haematoxylin 
and eosin (H&E) stained pancreas sections. Islet lesions were classified 
as either i) diffuse atrophy if all islets were affected ii) focal atrophy if 
only a proportion of islets were atrophic and/or iii) insulitis if lymphocytic 
infiltration of islets was observed. Sections were assessed without prior 
knowledge of clinical status. 
Thyroid glands were taken at the same time and assessed for thyroiditis 
after formalin-fixation and H&E staining. Lesions were graded on a scale 
of 1 (mild) to 4 (severe) according to the severity of the infiltration and 
degree of follicular destruction. 
3.2.5 lmmunofluorescence 
Formalin-fixed sections of rat pancreas were examined for the presence 
and distribution of a (glucagon-synthesizing) and B (insulin -synthesizing) 
cells by indirect immunofluorescence. B cells were stained using a 
mouse anti-human insulin monoclonal antibody (Amersham Int., 
Amersham, U.K.) undiluted for 18 hours at 4°C, followed by a sheep anti­
mouse lgG-fluorescein isothiocyanate (FITC) conjugated antiserum 
(Silenus Laboratories, Melbourne, Australia) diluted 1 :40 for 1 hour at 
room temperature. a cells were stained in a similar manner using a rabbit 
anti-human glucagon polyclonal antibody (Amersham Int., Amersham, 
U.K.) followed by a goat anti-rabbit lgG-FITC conjugated antiserum (Miles
Veda, Israel). 
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3.2.6 Plasma Insulin and Lipid Analysis 
Plasma immune-reactive insulin (IRI) and lipid levels were analyzed in a 
proportion of samples from acute diabetic animals (prior to insulin 
treatment) or from normal (non-Tx-X) rats. IRI radioimmunoassays were 
performed by the Department of Medicine, Royal Postgraduate Medical 
School, London, U.K. and acetoacetate and B-hydroxybutyrate levels 
determined enzymatically by the Department of Biochemistry, School of 
Veterinary Studies, Murdoch University. 
3.2.7 Tests for Pathogens 
Serum samples from parent breeding stock rats were tested routinely (3 
month intervals, n=60) by the Department of Agriculture, South Australia 
for antibodies to the following common rodent pathogens: Mycoplasma 
pulmonis, murine hepatitis/rat coronavirus, murine cytomegalovirus, 
minute virus of mouse, pneumonia virus of mouse, Reovirus type 3, 
adenovirus, lymphocytic choriomeningitis, mouse encephalomyelitis, 
encephalo- myocarditis, Sendai, Kilham•s rat, Toolan HI and Hantaan 
viruses. A small group of parent breeding stock (n=6) were randomly 
selected every 2 months and pharyngeal and caecal samples examined 
for the presence of a range of recognized bacterial and parasitic 
pathogens (Pasteurella sp., Yersinia sp., Bordetella sp., Streptococcus 
sp., Listeria sp., Salmonella sp., Streptobacil/us monilliformis, Hexamita 
and pinworm). In addition, a smaller number of samples from SPF or 
conventional Tx-X rats were also tested. All samples were found to be 
negative on all occasions except one Tx-X, SPF-derived, non-diabetic 





stages of the liver parasite Taenia taeniaeformis were occasionally 
isolated from conventionally-derived animals. 
3.2.8 Statistical Analyses 
Comparison of incidence rates was by chi-squared analysis of 2 x 2 
contingency tables using the Yates• correction for sample numbers 
greater than 50 or Fishers• Exact Test for those less than 50 (Langley, 
1971). Mean values were compared using Student's t-test for unpaired 
samples. 
3.3 RESULTS 
3.3.1 Characterization of the Diabetic Syndrome 
i) Clinical Features
Onset of acute diabetes could be recognized visually by a rapid loss of 
body condition (greater than 5 grams total body weight in less than 24 
hours) and was confirmed by a concurrent increase in blood glucose 
levels. Blood glucose levels rose rapidly over a period of 2 to 3 days in 
untreated animals to levels of 50 to 60mM in some cases (Figure 3.2). 
Initiation of parenteral insulin therapy at onset of these symptoms was 
effective in stabilizing blood glucose levels and controlling weight loss, 
thus restoring body weight and condition in the majority of cases (Figure 
3.3). Once stabilized, diabetic rats could be maintained indefinitely on 
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Time after final irradiation (weeks) 
Figure 3.2. Blood glucose levels of Tx-X rats following final irradiation. 
Rats were bled weekly for 6 weeks following final irradiation and blood 
glucose levels determined. Animals not developing diabetes (squares) 
maintained relatively constant blood glucose levels throughout this period 
(n=20), while acute diabetic animals (circles) showed rapid increases in 
glucose levels at the onset of disease if not treated with insulin. 
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further loss of condition and hyperglycaemia, leading to death within 1 to 
3 days. IP glucose tolerance tests performed on newly-diagnosed 
diabetic rats showed a steady increase in blood glucose levels from 
initially elevated levels to levels greater than 30 mM after 120 minutes in 
most cases, indicating a profound disruption in glucose metabolism in 
these animals (Figure 3.4). 
A comparison of the plasma chemistry of acute diabetic Tx-X rats and 
normal rats is shown in Table 3.1. Diabetic animals had markedly raised 
levels of blood glucose, acetoacetate and B -hydroxybutyrate (P < 0.001) 
and correspondingly depressed circulating insulin levels in plasma 
samples taken prior to necropsy compared to age-matched controls 
(P < 0.001 ). Thus profound disturbances in glucose regulation and 
compensatory changes in fat metabolism were observed in diabetic rats. 
ii) Histopathology
Pancreatic sections taken from acute diabetic rats shortly after onset of 
clinical signs revealed severe lesions usually confined to the islets (Figure 
3.5). The degree of islet change generally reflected the clinical condition 
of the animal, ranging from diffuse atrophy in acute diabetic animals 
(Figure 3.5a) to varying degrees of insulitis and focal atrophy in chronic 
and non-diabetic Tx-X rats (Figure 3.5b). 
Based on the above clinical symptoms and/or islet histopathology, Tx-X 
rats could be classified into one of four groups: 1) - acute diabetes. 
These rats developed full clinical symptoms and showed islet lesions 
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Time from glucose challenge (min) 
Figure 3.4. IP glucose tolerance tests of acute diabetic (circles) and 
clinically non-diabetic (squares; n=5) Tx-X rats. Rats were starved 
overnight and challenged IP with glucose at time 0, then blood glucose 




Table 3.1. Plasma chemistry of acute diabetic and normal PVG rats. 
Parameter 
Glucose (mM) 
Insulin (pM) t 
Acetoacetate (mM) 
B -hydroxybutyrate (mM) 








50.9 ± 1.9 10.8 ± 0.4 
9.4 ± 3.3 49.9 ± 5.8 
0.97 ± 0.3 0.02 
9.11 ± 1.5 0.37 ± 0.1 
Hyperglycaemia with insulin-dependence. Samples taken at onset of clinical signs 
t Detection limit of assay = 5pM




Figure 3.5. Islet histopathology of Tx-X rats. Pancreas sections taken 
from a diabetic rat at disease-onset (a) and a non-diabetic rat at the end of 
the induction period (b) were formalin-fixed and stained by H&E (x250). 
a) Diffuse atrophy of an acute diabetic rat - note loss of islet cell mass.




c) Normal Tx-X rat islets (H&E; x250).
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retrospectively on the basis of islet lesions and hyperglycaemia detected 
in samples taken prior to necropsy. These animals maintained normal 
body weight and condition throughout the observation period and did not 
become insulin-dependent; 3) - normoglycaemic (non-diabetic) Tx-X rats 
with islet lesions at necropsy; 4) - normoglycaemic Tx-X rats with normal 
islets at necropsy. 
The frequency with which islet lesions (atrophy and/or insulitis) were 
observed in the above-described groups of Tx-X rats is summarized in 
Table 3.2. Diffuse atrophy was confined to the majority (75 percent) of 
acute diabetic animals, consistent with major impairment of B cell 
function within this group (P < 0.001 ). Focal atrophy, usually together 
with insulitis, was also common in acute diabetic rats (22 percent; P < 
0.001 compared with normals) and also in chronic diabetic rats (37 
percent). lnsulitis was rarely seen in animals with acute disease, but this 
was the most frequent lesion of chronic and non-diabetic Tx-X rats. Islet 
atrophy or insulitis were never observed in control unmanipulated PVG 
animals (n = 25). 
In addition, a high frequency of lymphocytic thyroiditis was observed in 
Tx-X rats. This lesion was characterized by mild to severe infiltration of 
lymphoid cells into the gland, resulting in partial to total loss of follicular 
integrity (Figure 3.6). As shown in Table 3.2, thyroiditis was observed 
with high frequency in chronic and non-diabetic Tx-X rats (63 percent and 
56 percent respectively) but at lower levels in acute diabetic animals (36 
percent). Thyroiditis occurred with an overall incidence of 49 percent, but 
















57 (75) II 
17 (22) II
2 (3) # 
27 (36) 
Hyperglycaemia with insulin-dependence 
t Hyperglycaemia without insulin-dependence
§ Normoglycaemic
II P < 0.001 compared with non-diabetic rats
# P < 0.01 compared with non-diabetic rats


















Figure 3.6. Lymphocytic thyroiditis of a Tx-X rat. Note heavy infiltration of 
mononuclear cells and destruction of thyroid follicles (H&E stain; x250). 
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The incidence of islet lesions within groups of Tx-X rats is shown in Figure 
3.7 (open bars). In some groups (for example, Group 18), 100 percent of 
animals with islet lesions developed acute disease, whereas for other 
groups (for example, Group 10) the proportion was less than 50 percent. 
Overall, incidence of islet lesions in Tx-X rats (whether acute diabetic or 
otherwise) ranged from 17 percent to 75 percent between groups, with an 
overall mean of 47 percent for all Tx-X rats in this study (n = 392). Acute 
diabetes or islet lesions were not detected in normal, unmanipulated PVG 
rats maintained over the same period (n=25). 
In order to determine the selectivity of the pathogenic process within islets 
during the course of the disease, sections of atrophied or infiltrated islets 
were stained by immunofluorescence to demonstrate the presence and 
distribution of a (glucagon-synthesizing) and B (insulin-synthesizing) cell 
types (Figure 3.8). Atrophic islets failed to stain with the insulin antibody, 
indicating that a complete loss of B cells was characteristic of end-stage 
atrophy (Figures 3.8a and e). In contrast, a cells were readily detected in 
atrophic islets and had become the predominant cell type, now in a 
central location (Figures 3.8b and f). In infiltrated islets there was an 
obvious loss of the normal structure, where although both a and B cells 
could still be detected in these islets, the B cells were dispersed 
throughout the islet rather than occupying their usual central location 
(Figures 3.8c and d). This data illustrates that B cells are the primary 
target for immunological destruction in islets of acute diabetic Tx-X rats. 
iii) Onset and Incidence
Onset of the acute diabetic syndrome in Tx-X rats occurred at all stages 
of the 1 O week development period, however a peak period of 
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Figure 3.7. Incidence of islet lesions (open bars) and acute diabetes 
(hatched bars) in sequential groups of Tx-X rats established at monthly 
intervals. Pancreas samples for histology were taken at the end of the 
induction period for non-diabetic animals or at time of disease onset for 
acute diabetic rats and assessed for islet lesions (insulitis or atrophy). 
Hatched bars within open bars indicate the proportion of animals with islet 
lesions that developed acute diabetes for each Tx-X group. 




Figure 3.8. lmmunofluorescent staining of Tx-X rat islets for a (glucagon) 
. and B (insulin) cell types. Sections of pancreas showing islet atrophy or 
insulitis were stained with an antibody to insulin or glucagon, labelled with 
a FITC-conjugated antiserum and photographed under a fluorescent 
microscope (x250 magnification). 
a) Atrophic islet stained for insulin showing complete loss of B cells.





c) Infiltrated islet stained for insulin showing dispersed B cells.





e) Normal islet stained for insulin showing central location of B cells.
f) Normal islet stained for glucagon showing peripheral location of a cells.
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susceptibility was observed at 4 weeks after final irradiation, with onset of 
disease being rare before week 3 or after week 8 (Figure 3.9). The 
incidence of acute diabetes in successive Tx-X groups established at one­
month intervals was previously shown in Figure. 3.5 (shaded bars). 
Although acute diabetes occurred regularly, there were considerable 
variations in incidence levels, ranging from 11 to 62 percent between 
groups. Overall, acute diabetes occurred with a mean incidence of 34 
percent for all Tx-X rats established over this period (392 · rats in 19 
separate groups). 
3.3.2 Factors Affecting Disease Expression 
i) Gender
In both humans and BB rats, diabetes occurs with close to an equal 
frequency in males and females. In contrast, female NOD mice are 
markedly more susceptible to disease. In order to investigate the 
influence of gender on the susceptibility of PVG rats to Tx-X-induced 
IDDM, groups of male and female SPF-derived rats were established. 
Mean levels of acute diabetes were slightly higher in males when 
compared with females, but this difference was not statistically significant 
(Table 3.3). Incidence of islet lesions, however, were significantly raised 
in male animals (P < 0.05). Disease onset was similar in both males and 
females, with all animals becoming diabetic between 10 and 60 days post 
irradiation and onset was at a similar rate in both groups during this period 
(Figure 3.10). 
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Figure 3.9. Incidence of acute diabetes in Tx-X rats following final 
irradiation. 
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n (%) n (%) 
20 (29) 1 (2) 
21 (36) 3 (5) 
41 (33) 4 (3) 
0 ,i 0 
o# 0 
o# 0 
§ Islet atrophy or insulitis in both diabetic and non-diabetic rats
II P < 0.05 compared with SPF female value
il P < 0.005 compared with SPF value
# P < 0.c001 compared with SPF value
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Figure 3.10. Comparison of the cumulative incidence of acute diabetes in 




Environmental factors have long been postulated to play a role in the 
pathogenesis of autoimmune disease in general and diabetes in 
particular, and various microbial agents have been shown to modify the 
course of disease in both BB rats and NOD mice (see section 2.4.3). In 
order to assess the possible influence of environmental factors in the 
pathogenesis of Tx-X-IDDM, disease expression was compared in 
genetically identical rats derived under clean (SPF) or conventional 
hygienic conditions (see Table 3.3). Conventionally-bred rats showed a 
strikingly reduced susceptibility to diabetes induction, with no 
conventionally-derived animals developing diabetes (n=51) compared 
with 41/126 (33 percent) of SPF controls (P <0.001). A significant (but not 
complete) reduction in the incidence of islet lesions was also observed in 
conventional as compared with control SPF animals (P <0.025). 
For thyroid lesions, conventionally-reared female animals remained 
susceptible to thyroiditis, with 9/16 (56 percent) of animals developing 
disease. In contrast, conventionally-reared male animals appeared less 
susceptible, with only 3/17 (18 percent) of rats developing thyroid lesions. 
iii) Genetic
Susceptibility to diabetes is known to have a strong genetic component as 
shown by the familial association of disease, and has been linked to 
various MHC class II genetic markers such as HLA-DR3 and DR4 in 
humans, 1-ANOD in the NOD mouse and RT1 u in the BB rat (see
sections 2.2.5 and 2.4.1 ). To examine the influence of MHC haplotype on 
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Tx-X induced IDDM, RT1 u/c cross-bred animals and a number of inbred 
SPF-derived rat strains of differing RT1 background were examined. 
F1 generation PVG (RT1 C)fWF (RT1 LI) crosses were established primarily 
to examine the influence of RT1 u superimposition on the PVG genetic 
background (Table 3.4). Male crossbred animals showed no significant 
difference in the frequency of diabetes or islet lesions when compared 
with male or female inbred animals, but the frequency of islet lesions was 
raised in this group when compared to female crossbred animals (53 and 
19 percent respectively; P <0.05). Acute diabetes occurred with a 
significantly higher frequency in female crossbred animals than in female 
inbred animals (50 and 29 percent respectively; P < 0.05), however no 
differences were observed between female and male crossbred animals. 
The incidence of islet lesions was lower in female crossbred animals 
when compared to female inbred animals, although this difference was 
not significantly different. When inbred rat strains differing at the RT1 
locus were compared for disease expression, only WAG strain rats 
(RT1 LI) were found to be susceptible to disease induction (Table 3.4). 
An interesting feature of crossbred Tx-X animals was the high variability in 
disease incidence levels between groups, particularly for female animals. 
The disease-onset profiles of three separate groups of crossbred animals 
established over a period of approximately 12 months are shown in Figure 
3.11. The first group established showed an increased susceptibility to 
disease induction in males when compared to females (60 and 40 percent 
respectively) with the majority of animals becoming diabetic before 40 
days post irradiation (Figure 3.11, group1 ). Subsequent groups followed 
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Acute t Chronic§ Lesions 11 
n (%) n (%) n (%) 
20 (29) 1 (2) 24 (35) 
15 (50) ,i 0 3/16 (19) 
1 (17) 0 2 (33) 
21 (36) 3 (5) 30 (52) ,i 
21 (38) 5 (9) 17/32 (53) 
+ 
No disease observed in Lou/m (n=5), SHR (n=6), DA (n=5) or F344 (n=4) strain female Tx-X rats 
maintained over the same period 
t Hyperglycaemia with insulin-dependence 
§ Hyperglycaemia without insulin-dependence
11 Islet atrophy or insulitis in both diabetic and non-diabetic rats 
,i P < 0.05 compared with PVG female value 
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Figure 3.11. Cummulative incidence of acute diabetes in 3 successive 




ranging from O to 100 percent in consecutive groups (Figure 3.11, groups 
2 and 3). 
3.4 DISCUSSION 
The data presented in this chapter demonstrates that a non-obese, 
insulin-dependent diabetic syndrome could be induced in rats not 
normally prone to the spontaneous development of this disease by a 
combination of early-age thymectomy and low-dose gamma irradiation 
(Tx-X), a procedure that modulates immune function. The syndrome was 
characterized by a rapid onset of symptoms including hyperglycaemia, 
ketoacidosis, insulinopaenia (Table 3.1) and diabetic animals were 
observed to suffer from polyphagia, polydipsia and polyuria. These 
observations, in conjunction with the fact that diabetic animals were 
dependent on exogenous insulin therapy for survival, illustrate that the 
clinical features of Tx-X - induced IDDM are analogous to those of human 
insulin-dependent diabetes mellitus. 
Onset of diabetes in Tx-X rats was rapid and accompanied by a 
precipitous weight loss and a concurrent rise in blood glucose levels 
(Figures 3.2 and 3.3) Diabetic rats became intolerant to exogenous 
glucose and were dependent on early insulin treatment for survival 
(Figures 3.3 and 3.4). These features are remarkably similar to those of 
the diabetic syndromes of both humans and BB rats, but differ from the 
NOD mouse where disease onset is characterized by less severe clinical 
features and less dependence on early insulin therapy. 
Tx-X induced IDDM had a rapid disease progression, with the majority of 
diabetic animals developing disease three to four weeks (with some one 
j I 
97 
or two weeks) after final irradiation (Figure 3.9). The observation that the 
number of animals developing diabetes reached a peak at four weeks 
post irradiation suggested that there was a 'window' period of disease 
susceptibility in Tx-X animals, after which time a relative resistance to 
diabetes onset developed. Whether this resistance to disease arose as a 
consequence of restored immunoregulation is not clear, however previous 
studies have shown that reconstitution of Tx-X rats with lymphoid cells 
taken from 11post-window 11 Tx-X donors does not restore regulatory 
capacity, suggesting that this is not the case (Ansar Ahmed et al., 1985). 
In contrast to the apparent rapid onset of Tx-X induced IDDM, the diabetic 
syndromes of both human and spontaneous animal models appear to 
have as a common feature an extended prediabetic period during which 
signs of autoimmune activity can be detected. In the Tx-X context, this 
infers that either an extended pre-disease phase was initiated early in the 
irradiation schedule or that the disease process in Tx-X PVG rats was 
more rapid and of a more severe nature, being initiated soon after final 
irradiation. In support of the latter hypothesis was the observation that 
autoantibodies to thyroid antigens in Tx-X rats are not detectable until 
after the final irradiation. 
Another feature common to the Tx-X-induced, human and BB rat IDDM 
syndromes is the close to equal incidence levels of disease in males and 
females. In Tx-X rats, the incidence of acute disease was slightly 
elevated in males (36 percent in males compared with 29 percent in 
females), but this was not statistically significant (Table 3.3). The 
frequency of islet lesions, however, was significantly raised in males 
(P < 0.05). Overall, the frequency of acute diabetes in females was 34 
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to 36 percent in males, suggesting that the influence of gender on IDDM 
inducement is minimal in Tx-X rats. In addition, comparison of the 
disease-onset profiles of male and female rats indicated a similar timing 
for disease initiation and a similar rate of disease onset (Figure 3.10). This 
is in contrast to the NOD mouse, where onset of disease is earlier and 
incidence levels are higher in females (see section 2.3.1 (ii)). 
Interestingly, for thyroiditis induction by Tx-X, females are markedly more 
susceptible, and in this case strong evidence has been presented 
indicating that steroid hormones can influence thyroiditis expression 
(Ansar Ahmed and Penhale, 1982; Ansar Ahmed et al., 1983). 
The influence of genetic differences at the MHC on the level of Tx-X 
induced IDDM was also investigated. Only WAG inbred rats of RT1 u
haplotype were found to be susceptible to Tx-X induced IDDM when 
compared to other rat strains, but only with a low frequency (Table 3.4). 
Interestingly, the RT1 u haplotype has been found to be essential for IDDM 
development in BB rats (see section 2.4.1 ). When this haplotype was 
introduced onto the PVG genetic background by crossbreeding with an 
RT1 u (WF) strain, however, a highly variable pattern of incidence levels 
was observed between individual groups of animals and also between 
male and female animals (Figure 3.11 ). The majority of this variability 
was confined to female RT1 c/u hybrid animals, in which disease incidence 
ranged from O to 100 percent in sequential groups compared to a less 
dramatic range of 40 to 60 percent in males. This high degree of 
variability must have been largely genetically determined, and suggests 
that the WF strain used for crossbreeding may not have been fully inbred 
and thus not homozygous at the MHC for RT1 u. These observations 




induction by the Tx-X procedure, but has the potential to confer enhanced 
disease susceptibility when introduced onto the PVG background. 
The ability of RT1 u to enhance the susceptibility of PVG rats to Tx-X 
induced diabetes has been clearly demonstrated by the recent studies of 
Fowell and Mason, who utilized the Tx-X protocol to induce IDDM in 
PVG.RT1 u congenic rats (Fowell et al., 1991; Fowell and Mason, 1993). 
One hundred percent of male rats and 70 percent of females developed 
disease, suggesting that introduction of RT1 u onto the PVG genetic 
background does act to enhance Tx-X-induced diabetes expression. 
Together, this data clearly indicates a multigenic influence on disease 
susceptibility involving genes both within and outside the MHC. 
The most common histopathological lesion of diabetic Tx-X rats was islet 
atrophy, where islets showed a reduction in cell number and size, while 
focal atrophy or insulitis were more common in less severely affected or 
clinically normal animals (Figure 3.5 and Table 3.2). lmmunofluorescent 
staining of the various islet lesion types demonstrated that the loss of cell 
numbers in atrophic islets was due to a specific destruction of B cells, 
and therefore characteristic of the end-stage atrophy seen in other IDDM 
syndromes. B cells were still demonstrable in infiltrated islets and other 
studies have shown that this infiltrate is composed of both CD4 + and 
coa+ T cells, macrophages, dendritic cells and NK cells (Fowell et al., 
1991 ). This suggests a dynamic disease process where lymphocytes 
invade the islet and then, once B cell destruction is complete, migrate 
rapidly from the lesion site, which manifests clinically as an acute 
syndrome. In addition however, the observations that 1) a "chronic" 
disease process was observed in some animals, where islet lesions and 
blood glucose changes could be detected but animals did not become 
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insulin-dependent, and 2) a large proportion of clinically normal animals 
had insulitis at necropsy, suggest that an additional trigger is required to 
make the transition from the initiation of islet attack to the complete 
destruction of B cells and development of the insulin-dependent 
syndrome. 
The association of Tx-X induced IDDM with lymphocytic thyroiditis 
provides further evidence that the diabetes was immune mediated and not 
the result of irradiation-induced damage per se (Figure 3.7). Thyroiditis is 
also a common feature of other animal models of IDDM, however the 
observations that 1) the peak onset time of the two conditions did not 
coincide; 2) that thyroiditis and IDDM were not always associated in the 
individual animal and 3) incidence levels of diabetes and thyroiditis 
differed, suggested that separate and specific initiating signals are 
involved in the pathogenesis of the two syndromes. 
An interesting feature of Tx-X induced IDDM was the high variability in 
incidence levels of disease seen between successive groups of 
genetically identical inbred animals maintained under similar conditions, 
and the fact that these incidence levels never reached 100 percent 
(Figure 3.5). This implies that non-genetically determined factor(s) 
influence the onset of disease in these animals. As none of the common 
viral pathogens could be detected (see section 3.2.7) it was hypothesized 
that flora of the gastrointestinal tract could be the source of this 
environmentally-determined factor. This inference was given support by 
previous studies demonstrating that the level of thyroiditis in SPF rats 
could be increased by the oral administration of fresh gastrointestinal 
contents from conventionally-derived rats (Penhale and Young, 1988). To 
test this hypothesis, the ability to induce disease in genetically identical 
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PVG rats derived under either clean (SPF) or non-barrier maintained 
conditions was compared. Surprisingly, conventionally-derived rats 
showed a striking resistance to disease induction compared with rats of 
SPF origin. Since these rats were of identical genotype, this suggests 
that in this case an environmentally-derived (gastrointestinal?) factor was 
encouraging a protective (suppressive?) immune response. It would thus 
be of interest to examine the cytokine profiles of T cells from' these 
protected animals for enhanced production of so-called •suppressive• 
cytokines. Administration of IL-4, for example, has been shown to prevent 
the onset of diabetes in NOD mice (Rapoport et al., 1993), while certain 
infectious agents have been shown to induce an IL-4 response by CD4+ 
T cells (Rocken et al., 1992). 
In a previous study, administration of intestinal contents from conventional 
rats to SPF animals markedly increased the susceptibility of these 
1
1conventionalized 11 SPF animals to thyroiditis inducement by Tx-X 
(Penhale and Young, 1988). In addition, these workers also observed a 
100 percent incidence of thyroiditis in conventional female PVG Tx-X 
animals, a level not observed in the present study. This data suggests 
that in the case of thyroiditis induced by this procedure, the environment 
can act to trigger disease onset, perhaps through the increased 
availability of cross-reactive autoantigenic epitopes. 
Taken together these results suggest that environmental factors can act 
either to enhance or suppress the onset of autoimmunity depending on 
the nature of the disease and/or the environmental factor. In addition, that 
the incidence of thyroiditis can be enhanced by increased environmental 
exposure, while diabetes onset is suppressed, suggests that different 
triggering mechanisms may be operating for the two diseases. This 
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dichotomy of environmental influence on the course of autoimmune 
disease induction within the same experimental system provides a unique 
opportunity to analyze the complex role of environmental factors in the 
pathogenesis of autoimmune disease. 
In conclusion, the diabetic syndrome observed in Tx-X rats is similar to 
human IDDM both clinically and pathologically. This syndrome also 
closely parallels that of the spontaneous syndromes observed in the BB 
rat and NOD mouse, although differs from the latter in some respects. 
Disease induction by the Tx-X procedure is strain related and can be 
modified by, but is not dependent upon, the presence of the diabetes­
determining RT1 u MHC haplotype of BB rats. Furthermore, disease 
susceptibility is also highly influenced by the environmental background of 
the animal, implicating a strong role for environmentally-derived factors in 
the pathogenesis of the disease. Finally, the suitability of this model for 
genetic studies, and the ability to manipulate it either towards disease 
induction or inhibition should provide further scope for detailed study of 
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4.1 INTRODUCTION 
The disruption of immunological tolerance to self components that occurs 
in autoimmune disease is characterized by the generation of both antibody 
and cellular immunoreactivity towards self antigens. In organ-specific 
autoimmune disease, an early sign of autoreactivity is often the generation 
of autoantibodies directed towards components of the target organ, such 
as ICA in human IDDM (see section 2.2.4 (i)). In addition, autoantibodies 
can be detected to target tissues in the early stages of other organ­
specific autoimmune diseases such as the thyroid in thyroiditis, gastric 
parietal cells in autoimmune gastritis and liver mitochondrial components 
in primary biliary cirrhosis (Roitt et al., 1964; Masala et al., 1980; Frazer et 
al., 1985). 
The role of antibody in the pathogenesis of autoimmune disease, 
however, has been difficult to establish primarily as a result of the inability 
to define target autoantigens. While it is possible that autoantibodies 
themselves may be pathogenic, it is more likely that their presence 
indicates a disruption of immunological tolerance to a tissue component to 
which a cellular immune response is generated. The detection of 
autoantibodies and the identification of the target autoantigens concerned 
is thus essential for the identification of potential cellular targets and for 
the development of specific prophylaxis or therapy for these diseases. 
Recently, examination of autoantibody specificities generated in a variety 
of autoimmune conditions has identified a number of putative 
autoantigens. These include thyroglobulin and thyroid peroxidase in 
autoimmune thyroiditis, the acetyl choline receptor in myasthenia gravis 
and myelin basic protein in multiple sclerosis. In addition, a number of 
i !_ 
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these molecules have been identified as enzymes involved in cellular 
processes of the target organ, for example thyroid peroxidase (an enzyme 
involved in thyroglobulin processing) in autoimmune thyroid disease, the 
H+K+ ATPase (gastric proton pump) in autoimmune gastritis, the pyruvate 
dehydrogenase complex in primary biliary cirrhosis and glutamic acid 
decarboxylase (GAD) in IDDM (Banga and McGregor, 1991 ). Although 
shown in vitro to inhibit enzyme activity and also in vivo in some cases, 
these autoantibodies generally cannot transfer disease to unaffected 
recipients and their role in the pathogenesis of autoimmune disease has 
not yet been established. 
Several approaches are available for the detection and analysis of 
antibody specificities in autoimmune disease. The classical approach has 
been to analyze antibody binding to whole tissue sections of the target 
organ, usually visualized by immunofluorescent staining. A good example 
of this approach was the detection of autoantibodies to islet cells (ICA) in 
, IDDM as described in section 2.2.4(i) and other examples include the 
detection of anti-microsomal antibodies in autoimmune thyroid diseases 
(Khoury et al., 1984; Banga et al., 1986), primary biliary cirrhosis (Frazer 
et al., 1985) and other autoimmune disorders (Betterle et al., 1985), and 
the demonstration of parietal cell antibodies in autoimmune gastritis 
(Masala et al., 1980). lmmunofluorescence allows the visual localization 
-...,\ of antibody binding within the tissue, but suffers from a lack of sensitivity 
,, 
\
d reproducibility and has limited use as a quantitative assay. 
\ 
Th� enzyme-linked immunosorbent assay (ELISA) is a variation on the 
im�unofluorescent approach that utilizes an enzyme-linked secondary 
anti�'rrum in conjunction with a coloured enzyme substrate to detect 
antibd�y bound to antigen immobilized on a solid matrix. The ELISA 
[ I 
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system is widely used as a quantitative assay and has been used to 
determine antibody levels to mitochondrial (Surh et al., 1988; Zurgil et al., 
1989), gastric parietal cell (Chuang et al., 1992) and thyroid autoantigens 
(Chan et al., 1987; Koh no et al., 1988) and pancreatic components 
(Moncayo et al., 1988). This technique is more sensitive than 
immunofluorescence and is quantitative, but requires purified antigens in 
order to determine sub-cellular antibody specificity. 
Although the above described assays provide information on the tissue or 
cellular specificity of autoantibody binding, they do not allow sub-cellular 
identification of multiple autoantigens. lmmunoblotting is a technique that 
utilizes the separation of intracellular components by sodium dodecyl 
sulphate - polyacrylamide gel electrophoresis (SOS-PAGE) combined with 
the electro-transfer of the denatured proteins to a solid-phase for 
subsequent detection by antibody (Laemmli, 1970; Towbin et al., 1979). 
This technique has allowed the analysis of antibody specificity at the sub­
cellular level in a number of autoimmune diseases including thyroiditis 
(Banga et al., 1984; Hamada et al., 1987), primary biliary cirrhosis 
(Fusconi et al., 1992) and to a limited extent in IDDM (Karounos et al., 
1990). 
While immunoblotting has had many useful applications in the study of 
antibody specificity generated in autoimmune diseases, the denaturation 
of proteins before reaction with antibody often produces a heterogeneous 
pattern of antibody specificities that can be difficult to interpret. This was 
well illustrated by the inconclusive immunoblotting results seen with IDDM 
sera when islet cell extracts were used as antigen (Karounos et al., 1990; 
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that recognize conformational epitopes on a protein antigen will not be 
detected under the denaturing conditions of this technique. 
lmmunoprecipitation is an alternative to immunoblotting that maintains the 
integrity of the native antigen and allows detection of antibodies that 
recognize conformational epitopes. In this procedure, intracellular 
proteins are metabolically labelled with a radioactive isotope, then 
immunoprecipitated from the cellular extract by specific antibody, 
harvested and analysed by SOS-PAGE and autoradiography. A good 
example of the value of this technique was described in section 2.2.4(i) for 
the identification of the 64kDa islet cell protein in IDDM, and the technique 
has also been used to analyze antibody specificities to autoantigens in 
other autoimmune diseases such as thyroid microsomal antigens in 
thyroiditis (Kajita et al., 1985; Maastricht et al., 1992). 
This chapter describes the use of the above techniques to analyze 
autoantibody specificities to islet and other tissues generated by the Tx-X
procedure. The relationship of these autoantibody specificities to those 
generated in human IDDM and other animal models of diabetes is 
discussed. 
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4.2 MATERIALS AND METHODS 
4.2.1 lmmunofluorescent Assays 
i) Detection of Islet Cell Antibodies
Islet cell antibodies (ICA) were initially detected by immunofluorescent 
assays performed on sections of protease treated, formalin-fixed canine 
tissue. Later assays were performed on cryostat-sections of human Type 
0 pancreatic material in conjunction with the Department of Internal 
Medicine, University Hospital, Uppsala, Sweden. Tissue sections were 
overlayed with diabetic or normal rat serum diluted 1 :50 in phosphate 
buffered saline (PBS - see section 5.2.1) containing 1 percent aprotinin 
(Boehringer Mannheim GmbH, Mannheim, Germany) and 1 0mM 
benzamidine-HCI (Sigma Chemicals, Mo, USA) and incubated overnight 
at 4°C. The sections were then washed 3 times in PBS and overlayed 
with a 1 :40 dilution of anti-rat lgG-FITC (Dakopatts, Denmark). After 2 
hours at room temperature the sections were washed, mounted and 
viewed under a fluorescent microscope (Olympus, Japan). 
ii) Detection of Thyroid Autoantibodies
Autoantibodies to thyroid components were detected by 
immunofluorescence in a similar manner to ICA using protease-digested, 
formalin-fixed sections of normal rat thyroid. Tx-X rat serum samples 
were diluted 1 :50 in PBS and incubated on tissue sections overnight and 
then overlayed with anti-rat lgG-FITC (Silenus, Melbourne, Australia) as 
described above . 
i 1. 
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4.2.2 Enzyme-linked lmmunosorbent Assay (ELISA) 
i) Preparation of Antigens
Insulin 
To detect autoantibodies to insulin (IAA), a commercial preparation of 
porcine insulin (CSL Novo, Melbourne, Australia) was diluted to 1 µg/ml in 
ELISA coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6). 
Rat Pancreas Extract 
Pancreatic autoantibodies (PAA) were detected according to the method 
of Moncayo et al., 1988. Briefly, adult normal rat pancreata were minced 
in ice-cold 20mM Tris-HCI (pH 7.4), homogenized in a glass homogenizer 
and filtered through one-ply of gauze. The filtrate was then centrifuged at 
8000xg tor 30min at 4° C (Sorvall®, DuPont, USA) and then 
ultracentrifuged at 80000xg tor 30min (Beckman, USA). Protein 
concentration was determined by the Bradford assay (Bio-Rad, CA, USA) 
and preparations were adjusted to 5µg / ml in ELISA coating buffer . 
Rat Thyroglobulin 
Four grams of rat thyroids were placed in 1 0 ml of ice-cold borate buffer 
(12.SmM Na2B4O7, 150mM NaCl, pH 7.4) and homogenized in a Polytron 
PCU-2 tissue homogenizer (Kinematica, Luzern, Switzerland) on ice until 
all tissue had been disrupted. After standing on ice for 30 minutes, the 
thyroid extract (TgE) was filtered through cotton wool, centrifuged at 
21 000xg tor 30 minutes at 4°C and the supernatant stored at -80°C. To 
prepare purified rat thyroglobulin (rTg}, 1 to 2ml of TgE was loaded onto a 
K26/100 sephacryl S-300 molecular-weight exclusion chromatography 
column (Pharmacia, Uppsala, Sweden) and run overnight at 4°C. 
I I_ 
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Fractions representing the major peak were collected, concentrated in a 
Centriprep® microconcentrator (Amicon, MA, USA) and adjusted to 
25µg/ml in ELISA coating buffer. 
ii} ELISA Protocol
Antigen preparations diluted in coating buffer were used to sensitize 96-
well microtitre plates (Disposable Products, Adelaide, Australia). One 
hundred µI of each antigen solution was added per well and incubated at 
4°C for 24 hours in the case of whole pancreas and purified rTg, or for 48 
hours in the case of the porcine insulin preparation. 
After sensitization, plates were washed 3 times with an 0.05 percent 
solution of Tween-20 (Boehringer Mannheim GmbH, Mannheim, 
Germany) in PBS (PSST) and non-specific binding sites blocked using 
PBS containing 0.5 percent Tween-20 for 1 hour at room temperature. 
One hundred µI per well of rat serum diluted 1 :50 in PSST was then 
incubated overnight at 4°C, followed by an anti-rat lgG-alkaline 
phosphatase conjugated antiserum (Bio-Rad, CA, USA) diluted 1 :5000 in 
PSST and incubated for 2 hours at room temperature. Bound antibodies 
were detected colorimetrically using a 1 mg/ml solution of the alkaline 
phosphatase substrate 4-nitrophenol phosphate (4-NPP; Boehringer 
Mannheim GmbH, Mannheim, Germany) diluted in substrate buffer (1 O 
percent v/v diethanolamine, 0.05mM MgCl2, pH9.8). After 15 to 30 
minutes at room temperature optical density was determined at 405nm 
(Titertek Multiskan®; Flow Laboratories, Helsinki, Finland). 
i !_ 
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4.2.3 lmmunoprecipitation Assay 
i) Preparation of Rat Islets
Pancreatic islets were isolated from 200 to 250 gram male PVG rats by a 
modification of the collagenase digestion technique (Wollheim et al., 
1990). Animals were killed, bled by cardiac puncture and the common bile 
duct exposed and clamped at the entry point to the duodenum. The duct 
was then cannulated toward the hilus of the liver and 5ml of a 1 mg/ml 
solution of collagenase Type V (Sigma Chemicals, MO, USA) dissolved in 
Hank's Balanced Salt Solution containing HEPES (HBSS-HEPES - see 
section 5.2.1) was injected slowly until the pancreas was fully distended. 
The tissue was then removed to a siliconized and sterile container, 
incubated for 12 minutes at 37°C, resuspended in ice-cold HBSS-HEPES 
and disrupted by vigorous shaking for 10 seconds. After washing 2 times 
in ice-cold HBSS-HEPES containing 0.35 percent bovine serum albumin 
(HBSS-HEPES/BSA) by spinning briefly at 2000 rpm and vigorously 
resuspending through a constricted pipette tip, tissue pieces were filtered 
through nylon mesh (pore size approximately 0.5mm2) and washed again 
in HBSS-HEPES / BSA. The final washed pellet was then resuspended to 
a volume of 10ml per pancreas in Ficoll-Paque (Pharmacia LKB, Uppsala, 
Sweden), carefully overlayed with an equal volume of HBSS-HEPES/BSA 
warmed to room temperature and centrifuged at 900xg for 20 minutes at 
1 a0c. Purified islets were collected from the interface, washed a further 3 
times in HBSS-HEPES/BSA using a sterile, siliconized centrifuge tube and 
then resuspended in complete RPMI (see section 5.2.1 ). The islets were 
then hand-picked twice under a stereo-microscope. 
>1
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ii) 35s-methionine Labelling of Islets and lmmunoprecipitation of
Islet Cell Proteins
Purified islets were resuspended to 1000 in 2ml of complete RPMI and 
allowed to recover overnight at 37°C in 5 percent CO2. The islets were 
then washed once in methionine-free RPMI (Gibco BAL, MD, USA) then 
resuspended to 500 islets in 2ml of labelling medium (methionine-free 
RPMI containing 20mM HEPES, 0.2 percent BSA, 16.7mM D-glucose, 
2mM glutamine, 0.04 percent NaHCO3 and 0.05mM 2-ME, pH7.4) and 
incubated for 30 minutes prior to adding 0.5 mCi of 35S-methionine 
(Amersham Int., Amersham, UK) per 500 islets. After incubating for 7 
hours at 37°C in 5 percent CO2, labelled islets were then washed twice in 
HBSS-HEPES containing 0.2 percent BSA and 0.01 percent D-L 
methionine and once in 150mM NaCl, 1 0mM HEPES, 0.01 percent D-L 
methionine, 1 0mM benzamidine-HCI (pH 7.4), then resuspended to 250 
islets per 100µ1 of ice-cold extraction buffer (150mM NaCl, 20mM Tris-HCI 
pH7.4), 2 percent v/v Triton X-100 [Boehringer Mannheim GmbH, 
Mannheim, Germany], 0.5 percent aprotinin, 1 0mM benzamidine HCI, 
0.1 mM p-chloromercuribenzenesulphonic acid). The islets were then 
disrupted on ice using a glass homogenizer, extracted for a further 2 hours 
on ice and centrifuged at 1 0 000xg for 30 minutes at 4°C in a refrigerated 
microfuge ( International Equipment Company, MA, USA). The 
supernatant was collected, divided into 100µ1 aliquots and stored at -so0c.
To immunoprecipitate islet cell proteins, aliquots of labelled islet extract 
were thawed on ice and pre-cleared by adding 25µ1 of normal rat or 
human serum and incubating overnight at 4°C. Immune complexes were 
then removed on protein-G Sepharose (PGS (Pharmacia, Uppsala, 
Sweden) by incubating for 1 hour at 4°C and then microcentrifuging for 30 
l I_ 
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seconds at maximum speed (Clements, Sydney, Australia). Twenty five µI 
of test rat or human serum was added to the supernatant and incubated 
overnight at 4°C. Immune complexes were recovered on PGS for 2 hours 
at 4°C followed by micro-centrifugation, and the PGS pellet washed in 6 
changes of 150mM NaCl, 20mM Tris-HCI (pH7.4), 0.05mM 2-ME, 
1 percent v/v Triton X-100). 
iii) SDS-PAGE and Autoradiography
lmmunoprecipitated proteins were visualized by sodium dodecyl sulphate­
polyacrylam ide gel electrophoresis (SOS-PAGE) followed by 
autoradiography. Proteins bound to the final washed PGS pellet were 
solubilized in sample buffer (0.5mM Tris-HCI [pH6.8], 2 percent SOS, 10 
percent glycerol, 5 percent 2-ME, 0.001 percent bromophenol blue) by 
resuspending the pellet in 50µ1 and boiling for 3 minutes. The samples 
were then quickly centrifuged and loaded onto 16cm x 15cm x 0. 75mm 
SOS-polyacrylamide slab gels (Protean II electrophoresis system - Bio­
Rad, CA, USA) consisting of a 10 percent acrylamide resolving gel in 
1.5mM Tris-HCI (pH 8.8) and a 4 percent acrylamide stacking gel in 
0.5mM Tris-HCI (pH 6.8). Electrophoresis was at 40mA constant current 
for 3.5 hours using the buffer system of Laemmli (Laemmli, 1970). 
Commercial molecular weight standards were run on each gel (Sigma 
Chemicals, MO, USA). Following electrophoresis, gels were stained for 1 
hour in 0.2 percent Coomassie Blue (Koch-Light, Suffolk, UK) and fixed 
overnight in destainer (2 percent v/v glacial acetic acid, 30 percent v/v 
methanol). 
Oestained gels were processed for fluorography by soaking in Amplify 
(Amersham Int., Amersham, UK) for 30 minutes followed by drying at 
i !_ -
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70°C for 3 hours in a slab-gel dryer (Bio-Rad, CA, USA). The dried gel 
was then loaded into an autoradiography cassette with intensifying 
screens (Amersham Int., Amersham, UK) and exposed to Kodak X-Omat 
AR X-ray film at -ao0c for 2 to 4 weeks. 
4.2.4 lmmunoblotting 
To determine the binding specificities of anti-islet cell antibodies, islet cell 
proteins were subjected to SOS-PAGE and immunoblotting. SOS-PAGE 
conditions were as described in 4.2.3. Purified rat islets were 
resuspended to a concentration of 2x103 / ml in sample buffer and boiled
for 5 minutes. Islet extract was then loaded onto preparative SOS-PAGE 
gels consisting of a 15 percent resolving gel and 4 percent stacking gel. 
600µ1 of sample was loaded for 16cm x 15cm x 0.75mm gels, and 200µ1 
for 10cm x 6cm x 0.5mm gels (mini-Protean II system - Bio-Rad, CA, 
USA). Molecular weight standards (Sigma Chemicals, MO, USA) were 
also included. 
Following electrophoresis, separated proteins were transferred to 
nitrocellulose membrane (Hybond C - Amersham Int., Amersham, UK) 
using the Transblot or mini-Transblot transfer systems (Bio-Rad, CA, 
USA) and transfer buffer (25mM Tris-HCI, 192mM glycine, 20 percent v/v 
methanol, pH 8.3). Transfer chambers were cooled to 4°C and transfer 
conditions were 100 volts constant for 1 hour using the mini-Transblot 
system or 30 volts constant overnight for the Transblot system. After 
transfer, nitrocellulose membranes were either cut into strips or left intact, 
blocked in 3 percent BSA in PBS for 30 minutes at room temperature and 
washed three times in PBST. In some cases nitrocellulose membranes 
were stained for total protein using amido black stain (Bio-Rad, CA, USA) . 
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For large-scale screening of serum samples, intact nitrocellulose 
membranes were loaded on a Miniblotter® screening chamber 
(lmmunetics, MA, USA) and test or control rat sera diluted 1 :50 in PBST 
loaded into each lane. In some cases individual nitrocellulose strips were 
incubated with larger volumes (2ml) of diluted sera. Membranes were 
incubated overnight at 4°C, washed and then incubated with an anti-rat 
lgG - horseradish peroxidase conjugated antiserum (BioRad, CA, USA) 
diluted 1 :3000 for 1 hour at room temperature. Bound antibodies were 
then detected by the Enhanced Chemiluminescent (EGL) system 
(Amersham Int, Amersham, UK) using Fuji RXO-G X-ray film and 30 
second to 2 minute exposures. 
4.3 RESULTS 
4.3.1 Detection of Autoantibodies by lmmunofluorescence 
i) Islet Cell Antibodies (ICA)
Typical immunofluorescent staining patterns for diabetic sera on islet 
sections are shown in Figure 4.1. Initially, to avoid high background 
staining seen with rat pancreas, canine pancreas sections were used as 
substrate. ICA were detected under these conditions in 4/16 (25 percent) 
of plasma samples taken from acute diabetic rats (Figure 4.1 a). These 
antibodies had a range of titres from 2 to 16, indicating that they were 
present in low concentrations. Antibody staining was seen across the 
whole islet, showing no specificity for B cells (whole-islet staining). ICA 





Figure 4.1. lmmunofluorescent staining of islets. Formalin-fixed canine or 
frozen human islet sections were incubated with sera from diabetic rats 
taken at time of disease onset, then overlayed with an anti-rat lgG-FITC 
conjugate and photographed under a fluorescent microscope. 
a) Canine islet (x400}.
b) Human islet (x250).
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ICA were also detected with low frequency in diabetic sera using human 
islet tissue as substrate. For the 100 serum samples screened, 8 were 
consistently positive, and all gave a 'granular' staining pattern that 
appeared to be B cell selective (Figure 4.1 b) ICA were not detected 
under these conditions in clinically unaffected Tx-X or normal PVG rats 
(n=20). 
ii) Thyroid Autoantibodies
Autoantibodies to thyroid components were detected by 
immunofluorescent staining of rat thyroid sections in a significant 
proportion of Tx-X rats (Figure 4.2). Strong reactivity was detected 
towards both thyroglobulin and microsomal components. This type of 
antibody was detected in 100 percent of serum samples from rats showing 
thyroid lesions at necropsy (n=36) and 64 percent of samples from Tx-X 
rats with normal thyroids at necropsy (n=34). In general, the intensity of 
fluorescence correlated with the severity of the thyroid lesion. 
4.3.2 Detection of Autoantibodies by ELISA 
i) Pancreatic Autoantibodies
In an attempt to develop an assay system for the rapid detection of 
autoantibodies to pancreatic components, whole pancreas extract was 
used as antigen in an ELISA system. Autoantibodies to pancreas extract 
· were detected at levels significantly greater (optical density of >2 S.D.)
than those of normal animals in 3 of 3 acute diabetic plasma samples
taken at onset of disease and in 8/27 (30 percent) of non-diabetic terminal
plasma samples representing animals from a single Tx-X group.
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Figure 4.2. lmmunofluorescent staining of rat thyroid section with serum 
from a thyroiditic Tx-X rat showing antibody binding to microsomal 
components (x 250). 
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3/8 (38 percent) of animals that were positive had pancreatic lesions at 
necropsy as compared to 4/19 (21 percent) of animals that were negative 
for this type of antibody (Table 4.1 ). 
ii) Insulin Autoantibodies (IAA)
IAA were detected in 5/26 (19 percent) of acute diabetic animals and in 
5/29 (17 percent) of� clinically non-diabetic Tx-X rats that developed islet 
lesions (Table 4.1 ). The incidence of IAA was significantly raised when 
compared with Tx-X rats with normal islet histology (0/36; P <0.001 ). 
iii) Thyroglobulin Autoantibodies (TgAA)
TgAA were detected in a high proportion of both acute diabetic and 
clinically unaffected Tx-X rats (Table 4.1 ). 30 percent (12/40) of acute 
diabetic animals and 48/107 (45 percent) of non-acute diabetic Tx-X 
animals examined during this study had significantly raised TgAA levels. 
Of the latter group, TgAA were detected in 8/24 (33 percent) of Tx-X rats 
with islet lesions at necropsy and 40/83 (48 percent) of Tx-X rats with 
normal pancreas histology. Generally, raised TgAA levels correlated well 
with the presence of thyroid lesions in the individual animal, with 7/12 (58 
percent) of TgAA positive acute diabetic animals and 41/48 (85 percent) of 
TgAA positive non-diabetic Tx-X animals showing signs of mild to severe 
thyroid infiltration. 
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Table 4.1. Incidence of autoantibodies to pancreas extract, 































* Positive value calculated as an O.D.405 reading of 2 SD or greater
than mean value for normal PVG controls (n > 10). 
t P<0.001 compared with Tx-X rats with islet lesions and acute diabetic
rats. 
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4.3.3 lmmunoblotting Assays 
Using the high sensitivity of the chemiluminescent reaction, 
immunoblotting of diabetic sera against islet proteins revealed antibody 
specificities to a number of protein bands. Initial experiments revealed 
reasonably strong antibody reactivity in diabetic sera reacting to islet 
proteins with a range of molecular weights (Figure 4.3 - lanes 1 to 12), 
with some weaker reactivity observed in normal sera (Figure 4.3 - lanes 
13 to 16). Protein bands recognized by diabetic sera ranged in molecular 
weight from 19 to 52kDa, with the strongest reacting bands at 19kDa 
(Figure 4.3 - lane 1) and 33kDa (Figure 4.3 - lanes 4 and 10). It was not 
possible, however, to identify antibody reactivity to a single disease­
associated protein band in diabetic sera. 
A similar pattern was seen when a larger group of diabetic and normal 
sera were screened on a different occasion using a different islet extract 
(Figure 4.4). Although in this experiment a greater degree of reactivity in 
normal serum was observed (lanes 21 to 36), this was generally weaker 
and directed towards bands other than those recognized by diabetic sera 
(lanes 1 to 20). Strong reactions were again observed to the 33kDa band 
in a number of sera (lanes 1, 5, 10, 17, 19) and also to some higher 
molecular weight bands of 76 and 114kDa (lanes 10 and 12 respectively). 
Again however, no single disease-associated band could be identified. 
Serial dilution of diabetic sera showed that antibody titres to these bands 
. ranged from 100 for the 33kDa band, to approximately 400 for the 19kDa 
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Figure 4.3. lmmunoblotting of diabetic and normal rat sera against islet­
cell extract. Rat islet extract was resolved by SOS-PAGE, transferred to 
nitrocellulose membrane then incubated with acute diabetic (1-12) or 
normal PVG (13-16) rat sera. Bound antibodies were detected by an anti­












Figure 4.4. lmmunoblotting of acute diabetic (lanes 1-20) and normal 
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Figure 4.5. Antibody titres of sera from diabetic rats reactive with islet cell 
extract by immunoblotting. Serum samples previously identified as 
reacting with different rat islet cell proteins by immunoblotting were serially 
diluted and re-examined by immunoblotting against rat islet extract. 
124 
In addition, serum samples from non-acute diabetic Tx-X rats were also 
screened for islet reactivity. Rats were divided into two groups on the 
basis of the presence or absence of islet lesions at necropsy, and 
screened by immunoblotting against rat islet extract (Figure 4.6). 
Although some sera did react strongly in both groups to one or more 
protein bands, overall reactivity was reduced in these sera and there was 
no difference between serum samples from rats with islet lesions 
compared to those with normal islet histology . 
The frequency of antibodies to the various islet cell protein bands in 
diabetic and Tx-X sera is summarized in Table 4.2. The most frequently 
detected band was at 33kDa, being recognized by 8/32 (25 percent) of 
acute diabetic serum samples and 2/20 (1 O percent) of samples from non­
acute diabetic Tx-X rats with islet lesions at necropsy. Overall, positive 
reactions to at least one islet protein band was observed in 24/32 (75 
percent) of diabetic serum samples compared to 6/20 (30 percent) of Tx-X 
rats with islet lesions and 3/20 (15 percent) of Tx-X rats with no islet 
lesions. 
To examine the tissue specificity of islet-reactive antibodies, 
immunoblotting was performed using liver, kidney, lymph node, testis, 
salivary and adrenal gland extracts (Figure 4.7a). Diabetic sera reacting 
with islet proteins reacted only with liver extract, where weak reactions 
were observed to the 114 and 76kDa bands, and with lymph node extract, 
where unique bands at approximately 30 and 28 kDa were observed 
. (Figure 4.7b) 
Tissue specificity was also confirmed by adsorption experiments, where 
islet-reactive sera were adsorbed against nitrocellulose membranes 
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Figure 4.6. _ lmmunoblotting analysis of non-acute diabetic Tx-X rat sera 
against islet cell extract. Sera were selected from rats that had developed 
islet lesions, or from those with a normal pancreas histology, at the end of 
the induction period without signs of hyperglycaemia. 
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Table 4.2. Frequency of reactivity to islet cell protein bands in serum 
samples from Tx-X rats by immunoblotting. 
Protein Acute Tx-X with Tx-X without Normal PVG 
Band Diabetic Islet Lesions Islet Lesions (non-Tx-X) 
(kDa) n (%) n (%) n (%) n (%) 
n 32 20 20 20 
114 3 (9) 1 (5) 1 (5) 0 
76 2 (6) 1 (5) 0 0 
52 4 (12) 1 (5) 1 (5) 1 (5) 
49 3 (9) 0 1 (5) 0 
33 8 (25) 2 (10) 0 4 (20) * 
30 ·2 (6) 0 0 1 (5) 
19 2 (6) 1 (5) 0 1 (5) * 
Total 24 (75) 6 (30) 3 (15) 7 (35) 
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Figure 4.7. Tissue specificity of islet-cell reactive diabetic sera. 
a) Amide Black stain of tissue extracts resolved by SOS-PAGE and
transferre.d to nitrocellulose membrane. (Is - islet; LN - lymph node; Li -
liver; Ki - kidney; Te - testis; Ad - adrenal gland; Sal - salivary gland) 
b) Serum samples previously shown to react with islet cell extract by
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c) Islet-cell reactive diabetic sera (1-5) were pre-adsorbed against
nitrocellulose-bound extracts of liver, kidney and lymph node, then 
immunoblotted against rat islet cell extract. 
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sensitized with SOS-PAGE resolved liver, kidney or lymph node extracts. 
Repeated adsorption of these sera against the sensitized membranes did 
not remove reactivity to a range of islet proteins, indicating the islet 
specificity of these antibodies (Figure 4.7c). 
4.3.4 · lmmunoprecipitation Assay 
Preliminary studies using the immunoprecipitation assay to detect 
antibody reactivity to native islet cell proteins identified antibodies to 
a64kDa protein in acute diabetic rat sera (Figure 4.8). This band co­
migrated with a similar-sized protein recognized by both human IDDM and 
Stiff Man Syndrome (SMS) sera - a rare neurological disorder in which a 
significant proportion of patients develop I DOM and antibodies to a 64kDa 
islet cell protein (Baekkeskov et al., 1990). At this stage a small number 
of normal rat serum samples have been negative for anti-64kDa reactivity 
and studies are currently in progress to screen a larger number of both 
acute diabetic and normal samples to determine the incidence of these 
antibodies and their relationship to the disease process. 
4.4 DISCUSSION 
The data presented above demonstrates that the production of 
autoantibodies to self-components is a regular feature of Tx-X rats, 
providing further evidence for an immune-mediated pathogenesis of 
autoimmunity in this model. Using the classical approach of 
immunofluorescence, autoantibodies to islet cell antigens were detected in 
a proportion of acute diabetic Tx-X animals using fixed canine islet� as 
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Figure 4.8. lmmunoprecipitation of rat islet-cell proteins. Purified rat islets 
were metabolically labelled with 35S-methionine then extracted and
incubated with serum samples. Immune complexes were then harvested 
on Protein-G sepharose, separated by SOS-PAGE and visualized by 
autoradiography. 
Lane 1 - 64kDa positive human IDDM serum. 
Lane 2 - SMS serum. 
Lanes 3 -6 - acute diabetic Tx-X rat sera. 
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present in low titres (Figure 4.1 a). The staining pattern was similar to that 
described by Bottazzo et al. for human ICA (Bottazzo et al., 1974) where 
the whole islet was stained with no apparent specificity for particular cell 
types. In contrast, a restricted number of sera from diabetic Tx-X animals 
demonstrated a 11granular 11 , B-cell specific staining pattern when human 
tissue was used as substrate (Figure 4.1 b), similar to that recently 
described for human ICA (Genovese et al., 1992; Timsit et al., 1992). 
Again however, these antibodies were difficult to detect and were present 
in low titres, and to date only a small number of animals have been tested. 
Nevertheless, this is the first report of this particular type of staining 
pattern in an animal model of IDDM and further studies are required to 
determine the value of these antibodies in predicting the onset of IDDM in 
Tx-X rats. 
Assay variability appears to be a common feature in the detection of ICA 
by immunofluorescence, as illustrated an international workshop on the 
standardization of ICA where a high degree of variability in precision and 
limits of ICA detection was seen when 15 standard ICA sera were tested 
in 41 different laboratories (Bonifacio et al., 1990b). The authors ascribed 
this variability to a combination of differences in methodology and also 
variable antigen expression in tissue substrates used. In addition, ICA 
cannot be detected in another rat model of IDDM, the BB rat (Like et al., 
1982a; Elder et al., 1982; Maclaren et al., 1983; Dyrberg et al., 1983). 
This suggests that a combination of methodology, substrate variability and 
dealing with low-titre antibodies of rat origin may have contributed to the 
difficulty in detecting ICA in Tx-X rats by immunofluorescence. This data 
also questions the significance of the role of these antibodies in the 
pathogenesis of the disease. 
-_-
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In contrast to ICA, autoantibodies to thyroid antigens were readily 
detected in Tx-X rats, whether diabetic or otherwise (Figure 4.2). Again, a 
number of tissue components were stained including thyroglobulin and 
thyroid follicular cells, illustrating the polyclonal nature of the antibody 
response to this tissue. 
By ELISA, autoantibodies to soluble antigens could also be detected in 
Tx-X rats (Table 4.1 ). Autoantibodies to pancreatic extract were readily 
detected in all Tx-X animals, but did appear to be more prevalent in acute 
diabetic animals. Nevertheless, these antibodies were not disease 
specific in that they did not discriminate between Tx-X rats with islet 
lesions and those with normal pancreas histology at necropsy. In 
contrast, autoantibodies to insulin (IAA) did appear to discriminate 
between Tx-X rats with or without islet lesions, being more prevalent in 
the former group. No difference was observed, however, in the IAA levels 
of Tx-X rats with islet lesions and those of acute diabetic animals, with IAA 
being detected in both groups at a low frequency (17 to 19 percent). The 
low frequency of IAA seen in diabetic animals limits their use as predictive 
markers for disease onset, and this is consistent with findings in the BB 
rat where IAA were either not detected or were present at low levels and 
had limited predictive value (Dean et al., 1987; Markholst et al., 1990; 
Diaz et al., 1991 ). Similarly in humans, IAA appear to have a poor 
predictive value for disease onset (see section 2.2.4). 
In contrast, autoantibodies to purified rat thyroglobulin (TgAA) were a 
common feature of Tx-X rats, detectable with high frequency in most 
groups. Both acute diabetic and non-diabetic Tx-X rats with islet lesions 
showed TgAA incidence levels of around 30 percent, and the frequency of 
detection increased in Tx-X rats without islet lesions at necropsy. This 
1
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suggests that Tx-X rats with no on-going islet autoimmunity are able to 
generate a more severe thyroid autoimmune response, reflected by the 
reduced frequency of thyroid lesions in diabetic rats (see Table 3.2). 
Raised T gAA levels correlated well with the presence of thyroid lesions, 
and again this correlation was greater in Tx-X rats without on-going islet 
autoimmunity. Antibody titre however did not correlate with severity of 
thyroid lesions, which is in accordance with earlier studies in this model 
demonstrating a relationship between TgAA and thyroiditis incidence, but 
not TgAA levels and thyroiditis severity (Penhale et al., 1973). 
In an attempt to analyze the specificities of antibodies to islet cell proteins, 
immunoblotting was performed on lysates of purified islet cells. Using this 
technique, a heterogeneous pattern of immunoreactivity to islet cell 
proteins was observed (Figures 4.3 and 4.4). This immunoreactivity did 
appear to be disease related however, in that the majority was confined to 
diabetic sera (75 percent) and to a lesser extent in sera from non-diabetic 
Tx-X rats with islet lesions at necropsy (30 percent) or with normal islet 
histology (15 percent) (Table 4.2). A proportion of normal sera, however, 
also showed anti-islet cell reactivity by this procedure but in most cases 
this was directed towards different protein bands than those recognized 
by diabetic sera or were of a much lower intensity and probably reflects 
the high sensitivity of this assay procedure. These results are in contrast 
to those of the immunofluorescent assay, where ICA were difficult to 
detect and present at low frequency. The response was also tissue 
specific in that no reactivity was seen to a range of non-islet tissues and 
could not be removed by prior adsorbtion to membrane - bound tissue 
extracts. 
- - -- - - I 
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The heterogeneous pattern of immunoreactivity seen by immunoblotting 
illustrates one of the disadvantages of using this technique. A range of 
protein bands in islet cell extract were recognized, with no single protein 
being recognized with a frequency of more than 25 percent. This 
suggests that either a highly polyclonal response to islet cell proteins is 
generated in diabetic Tx-X rats and/or that these antibodies are 
recognizing peptides generated during the denaturation and reducing 
conditions of this technique from a smaller number of native proteins 
molecules. Although the majority of immunoreactivity (25 percent) was to 
a 33kDa islet cell protein, the strongest reactivity was directed towards a 
52kDa protein in 12 percent of cases. Interestingly, antibodies to a 
protein of the same molecular weight (52 kDa) were identified with a 
slightly higher frequency and similar titre by Karounos and associates 
using human and NOD mouse serum by immunoblotting of human islet 
cell extracts, suggesting that they may be the same protein (Karounos et 
al., 1990; Karounos and Thomas, 1990). The 52kDa protein was found to 
be membrane - bound, but was only detected using the insulinoma cell 
line RINm5 as antigen and not purified islet cells. This fact, in conjunction 
with the low frequency of autoantibodies to this protein in human, NOD 
mouse and Tx-X rat suggests that this antigen may not be of pathogenic 
significance. In contrast, no immunoreactivity to a 33kDa islet cell protein 
was reported. These workers also observed a diversity of antibody 
specificities using this technique and were unable to identify a single 
disease-associated protein band. 
Of particular interest is the identification of antibody reactivity towards a 
64 kDa protein band in diabetic Tx-X sera by immunoprecipitation (Figure 
4.8). A protein of this molecular weight was not detected under the 
denaturing and reducing conditions of immunoblotting, indicating that 
i_ .. -
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either anti-64kDa antibodies recognize a conformational epitope on the 
native antigen or that the antigen is particularly sensitive to denaturation 
and degradation. This highlights the value of using this technique to 
detect conformation-restricted antibody binding or binding to native 
antigens. The assay was not suited to screening large numbers of serum 
samples however, hence the distribution of antibodies to the 64kDa 
antigen among different groups of Tx-X could not be determined. 
To date anti-64kDa antibodies have proved to be the most consistent 
immunological feature of human, BB rat and NOD mouse syndromes and 
has potential as a candidate autoantigen in IDDM (see sections 2.2.4(i), 
2.3.1 (i) and (ii)). Due to the demanding nature of the immunoprecipitation 
assay however, further work is required to establish the disease specificity 
of antibodies to this protein in Tx-X rats and their value as predictive 
markers of disease onset. 
In conclusion, the data presented in this chapter demonstrates that Tx-X
rats are capable of generating an autoantibody response towards a range 
of islet cell and thyroid components which can be detected by a number of 
assay systems. 
The classical approach of immunofluorescence readily detected 
antibodies to thyroid components, but appeared to have limited value in 
the detection of islet cell antibodies due to the limitations of lack sensitivity 
and reproducibility. The ability to more readily detect antibodies to 
thyroglobulin could be related to the size of the molecule and the 
presence of multiple epitopes compared to islet cell antigens. 
Nevertheless, ICA were detected in a small number of diabetic Tx-X rats 
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and showed a binding pattern to islet cells similar to that seen with human 
serum. 
By ELISA, antibodies to soluble antigens (insulin, pancreas, thyroglobulin) 
were readily detected, particularly in the case of purified rat thyroglobulin 
and pancreas extract and the immunoprecipitation assay identified 
antibodies to a 64kDa islet cell protein similar to that recognized by 
human sera. In contrast, the increased sensitivity of the immunoblotting 
assay allowed detection of antibodies to islet cell proteins in a large 
proportion of diabetic sera, but this technique produced a complex pattern 
of immunoreactivity that was difficult to interpret. The ability to more 
readily detect antibody reactivity toward thyroid as compared with islet 
components may indicate a more active role for autoantibody in the 
pathogenesis of thyroid disease but suggests that humoral immunity 
probably does not play a primary role in the pathogenesis of Tx-X induced 
IDDM. 
Finally, this data provides further evidence for disrupted immunoregulation 
in Tx-X rats and supports an autoimmune pathogenesis for Tx-X induced 
IDDM. 
- - - - - I 
CHAPTER 5.0 
CELL-MEDIATED IMMUNITY STUDIES 
-_-_- -- --_--- - - I 
-
·,--- - - - - - - - - --- ---:__- - -_----- - -- - __--_ __--_-1 
CONTENTS 
137 
5.1 GENERAL INTRODUCTION .......................................................... 138 
5.2 ADOPTIVE CELL TRANSFER STUDIES ...................................... 141 
5.3 IN VITRO CELL PROLIFERATION STUDIES .............................. 161 
5.4 IN VITRO MACROPHAGE DEPLETION STUDIES ...................... 177 
---:: - -_- __ _:::_:,:-_-__ --
---1 
-
_·----- - - - -------"'.::- - --------_:-_:-_:: _ ___:::__-_1_ 
138 
5.1 GENERAL INTRODUCTION 
Observations in diabetes and other autoimmune syndromes, both in man 
and experimental animal models, suggest a strong role for cell-mediated 
immune mechanisms in the pathogenesis of disease. The presence of 
insulitis in IDDM, and chronic inflammation of target tissues in thyroiditis, 
rheumatoid arthritis and autoimmune encephalomyelitis provides local 
evidence for a cellular immune mechanism in the generation of the 
autoimmune pathology seen in these diseases. This hypothesis is further 
supported by the ability to inhibit disease-onset in animal models of IDDM 
by treatment with anti-lymphocyte serum, immunosuppressive agents or 
neonatal thymectomy (see section 2.4.2(ii)). Moreover, attempts to induce 
organ specific autoimmunity by passive transfer of autoantibodies have 
been almost entirely unsuccessful. 
Central to the issue of autoimmunity and maintenance of self tolerance 
has been the question of how potentially self-reactive lymphocytes, arising 
as a result of random rearrangement of genes coding for receptor 
elements, are either eliminated or regulated during development under 
normal circumstances. This first led to concept of clonal deletion, first 
proposed by Burnet in 1959, whereby potentially autoreactive clones of 
lymphocytes are deleted during the early stages of development (Burnet, 
1959). 
While clonal deletion has generally been accepted as playing a role in the 
initiation of self tolerance, this mechanism cannot account for a number of 
observations, including the demonstration of autoreactive lymphocytes in 
the circulation of normal individuals. This has lead to the existence of the 
phenomenon of peripheral tolerance mechanisms, whereby autoreactive 
- --,_-c-c_-__ [_ :------ _-_-_- -_
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clones escaping intrathymic clonal deletion are functionally inactivated 
upon antigen recognition (anergy) or are actively antagonized by 
suppressive cells in the periphery (Cruse and Lewis, 1992). 
While the mechanisms of clonal deletion and anergy have attracted a 
considerable amount of attention, relatively less is known about the 
mechanism of suppression, due mainly to the difficulty of cloning and 
characterizing suppressive T cells. Nevertheless, the concept of 
suppression cannot be disclaimed as several studies have demonstrated 
that reconstitution of diabetes-prone animals with spleen cells from normal 
donors protect recipients from disease in the case of both BB rats and 
NOD mice (Burstein et al., 1989; Hutchings and Cooke, 1990). In 
addition, suppressor T-cell lines capable of inhibiting the adoptive transfer 
of experimental allergic encaphalomyelitis from diseased to normal rats 
have been generated (Ellerman et al., 1988). 
For the Tx-X model, studies have shown that transfusions of lymphocytes 
from normal, unmanipulated rats after completion of the induction protocol 
can prevent the onset of autoimmunity in recipient Tx-X animals (Penhale 
et al., 1976; Fowell and Mason, 1993), suggesting the presence of a 
population of cells in normal animals capable of inhibiting the action of 
potentially autoreactive T cells in the periphery. 
Considered together, the available data suggests that the development of 
self tolerance is likely to arise as a consequence of a combination of the 
above described mechanisms - deletion, anergy and suppression. In 
addition, increasing evidence suggests that the maintenance of self 
tolerance is a dynamic process involving a carefully regulated balance 
between auto-reactive and -suppressive elements of the immune system. 
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Disruption of this balance may lead to the generation of autoreactivity and 
autoimmune disease. 
The following sections describe a series of in vivo and in vitro cell studies 
in Tx-X rats designed to detect the presence of autoreactive cells in these 
animals, and to examine the role of cellular immunity in the induction and 
regulation of autoimmunity in these animals. 
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The most direct evidence for a role for cellular mechanisms in the 
pathogenesis of autoimmune disease has come from adoptive-cell 
transfer studies in experimental animal models. For example, lymphoid 
cells isolated from donor animals in which autoimmune disease had been 
induced by immunization with myelin basic protein or thyroglobulin were 
capable of transferring encephalomyelitis or thyroiditis respectively to 
naive, syngeneic recipients (McMaster and Lerner, 1967; Ben-Nun et al., 
1981; Maron et al., 1983; Takenaka et al., 1984; Kotani et al., 1990). For 
experimental IDDM, several studies have reported the passive transfer of 
disease using lymphoid cells isolated from affected donors, both for BB 
rats and NOD mice (Poussier et al., 1983; Koevary et al., 1983; Wicker et 
al., 1986a; Wicker et al., 1986b). Furthermore, studies in neonatally­
thymectomized mice (Sakaguchi et al., 1982) and Tx-X rats (Fawell and 
Mason, 1993) have shown that a population of T cells present in normal 
animals are capable of suppressing the onset of disease in these animals. 
Together, these studies suggest provide strong evidence that in these 
model systems the auotimmune pathology is mediated by a population of 
autoreactive T cells, which in the normal animal are under control of an 
active T cell-mediated suppressive mechanism. Disruption of this 
suppressor/inducer balance unmasks the autoreactive potential of these 
cells and leads to the autoimmune pathology observed. 
The following section describes a series of cell reconstitution and transfer 
studies in Tx-X rats designed to test this suppressor/inducer imbalance 
hypothesis and examine the role of cell mediated immune mechanisms in 
the pathogenesis of Tx-X induced autoimmune disease. 
_____ J 
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5.2.2 MATERIALS AND METHODS 
i) Tissue Culture Reagents and Media
Phosphate Buffered Saline (PBS) 
PBS (pH 7.3) was prepared from tablets (Oxoid, Basingstoke, U.K.) to 
give a final concentration of 137mM NaCl, 2.7mM KCI, 8.1 mM Na2HPO4 
and 1.5mM KH2PO4. 
Ca2+.free Krebs-Ringer Bicarbonate-HEPES (Ca2+.free KRB-HEPES) 
Stock solutions of Ca2+-free KRB-HEPES were prepared as follows: 
Stock solution A: 633mM NaCl, 23.BmM KCI, 5.9mM KH2PO4, 5.9mM 
MgSO4.7H2O. 
Stock solution B: 31.2mM NaHCO3, 97.6mM NaCl. 
Immediately prior to use, a working solution consisting of 20ml Solution A, 
16ml Solution B, 1 ml of 1 M HEPES (N-[2-hydroxyethyl]piperazin-N 1-[2-
ethanesulfonic acid]) - ICN Biomedicals, NSW, Australia) and 58ml ddH2O 
was prepared. The solution was equilibrated in air for 1 O minutes and the 
pH adjusted to 7.4 with 1 M Na OH. 
Hanks Balanced Salt Solution-HEPES (HBSS-HEPES) 
HBSS was purchased as a 10-times concentrate from Gibco BAL, MD, 
USA. A working solution of HBSS-HEPES was prepared by 
supplementing normal strength HBSS with 20mM HEPES and 4.3mM 
NaHCO3, adjusting the pH to 7.3 with 1 M NaOH and filter sterilizing. 
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Complete-RPMI 
RPMl-1640 medium was purchased from Gibco BRL, MD, USA. 
Glutamine, penicillin and streptomycin were from Sigma Chemical Co., 
MO, USA. Complete-RPM! was prepared by supplementing normal­
strength RPMI with 20mM HEPES, 2mM glutamine, 0.05mM 2-ME, 
1 00U/ml penicillin, 1 00ug/ml streptomycin. The solution was adjusted to 
pH7.3 with 1 M NaOH and filter sterilized. Heat-inactivated FCS or NRS 
were added prior to use as required. 
Mitogens 
Concanavalin A (ConA), phytohaemagglutinin (PHA) and pokeweed 
mitogen (PWM) were purchased from Sigma Chemical Co., MO, USA. 
Stock solutions were made to a concentration of 200 µg/ml in RPMI and 
used at a working concentration of 5µg/ml for ConA and PHA, or 1 µg/ml 
for PWM. 
ii) Preparation of Rat Spleen Cells
Donor rats were killed by CO2 inhalation and their spleens removed 
aseptically. Single cell suspensions were prepared by gently pressing 
chopped tissue through a stainless steel mesh (0.5mm2) then washed 
three times with HBSS-HEPES. Cell viability was assessed by Trypan 
Blue exclusion and cell numbers determined using a haemocytometer. 
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iii) Lymphoid Cell Reconstitution of Tx-X rats
For lymphoid-cell reconstitution experiments, freshly-isolated spleen cells 
from normal PVG donors were adjusted to 1 x1 oa cells in 1 ml of PBS and 
administered IP to Tx-X rats 24 hours after final irradiation. After the 
usual disease-development period (10 weeks - see Figure 1 ), 
reconstituted animals were killed and blood, pancreas and thyroid 
analyzed as previously described (chapter 3.0). 
iv) Adoptive Cell Transfers
Selection of Cell Donors and Recipients 
Spleen cell donors for the transfer of diabetes were selected on the basis 
of recent-onset acute IDDM which had been stabilized by insulin-therapy. 
Recipients were young (3 or 6 week old) normal female PVG rats, 
irradiated adult female PVG rats or Tx-X rats that had not become diabetic 
8 to 9 weeks after final irradiation and that showed normal glucose 
tolerance (see below). 
Donors for the adoptive transfer of thyroiditis were post-diabetic stage Tx­
X rats (8 to 1 O weeks after final irradiation) that showed elevated levels of 
autoantibodies to rat thyroglobulin by ELISA (see section 4.3.2). 
Recipients were either normal or gamma-irradiated (2.5 Gray 24 hours 
prior to cell transfer) age-matched female PVG rats. 
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Preparation and Transfer of Spleen Cells 
Single-cell spleen suspensions were prepared as described above, 
depleted of erythrocytes by hypotonic lysis and resuspended to a 
concentration of 2x10
6 
cells per ml in complete RPMI supplemented with
10 percent FCS or 5 percent NRS and 2.5µg/ml ConA. Cells were 
cultured for 72 hours in 5 percent CO2 at 37°C in plastic tissue culture 
vessels (ICN Biomedicals, NSW, Australia) using 10ml volumes. Cells 
were prepared for transfer by harvesting and washing 3 times in PBS. 
Clumps were dispersed by gently passing the solution through a fine­
gauge needle and the cells checked for viability and counted. Washed 
SpC preparations were resuspended to the required concentration in a 
volume 0.5 ml of PBS and transferred to recipients IV via the caudal vein. 
Recipients were then killed ten days after cell transfer and blood, 
pancreas and thyroid analyzed as previously described (chapter 3.0). 
Glucose Tolerance Testing 
In the case of Tx-X recipients of diabetic cells, intraperitoneal glucose 
tolerance tests (IPGTT) were performed in order to select appropriate 
recipients prior to cell transfer, and also following transfer to test for 
abnormal glucose regulation. Blood glucose levels were determined 
immediately prior to the IP administration of a solution of D-glucose (BDH 
Chemicals, Poole, U.K.) in PBS (2mg glucose per gram body weight) and 
thereafter at 30, 60, 120, and 300 minute intervals. Tests were performed 
at the same time of day on non-fasted animals and only those showing a 
blood glucose increase within normal limits were selected as cell-transfer 
recipients. Recipient animals, together with Tx-X controls, were re-tested 
I • 
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as above for glucose intolerance 10 days after transfer then necropsied 
and examined for hyperglycaemia and islet lesions. 
5.2.3 RESULTS 
i) Lymphocyte-reconstitution of Tx-X Rats
The transfer of viable lymphoid cells isolated from normal (non-Tx-X) PVG 
donors to Tx-X rats shortly after final irradiation was effective in inhibiting 
the onset of both diabetes and thyroiditis in recipient rats (Table 5.1 ). 
Levels of both acute diabetes and islet lesions were reduced in 
reconstituted rats when compared with non-reconstituted Tx-X controls (P 
<0.001) . In addition, incidence levels of thyroid lesions were dramatically 
reduced in reconstituted animals (P < 0.001) but TgAA levels were not 
affected (Table 5; 1 ). 
ii) Adoptive Transfer of Diabetes
Attempts to adoptively transfer diabetes using lymphoid cells from acute 
diabetic donors are summarized in Table 5.2. Although acute disease 
was not observed in any recipient, islet lesions were induced in a 
proportion (2/7) of normal 3 week old and adult irradiated (2/6) female 
SPF-derived recipients and in all (4/4) non-diabetic Tx-X recipients (Figure 
5.1 ). In addition, all Tx-X recipients displayed abnormal glucose tolerance 
1 0 days after cell transfer compared with a group of non-diabetic Tx-X
controls maintained concurrently (Figure 5.2), suggesting these rats were 





Table 5.1. Effect of normal lymphocyte reconstitution on the 
development of autoimmune disease in Tx-X rats. 
Disease Reconstituted * Control Tx-X 
n (%) n (%) 
n 25 47 
Diabetes 
Acute Diabetes 1 (4) 10 (21) 
Islet Lesions 2 (8) t 17 (36) 
Thyroiditis 
Thy__roid Lesions 5 (20) § 28 (62) 
TgAA (00405) 0.39 ± 0.08 0.41 ± 0.06 
* Each received 1x108 viable syngeneic spleen cells IP 24 hours after
final irradiation. 
t P < 0.01 compared with controls.
§ P < 0.001 compared with controls.
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Table 5.2. Incidence of acute diabetes, islet lesions and 




Acute Islet Glucose 
Diabetes Lesions Intolerance # 
Normal 
3 weeks old 0/7 2/7 NT 
6 weeks old 0/3 0/3 NT 
Irradiated Adult t 0/6 2/6 NT 
Tx-X § 0/4 4/4 4/4 
* Each received 5 to 20x1 O 6 ConA-activated spleen cells from acute
diabetic donors transferred IV.
t 1 x 2.5 Gray whole-body irradiation 1 day prior to transfer. 
§ All recipients showed normal glucose tolerance prior to transfer. Control
Tx-X rats (n=5) maintained concurrently showed no abnormalities.
# As determined by IPG TT 1 O days post-transfer. 
NT= not tested. 
I I 
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Figure 5.1. Section of pancreatic islets of a recipient of diabetic lymphoid 
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Time from glucose challenge (min) 
Figure 5.2 IP glucose tolerance tests of Tx-X adoptive transfer recipients. 
Tx-X rats received 0.5 to 2.0x107 activated spleen cells IV from diabetic 
donors and were challenged IP 1 0 days later with glucose and blood 
glucose levels followed for the following 2 hours (open circles). Age­
matched Tx-X rats (n=5) were used as controls (closed squares). 
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iii) Adoptive Transfer of Thyroiditis
In contrast to diabetes, thyroid lesions and thyroglobulin autoantibody 
production were readily transferred to both irradiated and normal 
recipients, but success was dependent upon the route of transfer and the 
cell dose used. Thus, transfer by the IV route was effective in inducing 
thyroid lesions and raised anti-Tg antibody levels in 11/15 (73 percent) of 
recipients (Figure 5.3; Table 5.3). In contrast, IP transfers failed to 
produce thyroiditis in any recipient animal. 
The incidence and severity of thyroiditis in cell transfer recipients could 
also be modified by the number of cells used for transfer (Table 5.4). 
Thus, 5x107 activated thyroiditic spleen cells were capable of transferring 
disease to 4/4 normal PVG recipients with a mean pathology score of 2.0. 
Decreasing cell numbers resulted in a decline in incidence and severity of 
the lesion, with 2x107 cells inducing lesions in only 1 of 4 recipients with a 
mean pathology score of 1.0. 
Transfers to irradiated recipients tended to follow the same pattern, except 
in the case of recipients of 4x107 cells, where 3/3 recipients developed 
thyroid lesions with a mean pathology score of 3.0, possibly due to the 
unintentional inclusion of a diabetic rat as a cell donor. Levels of anti-Tg 
autoantibodies tended not to be influenced by cell dose, remaining 
elevated in most cases (OD405 levels of 0.4 to 0.8) except for normal and 
irradiated recipients of 5x107 cells where antibody levels remained low. 
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Figure 5.3. Thyroid lesion of an adoptive cell transfer recipient of thyroiditic 
lymphoid cells showing cellular infiltration and loss of follicular integrity 
(H&E; x250). 
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Table 5.3. Influence of cell transfer route on the ability to adoptively 
transfer thyroiditis. 
Route of Number of Incidence of Thyroid TgAA 
Transfer 
* 
Transferst Thyroiditis Pathology (OD405) 
n (%) Score (x ± SEM) 
(x ± SEM) 
IP 13 0 0 0.2 ± 0.1 
IV 15 11 (73) 1.4 ± 0.2 0.6 ± 0.1 
*
Recipients were adult female normal PVG rats.
t Donors were Tg Ab+ and non-diabetic 1 o week post-irradiation Tx-X rats. Rats 
received 20 x106 ConA - activated spleen cells per transfer. 
P < 0.001 for all comparisons. 
- - -- - -_ T
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Table 5.4. Influence of cell-dose and recipient type on the adoptive 






























(x ± SEM) 
2.0 
1.4 ± 0.4 
1.0 ± 0.6 
1.0 




Donors were Tg AA+ , non-diabetic 10 week post-irradiation Tx-X rats. 
TgAA 
(OD405) 




0.6 ± 0.1 
0.4 ± 0.2 
0.2 
0.5 ± 0.1 
t Spleen cells from 4 to 5 donor rats were bulked prior to in vitro ConA activation and 
IV transfer. 
§ Included 1 diabetic donor animal.
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These studies have provided evidence of a role for cell-mediated immunity 
in the pathogenesis of Tx-X induced autoimmune disease, and give further 
support to the hypothesis that !DOM-induction by the Tx-X protocol is of 
an autoimmune origin. 
Reconstitution of Tx-X rats with lymphoid cells from normal, syngeneic 
donors shortly after completion of the induction protocol significantly 
reduced the incidence of islet lesions (atrophy or insulitis) and lowered the 
incidence levels of acute diabetes (Table 5.1 ). 
In addition, thyroid lesions were also significantly reduced in reconstituted 
animals (Table 5.1 ), an observation that is in accordance with a previous 
study on thyroiditis in this model (Penhale et al., 1976). Autoantibody 
production to thyroglobulin was not influenced by reconstitution in the 
present study, with both reconstituted and control animals producing 
significant levels of this antibody. In contrast, Penhale and associates did 
observe a reduction in antibody production to thyroglobulin, however this 
result may have been due to the relatively greater number of spleen cells 
used for reconstitution (4 x1 QB compared with 1 x1 QB in the present study) 
(Penhale et al., 1976). 
Together, these observations provide support for the following 
hypotheses: 1) The Tx-X procedure selectively depletes or inactivates 
particular subpopulations of T-lymphocytes and does not induce complete 
immunosuppression. This was demonstrated by observations in the 
present study that Tx-X animals were capable of significant autoantibody 




influenced by lymphocyte reconstitution, suggesting that sufficient T­
helper and 8-cell function were present to initiate this response. This is 
also supported by studies demonstrating the presence of substantial 
numbers of T and B cells in lymphoid organs of Tx-X animals (A. Stone, P. 
Stumbles and J. Penhale, unpublished observations); 2) The Tx-X
procedure selectively modifies or depletes the suppressive activity of a 
population of T cells responsible for controlling potential cell-mediated 
autoreactivity in the normal animal. This is supported by the ability to 
restore this regulatory capacity by transfusions of lymphoid cells from 
normal animals. 
Recent studies of T-cell reconstitution in Tx-X rats by Fewell and 
associates have identified the T-cell subset responsible for restoring 
immunoregulatory capacity in reconstituted Tx-X rats (Fowell et al., 1991 ). 
Reconstitution of Tx-X rats with thoracic duct lymphocytes fractionated on 
the basis of expression of the leukocyte common antigen (CD45) identified 
a T-cell of the CD45RCl0w, CD4+ phenotype capable of completely 
abrogating the expression of diabetes. In coqtrast, CD4+, CD45RChigh T­
cells had no suppressive effect, and were capable of inducing a severe 
wasting syndrome in congenitally athymic rats. 
CD4+, CD45RCl0w T-cells have been shown to secrete low levels of IL-2 
and IFNy and high levels of IL-4, and are therefore thought to represent a 
cell with so-called 11Th2 - like" characteristics - that is, the ability to 
suppress cell mediated responses and to provide B cell help (Mason, 
1992). In contrast, CD45RChigh, CD4+ T cells secrete high levels of IL-2 
and IFNy and appear to represent the 'Th1 11 cell type involved in cell-
mediated immune responses. The situation is complicated further however 
by heterogeneity within the CD45RCl0w population based on expression of 
--- l I 
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other markers such as Thy-1, RT6 and OX-40 (Fowell et al., 1991 ), so at 
this stage the exact nature of the cell type involved is unclear. In addition, 
the interaction of these cells with other cell types is yet to be determined, 
particularly in relation to cos+ T cells which have been shown to be 
essential for disease development in this model (Fowell et al., 1991 ). 
Studies in the BB rat have also shown that the course of disease 
development can be altered by cellular reconstitution, as transfusion of 
whole blood from DR-BB rats eliminated the occurrence of diabetes in DP 
animals (Rossini et al., 1983). Subsequent studies showed that a CD4+, 
RT6+ T-cell was responsible for the suppression (Rossini et al., 1984; 
Mordes et al., 1987; Burstein et al., 1989). 
Additional evidence for the pathological role of cell-mediated immunity in 
Tx-X-induced autoimmunity was provided by the ability to adoptively 
transfer disease to naive recipients using lymphoid cells from affected 
donors. Although acute diabetes could not be transferred using cells from 
diabetic donors, islet lesions were observed in a proportion of young 
normal and adult irradiated recipients (Table 5.2). Subsequent 
experiments on the adoptive transfer of thyroiditis using lymphoid cells 
from thyroiditic rats indicated that effective transfer of thyroid lesions could 
be achieved only if cells were transferred via the intravenous route (Table 
5.3). Moreover, the severity of the lesion induced varied in a dose 
dependent manner, as transfer of 2x107 cells induced mild lesions, 
whereas doses of 4 to 5 x 107 produced strong lesions in all recipients 
(Table 5.4). 
Thyroglobulin autoantibody production could also be adoptively 
transferred using cells from thyroiditic donors, although antibody titre 
l !_ -
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appeared to be independent of the number of cells transferred, being 
elevated to the same level in most cases regardless of the status of the 
recipient (irradiated or normal)(Table 5.4). The reason for this is unclear, 
but may indicate that autoantibody production can be adoptively 
transferred using relatively lower numbers of cells than that required for 
the transfer of lesions. The cell numbers used for transfer in this study 
were probably above the level required to observe a dose-dependent 
response for autoantibody production. 
In light of these results, the inability to induce acute diabetes by 
intravenous transfer was probably due to the sub-optimal number of cells 
available from acute diabetic donors for transfer (0.5 to 2 x 107). In
contrast, islet lesions were readily transferred to Tx-X recipients (Table 
5.2) and in addition all recipients developed abnormal tolerance to IP 
glucose challenge (Figure 5.2). The enhanced susceptibility to disease 
transfer seen in Tx-X recipients probably reflected the 
immunocompromised state of these animals. Again however, acute 
disease was not observed in any recipient, again probably due to the low 
number of cells available for transfer. An alternative approach would be to 
identify and isolate lymphocytes for adoptive transfer from pre-diabetic Tx­
X donors. Such cells would presumably be primed for B cell reactivity 
and may be more potent at transferring acute disease. 
Several studies have demonstrated the ability to transfer diabetes in both 
BB rats and NOD mice. Adoptive transfer of diabetes in the BB rat was 
first reported in 1983 by Koevary and associates using ConA-activated 
spleen cells from acutely-diabetic BB rats transferred into young diabetes­
prone animals (Koevary et al., 1983). In this situation however, successful 
transfer was assessed on the basis of accelerated disease onset in a 
1· __ 
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disease-prone animal and was therefore distinct from the present studies, 
where transfer was attempted into recipients not normally prone to 
disease. Subsequent studies showed that this effect could be mediated 
by CD4+ T cells (Metroz-Dayer et aL, 1990). Similarly, ConA-activated 
spleen cells from acutely diabetic DP-BB rats were able to transfer 
disease to RT6-depleted DR recipients (Greiner et al., 1987). 
In NOD mice, transfer of spleen cells from acutely diabetic animals to 
young (less than 6 weeks) NOD mice induced a higher frequency and 
earlier onset of symptoms than untreated littermates (Wicker et al., 
1986a). Again however, successful transfer determined on the basis of 
inducing disease in an animal already susceptible to spontaneous 
disease, making the interpretation of these results difficult. Subsequent 
experiments have shown that transfer of disease is also possible into 
neonatal NOD animals or immunodeficient NOD-scid/scid mice, and 
demonstrate a requirement for both CD4 + and CDS+ T cells (Bendelac et 
al., 1987; Christianson et al., 1993). 
In conclusion, these experiments provide strong evidence in favour of a 
pathological role for tissue-specific autoreactive T cells in the induction of 
autoimmune disease in Tx-X animals. The ability to transfer disease to 
naive recipients using activated lymphocytes from affected donors, in 
conjunction with the ability to suppress the onset of disease in Tx-X
animals by transfusion of lymphocytes from normal animals, argued in 
favour of the conclusion that the Tx-X protocol selectively depletes or 
inactivates a population of T cells that act to suppress the activity of these 
potentially autoreactive cells in the normal animal. The characteristics of 
this suppressive population remain to be fully determined, but at this stage 
they appear to be CD4+ T cells of the CD45RCl0w, RT6+ phenotype. 
\_- ! I 
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The observation that organ-specific autoimmune responses can be 
transferred to normal recipients using lymphoid cells from affected donors 
suggests a strong role for cell mediated autoimmune mechanisms in the 
pathogenesis of these diseases. Moreover, the fact that these 
autoreactive T cells are targeted to a specific tissue or cell type (for 
example, the B cell in IDDM) implies that these cells recognize and 
respond to an autoantigen(s) unique to the target tissue. It is thus of 
critical importance to identify these T-cell antigens as the first step in 
developing any specific therapeutic or prophylactic regime. 
Using autoantibodies as probes, it has been possible to identify putative 
target autoantigens in a number of autoimmune diseases which may then 
be utilized in in vitro proliferation assays in conjunction with autoreactive 
T cells to assess their role in T-cell activation. Using this approach, recent 
studies have detected in vitro proliferation of lymphocytes from diabetic 
patients to islet cell autoantigens such as GAD and the 38kDa secretory 
granule protein, and also to non-islet antigens such as heat shock 
proteins, particularly HSP65, and dietary proteins such as bovine serum 
albumin (see section 2.4.2(i)). 
This section describes attempts to identify reactivity of lymphoid cells from 
diabetic Tx-X rats to islet cell antigens in vitro, and to assess the potential 
role of previously-described autoantigens of other IDDM syndromes in the 
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5.3.2 MATERIALS AND METHODS 
i) Selection of Donors and Preparation of Cells
Non-diabetic Tx-X animals were selected on the basis of normal blood 
glucose readings and glucose tolerance. Acute diabetic donors were 
diabetic animals that had been stabilized by exogenous insulin therapy. 
Single spleen-cell suspensions were prepared as described in 5.2.2(ii). 
ii) Preparation of Antigens and Mitogens
Cellular Antigens 
Dispersed rat islet cells were prepared from intact islets isolated as 
previously described (see section 4.2.3). Islets were dispersed into single 
cell preparations by resuspending 1000 purified islets in 5ml of Ca2+-free 
KRB-HEPES solution containing 0.5 percent bovine serum albumin (KRB­
HEPES/BSA). After incubating for 1 minute at room temperature, the 
islets were centrifuged at 1800 rpm for 1 minute then resuspended in 1 ml 
of KRB-HEPES/BSA containing 3mM EGTA. After 15 minutes at room 
temperature, islets were centrifuged and resuspended in 5ml of KRB­
HEPES/BSA plus EGTA containing 0.1 percent trypsin (Difeo 1 :250, 
Michigan, USA), incubated for 5 minutes at room temperature with 
constant mixing then washed three times and resuspended in complete 
RPMI containing 10 percent FCS. Dispersed islet cells were allowed to 
recover overnight at 37°C in 5 percent CO2 then washed in complete 
RPMI-NRS and either used directly as antigen in proliferation assays 
(viable islets) or fixed in 1 percent paraformaldehyde (fixed islets) before 
being used as antigen. 
j I 
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Liver cells were prepared from rat liver by mincing the tissue and digesting 
with 1mg/ml collagenase Type V (Sigma Chemical Co., MO, USA) for 10 
minutes at 37°C. The cells were then washed in HBSS-HEPES and 
resuspended in complete RPMI-NRS. 
Heat Shock Proteins {HSP) 
Recombinant Mycobacterium bovis HSP65 and M. tuberculosis HSP70 
were kindly donated by the National Institute of Public Health and 
Environmental Protection, Bilthoven, The Netherlands. Lyophilized 
preparations were resuspended to 200 µg/ml in PBS, filter sterilized and 
stored at -20°C. 
Bovine Serum Albumin {BSA) 
BSA was purchased from Sigma Chemicals, MO, USA as a lyophilized 
powder. A 200 µg/ml stock solution was made in PBS, filter sterilized and 
stored at -20°C. 
Mitogens 
The T-cell mitogens ConA and PHA were prepared as described in 
section 5.2.2(i). 
iii) Proliferation Assay Conditions
All proliferation assays were performed in complete RPMI containing 5 
percent heat-inactivated normal rat serum (NRS). SpC suspensions were 
resuspended to 1x106 cells per ml and 200µ1 (2 x1 os cells) added in 
- t-
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triplicate for each mitogen or antigen concentration to wells of 96 well 
round-bottom tissue culture plates (ICN Biomedicals, NSW, Australia). 
Cells were cultured at 37°C in 5 percent CO2 for 72 hours with mitogens 
or 120 hours with antigen preparations. 
M-�H-thymidine Labelling and Scintillation Counting 
To assess cellular proliferation, 1 µCi of 3H-thymidine (Amersham Int., 
Amersham, UK) in a volume of 5µ1 of RPMI was added to each well 18 
hours prior to completion of the assay. At completion of the assay period 
cells were harvested onto glass-fibre filters using a Cambridge PHO® cell 
harvester (Cambridge Technology, MA, USA), dried overnight and 
dissolved in 2ml of scintillation cocktail (0.4 percent w/v Omnifluor [NEN 
Research, MA, USA], 33 percent v/v C:40 [Sigma Chemicals, WA, 
Australia], 67 percent v/v toluene). Counts per minute (CPM) were 
determined in a liquid scintillation counter (Tri-Garb® 4000, Packard 
Instrument Co., Illinois, USA) using a counting time of 3 minutes per tube. 
Mean CPM of triplicate wells are expressed as a stimulation index (SI) 
calculated as follows: 
SI= Mean CPM stimulated cells
Mean CPM unstimulated cells 
v) Statistical Analyses
Comparison of incidence rates was by chi-squared analysis of 2x2 
contingency tables using the Yates• correction for n>50 or Fishers• Exact 
Test for n�50 (Langley, 1971 ). Mean values were compared using 




i) Responses to Mitogens
In order to initially determine the proliferative capacity of lymphocytes from 
Tx-X animals, spleen-cell responses to a range of mitogens were 
assessed. A comparison of the proliferative responses from normal PVG, 
non-diabetic and diabetic Tx-X rat to the T cell mitogens ConA and PHA 
are shown in Figure 5.4. Normal PVG rat spleen cells showed a wide 
variation in responsiveness between individual animals to ConA and PHA, 
with SI values ranging from 60 to greater than 400 for ConA and 5 to 
approximately 200 for PHA (Figure 5.4a). Spleen cells from non-diabetic 
Tx-X animals showed an even broader range of responses to these 
mitogens, with SI values ranging from to 10 to greater than 450 for ConA 
and from 0 to 400 for PHA (Figure 5.4b). Note that overall, PHA 
responses of both normal PVG and TX-X rat cells were markedly reduced 
when compared to ConA values. Spleen cells from diabetic animals 
generally showed severely depressed responses to both ConA and PHA 
(Figure 5.4c). 
The above mitogen-stimulation results are summarized in Table 5.5. 
Normal PVG PHA responses were significantly depressed compared with 
ConA values (P <0.001 ). Diabetic animals also showed significantly 
depressed responses when compared with normal Tx-X and normal PVG 
rats (P <0.02 and 0.001 respectively). Note that there was no significant 
difference between ConA or PHA responses of normal Tx-X or PVG 
animals. In addition, Tx-X animals showed depressed B cell mitogenic 
activity as indicated by a reduced responsiveness to PWM compared with 
normal levels (P <0.02). 
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Figure 5.4. Proliferative responses of normal and Tx-X rat spleen cells to 
ConA and PHA. Spleen cells were isolated from normal PVG (a), clinically 
normal Tx-X (b) and acute diabetic (c) rats, cultured for 72 hours with 
ConA or PHA (5µg/ml) and proliferation assessed by 3H-thymidine 
incorporation. Symbols represent individual animals. 
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Table 5.5. Mitogen-induced proliferative responses of 








207 ± 24 t 
(n=17) 


















ConA and PHA were used at 5 µg/ml. PWM was used at 1 µg/ml. 
t P < 0.001 compared with normal PVG PHA and diabetic ConA
values. 
§ P < 0.02 compared with diabetic ConA value.
II P < 0.02 compared with normal PVG PWM value.
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The similarities and differences in lymphocyte mitogen responses between 
the above groups of animals were further highlighted by mitogen dose­
response curves (Figure 5.5). Although normal Tx-X animals occasionally 
showed spleen-cell ConA dose responses similar to those of normal PVG 
animals, these were observed to be highly variable as illustrated in Figure 
5.4, where some rats showed proliferative responses of an SI of 50 or 
less. Similarly, PHA responses of normal Tx-X rats were variable but 
generally depressed, tending to resemble those of diabetic animals, 
reaching a peak SI value of only 25 compared with values greater than 
100 for normal PVG animals. 
In contrast, diabetic animals showed consistently depressed proliferative 
responses to both ConA and PHA at all doses, reaching SI peaks of 
approximately 50 and 25 respectively (Figure 5.5). Note that high doses 
of mitogen (50µg/ml) appeared to be inhibitory for all groups, and that 
overall proliferative responses to PHA were depressed for each group of 
rats for all mitogen doses. 
ii) Responses to Antigens
To detect lymphocyte reactivity to various antigens implicated in IDDM, 
spleen cells from normal and Tx-X animals were used in proliferation 
assays in conjunction with a range of cellular and soluble antigens. 
Initially, to determine whether cellular autoreactivity to islet cells could be 
demonstrated in Tx-X animals, spleen cells from acute diabetic, normal 
Tx-X or normal PVG rats were co-cultured with purified rat islet cells 
(Figure 5.6). Low levels of reactivity to viable islet cells were observed 
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Figure 5.5 72 hour proliferative responses of spleen cells isolated from 
normal PVG (closed circles; n=8), clinically normal Tx-X (open squares; 
n=4) and acute diabetic rats ( closed squares; n=9) to various doses of 
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Figure 5.6 Proliferative responses of normal and Tx-X rat spleen cells to 
islet cell antigens. Spleen cells from normal PVG (a) and Tx-X (b) rats 
were cultured for 72 hours in the presence of viable or formalin-fixed 
dispersed islet cells, or viable liver cells as controls, and proliferation 
assessed by 3H-thymidine incorporation. 
Symbols represent individual animals. 
Open squares indicate acute diabetic rats. 
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both with normal spleen cells (Figure 5.6a) and Tx-X spleen cells (Figure 
5.6b) with no differences in levels of reactivity between acute diabetic and 
non-diabetic animals. 
In contrast, no reactivity was observed towards fixed islet cells (Figure 
5.6), indicating that either 1) a stimulatory factor may have been present in 
viable islet cell cultures; 2) that the fixation process destroyed any 
autoantigenic epitopes, or 3) that potential islet autoantigens were unable 
to be processed and presented by dedicated antigen presenting cells. 
To determine whether an HSP, particularly HSP65, may act as potential 
autoantigens in the Tx-X syndrome, cellular reactivity towards 
recombinant HSP65 and also HSP70 was assessed (Figure 5.7). A small 
degree of reactivity was observed only to HSP70, where one normal PVG 
animal showed an SI value of 25 (Figure 5.7a) and one normal PVG and 
one diabetic animal responded at lower levels (Figure 5.7a and b). In 
contrast, no reactivity was observed to either HSP65 or BSA in normal or 
Tx-X rats. 
5.3.4 DISCUSSION 
Although it is clear that cell-mediated immune mechanisms are important 
in the pathogenesis of Tx-X induced diabetes, lymphoid cells from Tx-X
animals generally showed poor proliferation in vitro.
Initially, in order to investigate the overall status of T cell reactivity of Tx-X
animals, in vitro spleen cell responses to T cell mitogens were examined. 
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Figure 5.7. Proliferative responses of spleen cells from normal and Tx-X 
rats to soluble antigens. 2x105 spleen cells from normal PVG (a) and Tx-
X (b) rats were cultured for 72 hours in the presence of 1 0µg/ml of each 
antigen. 
Symbols represent individual animals. 
Open squares indicate acute diabetic rats. 
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As expected, spleen cells from non-diabetic Tx-X animals showed 
reduced proliferation to ConA when compared to spleen cells from normal 
rats (Figures 5.4 and 5.5, Table 5.5). Furthermore, spleen cells from 
acute diabetic animals showed no significant proliferation to ConA, 
indicating a severe impairment of T cell function in these animals . The 
proliferation of spleen cells from rats of all groups to PHA were generally 
low, thus indicating this to be a poor rat T-cell mitogen. 
Attempts to characterize the target autoantigens of autoreactive T cells in 
Tx-X rats by in vitro lymphocyte proliferation proved inconclusive. In 
order to investigate potential B cell antigens in vitro, it was considered 
necessary initially to demonstrate that lymphocytes from diabetic Tx-X rats 
would proliferate in response to intact, viable B cells. Although low levels 
of proliferative activity were observed, this was matched by similar low 
levels of activity in normal animals, thus questioning the disease specificity 
of the response. These results, however, appear to be consistent with 
findings in the BB rat, where there have been no reports of T-cell reactivity 
to any islet cell antigens. Nevertheless, this does contrast with studies in 
humans and NOD mice, where there have been small number of reports 
of T cell reactivity to islet antigens. 
In humans, Harrison et al. reported the detection of T cells in peripheral 
blood reactive to human islets and pig pro-islets (Harrison et al., 1991 a). 
This group has also reported low levels of T cell reactivity towards 
sonicates of foetal pig pro-islets in preclinical patients, and this reactivity 
appeared to correlate well with ICA levels and progression to clinical 
disease (Harrison et al., 1992a). There have also been a small number of 
reports of CD4 + and coa+ T cell lines and clones generated to islet cell 
antigens (DeBerardinis et al., 1988; Kontiainen et al., 1991 ). 
1_-, 
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To date, there has only been one report of in vitro T cell reactivity to islet 
antigens in NOD mice (Burtles et al., 1992). These workers also 
demonstrated a similar degree of islet-cell reactivity in non-diabetes prone 
mice strains, suggesting that lack of tolerance to islet cell antigens may be 
a common feature of mice and that diabetes-development in NOD mice 
may be a result of a dysfunction in the regulation of these autoreactive 
cells. The difficulty in demonstrating in vitro T cell reactivity to islet 
antigens may be the result of a combination of several factors. Firstly, 
autoreactive T cells are probably present at low frequency and any 
proliferative response may not be detected under standard assay 
conditions. Secondly, the islet cell target antigen may only be transiently 
expressed under normal circumstances and may be particularly sensitive 
to degradation in vitro. Thirdly, appropriate presentation of antigen to T 
cells may not occur under in vitro conditions. 
Similarly, there have been few reports of in vitro T cell reactivity to purified 
islet cell antigens. Atkinson et al. reported peripheral blood lymphocyte 
responses to recombinant GAD65 in 67 percent of newly diagnosed IDDM 
patients and ICA+ relatives (Atkinson et al., 1991) and Roep et al. 
demonstrated T cell reactivity to the 38kDa insulin-secretory granule 
protein in 80 percent of recent-onset patients, and were able to generate T 
cell clones to this antigen (Roep et al., 1991 ). In NOD mice, Elias et al. 
reported T cell reactivity to the 65kDa heat shock protein (HSP65), but not 
to HSP70 (Elias et al., 1990). In addition, epitopes of the HSP65 molecule 
could be used to vaccinate against diabetes development (Elias et al., 
1991 ). These results contrast with the present study, where no T cell 
reactivity was observed towards HSP65 whereas low levels were detected 
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In conclusion, the ability to transfer disease to normal syngeneic recipients 
using lymphoid cells isolated from affected Tx-X rats demonstrates that 
islet-reactive T cells are generated during the diabetic syndrome and 
demonstrates an essential role of cellular immune mechanisms in the 
pathogenesis of diabetes and thyroiditis induced by this procedure. 
Although islet-reactive T cells could be demonstrated in Tx-X rats that 
were capable of transferring disease, demonstration of this reactivity in
vitro was difficult to achieve. Further work is required to determine the 
appropriate form of the antigen and the appropriate assay system for 
detecting the potentially low levels of T cell responses. The ability to 
suppress disease onset by reconstituting Tx-X animals with normal 
lymphoid cells supports the concept that maintenance of self-tolerance 
under normal circumstances is achieved in part by an active suppressive 
mechanisms and that the Tx-X procedure disrupts this immuno-regulatory 
mechanism. Finally these studies illustrate the value of this model for 
such studies in that normal, syngeneic animals are readily available for the 
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5.4.1 INTRODUCTION 
Although there is strong evidence in support of an important role for T 
cells in the pathogenesis of Tx-X-IDDM, the in vitro responses of spleen 
cells from diabetic Tx-X rats, and to a lesser extent non-diabetic rats, were 
characterized by poor proliferation in response to T-cell mitogens (see 
previous section). While this apparent paradox could be explained by the 
poor condition of cells from clinically diabetic animals, or the inability of 
these cells to produce appropriate growth factors, the poor 
responsiveness of spleen cells from clinically normal Tx-X animals in 
comparison to normal PVG rats raised the possibility that the proliferation 
of these cells was being suppressed in vitro . 
The phenomenon of in vitro suppression of lymphocyte proliferation has 
been observed in a number of experimental models of autoimmune 
disease, including both BB rats and NOD mice. In both these cases, a 
notable improvement in mitogen-induced proliferation was observed if 
spleen cell cultures were depleted of adherent cell populations prior to 
activation (Prud'homme et al., 1984; Woda and Padden, 1986; Yokono et 
al., 1989). For BB rats, removal or inactivation of macrophages 
significantly improved spleen cell proliferative responses to ConA and IL-2 
production, while adherent cells from diabetic rats could inhibit normal 
MHC-matched control cells (Prud'homme et al., 1984). In addition, 
Metroz-Dayer and associates showed that the removal of macrophages 
prior to in vitro ConA stimulation resulted in an enhanced incidence of 
diabetes in adoptive transfer recipients of spleen cells from diabetic NOD 
mice (Metroz-Dayer et al., 1990). Moreover, the presence of suppressor 
mac'rophages has also been described in other autoimmune diseases 
-! I_· - ·I
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such as rheumatoid arthritis and systemic lupus erythematosis (Zembda 
and Lammel, 1980; Sieper et al., 1992). 
The suppressive ability of macrophages has been recognized for some 
time (see Allison, 1978 and Unanue and Allen, 1987 for reviews). Initial 
studies showed that addition of peritoneal macrophages to rabbit spleen 
cell cultures could inhibit spleen cell DNA synthesis in response to antigen 
(Parkhouse and Dutton, 1966). Subsequent studies in rats also described 
this effect for allogeneic mixed lymphocyte reactions (Folch and 
Waksman, 1974; Oehler et al., 1977; Hoffman et al., 1990) and spleen cell 
responses to mitogens (Folch et al., 1973; Webb et al., 1980). It appears 
. that macrophages isolated from other sites are also capable of in vitro
cytostatic activity, as this effect has also been described for alveolar 
macrophages (Holt, 1979) although there is some evidence to suggest 
that the type of macrophage capable of suppression is species -
dependent (Holt, 1980). 
As a result of the above observations, and in an attempt to determine the 
basis for the poor in vitro proliferative responses to mitogens and 
antigens of lymphocytes from Tx-X rats, studies were undertaken to 
determine whether there was a role for suppressor macrophages in Tx-X­
induced IDDM. 
i.,· 
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5.4.2 MATERIALS AND METHODS 
i) Selection of Cell Donors
Tx-X spleen cell donors were either acute diabetic rats with recent-onset 
acute diabetes that had been stabilized with insulin, or normal rats 
showing normal blood glucose levels and IP glucose tolerance. Age­
matched non-Tx-X PVG rats (normal PVG) were used as a source of 
normal cells. 
ii) Depletion of Splenic Macrophages
Single-cell spleen suspensions were prepared as previously described 
(section 5.3.2(i)) and depleted of macrophages by plastic-adherence 
(Hunt, 1987). Washed cell suspensions were resuspended to 1 to 2 x 106 
cells/ml in complete RPMI containing 5 percent NRS (RPMI/NRS), and 5 
to 7 ml plated onto 60mm tissue-culture grade plastic dishes (Falcon®
3002; Becton Dickinson, NJ, USA) and incubated for 2 hours at 37°C in 5 
percent CO2. The non-adherent cells were then harvested and used 
directly in subsequent proliferation assays. 
iii) /n Vitro Proliferation Assay Conditions
Triplicate wells of 96 well tissue culture plates were established for each 
assay condition using 2x1 os responder cells per well in a volume of 200µ1 
of complete RPMI/NRS. ConA was added to each well at a final 
concentration of 5 µg/ml and all cultures were incubated for 72 hours at 
37°C in 5 percent CO2. In some cases PHA and PWM were used at 
concentrations of 5µg/ml and 1 µg/ml respectively. 3H-thymidine labelling 
: I_ 
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and cell harvesting were performed as previously described (section 
5.3.2(iv)). Results are expressed as a stimulation index (SI) calculated as 
follows: 
SI= mean CPM ConA-stimulated responder cells(+/- adherent cells) 
mean CPM non-depleted responder cells alone 
5.4.3 RESULTS 
i) Influence of Macrophage Depletion In Vitro
Responses to Mitogens 
To examine the possible influences of macrophage depletion on the in
vitro activity of lymphocytes from Tx-X rats, initial experiments were 
performed to compare the mitogen-induced responses of adherent cell­
depleted cultures compared to whole spleen cell cultures from Tx-X or 
normal PVG animals (Table 5.6). 
In response to ConA, macrophage depleted Tx-X spleen cells showed 
markedly improved proliferation (mean SI of 219 compared with 31 in 
controls; P <0.02) and this was also observed to a lesser extent in 
response to PWM (mean SI of 52 compared with 19 in controls) when 
compared to non-depleted Tx-X spleen cell controls. In contrast, 
macrophage depletion had no significant effect on normal PVG spleen 
cells for all mitogens (Table 5.6). 
I I 
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Table 5.6. Influence of adherent-cell depletion on mitogen-induced 
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The mitogenic responses of spleen cells from individual animals in the 
presence or absence of adherent macrophages are shown in Figure 5.8. 
For Tx-X animals, removal of adherent cells resulted in a uniform 
improvement in the proliferative responses to ConA and PWM in all cases 
(Figures 5.8b and f respectively), whereas there was little or no 
improvement in proliferation to PHA after macrophage depletion (Figure 
5.8d). In contrast, for normal PVG animals, there were no significant 
differences in the responses of depleted and non-depleted spleen cell 
cultures to the mitogens tested, although there was a considerable degree 
of individual variation, particularly for PHA and PWM responses (Figures 
5.8a,c,e). 
Disease Association 
In an attempt to quantify the suppressive influence of adherent cell 
populations on the mitogenic responses of lymphocytes, and to examine 
any disease-related effects, in vitro adherent-cell depletion and 
reconstitution studies were undertaken. 
Initially, splenic adherent cells were removed from diabetic rat spleen cell 
cultures and their proliferation to ConA compared with those of spleen 
cells isolated from clinically normal Tx-X animals (Table 5.7). For diabetic 
rats, macrophage depletion increased spleen cell proliferation to ConA by 
approximately 100 percent, although this was not statistically significant. 
In non-diabetic Tx-X animals, macrophage depletion resulted in a 
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Figure 5.8. Influence of macrophage depletion on the proliferative 
responses of spleen cells. Suspensions of normal PVG (a,c,e) or clinically 
normal Tx-X (b,d,f) spleen cells were depleted of macrophages by plastic 
adherence, then activated with ConA, PHA (5µg/ml) or PWM (1 µg/ml) for 
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Table 5. 7. Response of spleen cells from acute 
diabetic or clinically normal Tx-X rats following 
macrophage depletion. 
Adherent-eel I Acute Clinically 
Status Diabetic Normal 
(n=5) (n=13) 
Non-depleted 48± 15 83±23 
Depleted 83±38 185 ± 44 * 
Values are mean SI ± SEM 
* P < 0.05 compared with SI value of non-depleted cultures.
l I 
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From this data it appeared that the adherent cell populations of diabetic 
spleen cell cultures were suppressive. To assess whether the in vitro
suppressive capacity of splenic macrophages could be related to the 
disease status of the animal, normal PVG rat adherent-cell depleted 
spleen cell cultures were reconstituted in vitro with splenic adherent cells 
from either acute diabetic or clinically normal Tx-X rats (Figure 5.9). 
Adherent cells from diabetic animals did appear to have suppressive 
activity as they were capable of suppressing the proliferation of normal 
spleen cells to ConA (Figure 5.9a). The affect did not appear to be 
disease-related however, as adherent cells from clinically normal Tx-X rats 
suppressed the responses to the same degree (Figure 5.9b). 
ii) Adoptive Cell Transfers
In view of the improved in vitro proliferative responses of macrophage­
depleted spleen cell cultures to ConA, studies were undertaken to 
determine if this increased activation could enhance the ability to 
adoptively transfer disease to naive recipients using spleen cells from 
diabetic animals. 
Spleen cells isolated from acute diabetic rats were depleted of adherent­
cells then activated in vitro with ConA prior to IV transfer to 3-week old 
normal PVG rats (Table 5.8). Although neither acute disease or abnormal 
glucose tolerance were observed in recipient animals of spleen cells from 
acute diabetic rats, all developed islet lesions involving mild atrophy. This 
was an improvement on the results obtained when non-adherent cell 
depleted spleen cells were used, where only 2/7 (29%) of recipients 










Depleted Reconstituted Depleted Reconstituted 
Figure 5.9. In vitro reconstitution of normal spleen cell cultures with Tx-X­
derived adherent cells. Adherent-cell depleted spleen cell cultures from 
normal rats were reconstituted with adherent cells from either acute 
diabetic (a) or clinically normal (b) Tx-X rats, then cultured with ConA 
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Table 5.8. Incidence of acute diabetes, glucose intolerance and islet 
lesions in recipients of ConA-activated, macrophage depleted spleen cells 
isolated from Tx-X and normal donors. 
Cell Donors 
Acute Diabetic 

















* 3 week-old normal PVG recipients received 1-4x1 O 7 spleen cells IV depleted of adherent
cells prior to in vitro ConA stimulation.
t Selected on the basis of normal blood glucose and glucose tolerance prior to transfer.
§ Lesions were classified as atrophy and insulitis.





adherent-cell depletion did improve the mitogenic activation of 
autoaggressive cells. Nevertheless, the continued inability to transfer 
signs of acute disease suggests that the adoptive transfer conditions had 
still not been optimized, possibly as a result of low numbers of cells again 
being available for transfer. 
In contrast, no recipients of ConA-activated, adherent-cell depleted spleen 
cells from normal Tx-X or normal PVG animals developed islet lesions, or 
though there was some suggestion of mild islet change in 2 recipients of 
normal PVG cells (Table 5.8). The latter, although recorded, was 
considered to be an artefact of histological preparation. 
5.4.4 DISCUSSION 
The above studies have provided evidence that the Tx-X procedure, in 
addition to enhancing the activity of autoaggressive cells, is also 
enhancing the activity of mechanisms capable of suppressing the normal 
activity of lymphocytes in vitro. The above depletion studies suggest that 
this suppressive activity appears to be a function of adherent macrophage 
populations. 
Removal of adherent macrophages from spleen cell cultures of Tx-X rats 
significantly improved the proliferative response to ConA and to a lesser 
extent PWM, a phenomenon not observed for spleen cells isolated from 
normal (non-Tx-X) rats (Table 5.6). The failure to improve mitogen 
responsiveness to PHA may possibly be due to this being a poor rat T-cell 
mitogen. This improved mitogen-induced proliferation was a consistent 




normal animals in most cases (Figure 5.8) and argues in favour of 
increased activity or numbers of suppressive adherent cells in Tx-X rats 
compared to normal animals. 
These findings extend those of several studies describing suppressor 
macrophages in rat spleen (Parkhouse and Dutton, 1966; Folch and 
Waksman, 1974; Oehler et al., 1977; Webb et al., 1980). Particularly 
relevant are studies of the BB rat and NOD mouse models of IDDM, 
where removal of adherent cells from spleen cell cultures markedly 
improved the mitogen responsiveness of these cells (Woda and Padden, 
1986; Yokono et al., 1989) and allowed increased synthesis of IL-2 
(Prud'homme et al., 1984). Although not examined in this study, 
preliminary evidence suggests that macrophage depletion also improves 
IL-2 secretion by Tx-X rat spleen cells in response to ConA. 
Having established that increased macrophage-suppressive activity was a 
consistent feature of Tx-X animals, it was of interest to determine whether 
this phenomenon could be related to the occurrence of diabetes in Tx-X 
animals. Thus, spleen cells from diabetic and non-diabetic Tx-X animals 
were compared for improved proliferative capacity to ConA after removal 
of their adherent cells. As shown in Table 5.7, removal of adherent cells 
from spleen cell cultures of diabetic rats improved the ConA-induced 
proliferative responses, however this improvement did not reach statistical 
significance and was not as pronounced as that seen for non-diabetic Tx­
X animals. 
The suppressive activity of splenic macrophages isolated from diabetic 
animals was further demonstrated by their ability to substantially inhibit the 




suppression was similar to that seen with clinically normal Tx-X animals 
(Figure 5.9). Overall, this data suggests that macrophages isolated from 
diabetic animals do have considerable suppressive activity, however the 
degree of suppressive activity did not correlate with the occurrence of 
acute disease, being similar in both affected and unaffected Tx-X animals. 
Finally, there was an indication that macrophage-depletion of spleen cells 
from Tx-X rats prior to ConA activation and adoptive transfer improved the 
ability to transfer islet lesions, presumably as a result of improved T-cell 
activation (Table 5.8). These results are consistent with those of Metroz­
Dayer et al., who demonstrated a similar phenomenon in the BB rat 
(Metroz-Dayer et al., 1990), and thus consistent with the hypothesis that 
macrophage depletion leads to improved T-cell activation by mitogens in 
the rat. 
A number of mechanisms have been proposed to explain the molecular 
basis of macrophage suppression, including a role for prostaglandins, 
hydrogen peroxide and soluble protein messengers (Metzger et al, 1980; 
Unanue and Allen, 1987; Hoffman et al., 1990). Macrophage suppressive 
activity, however, appears to require activated macrophages (Metzger et 
al., 1980; Hoffman et al., 1990) and in the Tx-X model, this is supported by 
immunohistochemical studies demonstrating increased numbers of 
activated macrophages (la+) in both the spleen and other lymphoid 
organs such as peripheral lymph nodes and gut-associated lymphoid 
tissue (Stone and Penhale, unpublished observations). Macrophages 
may be activated by a number of signals, including microbial antigens, 
immune complexes, complement components and cytokines such as I FNy 
(Allison, 1978; Albina et al., 1991 ). 
i I 
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Recently nitric oxide (NO), a product of L-arginine metabolism via the nitric 
oxide synthetase pathway, has emerged as the favoured mediator of 
lymphocyte suppression by activated rat macrophages. Several studies 
have shown that the inhibition of NO synthesis by NG-monomethyl-L­
arginine (NGMMA), an inhibitory analogue of L-arginine, augments the 
response of rat lymphocytes to ConA (Albina et al., 1991; Mills, 1991; 
Kawabe et al, 1992) and to alloantigens (Hoffman et al., 1990). Of 
particular interest is that IFNy, a product of activated Th1-type, CD4+ T-
cells stimulates the NO synthesis pathway of macrophages, while IL-4, a 
product of Th2-type T-cells, is a potent inhibitor of this pathway (Albina et 
al., 1991; AI-Ramadi et al., 1992; Appelberg et al., 1992). 
In addition to its suppressive effects of on lymphocyte proliferation, NO 
synthesis by islet B cells has also been shown to be mediator of IL-1 B­
induced inhibition of insulin secretion and B cell destruction (Corbett et al., 
1992). The effect was shown to B cell specific, as IL-1 B did not affect the 
metabolic activity of islet a cells. Furthermore, NGMAA has been shown 
to prevent the non-specific destruction of islet cells by activated 
macrophages (Kroncke et al., 1991) and the IL-1 B -induced inhibition of 
glucose-stimulated insulin secretion by islets (Southern et al., 1990). 
In conclusion, the above data is consistent with the hypothesis that the Tx­
X procedure is enhancing the activity of a population of cells that, at least 
in the spleen, are capable of suppressing normal lymphocyte function, 
possibly via the actions of NO. This presents somewhat of a paradox, 
however, as data from this and previous sections have demonstrated a 
strong role for cell mediated immune mechanisms in the pathogenesis of 
Tx-X induced disease. Thus, the possibility arises that the suppressive 
activity of macrophages in Tx-X rats is acting on T-cells in a selective 
i I_·-
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manner, antagonizing the actions of 1Th2 11 type suppressive cells, while 
promoting the activity of 11Th 1 11 type effector cells. At present there is no 
evidence that NO has such selective inhibitory activity, however the 
questions of whether this suppressive activity is mediated by NO, and the 
possible role of increased NO production in vivo in the pathogenesis of 
disease, are currently being investigated . 
. I 
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ORAL TOLERANCE STUDIES 
! I -
_- __ - _J _  ,-·-
-- - ----- ---:_-_-- _-_---- -_-___ _:-r-- -;_-_.,;-_::-_�-_---:...,:-__:-,.:-_-.,.::_-_ ____;;_-.,:_,..:.:.:. ·· 
-------L -----=-- -�� ---
194 
CONTENTS 
6.1 INTRODUCTION ................................................................. 195 
6.2 MATERIALS AND METHODS ............................................. 199 
6.2.1 Induction of Oral Tolerance .................................... 199 
6.2.2 Assessment of Immunological Tolerance .............. 199 
i) Delayed-type Hypersensitivity (DTH) ................. 199 
ii) In Vitro Lymphocyte Proliferation Assays ....... 201 
iii) Humeral Immunity to OVA ............................... 201 
6.3 RES UL TS ............................................................................ 202 
6.3.1 Cell-mediated Immunity .......................................... 202 
i) DTH Responses ................................................ 202 
ii) In Vitro Proliferative Responses ...................... 204 
6.3.2 Humoral lmmunity .................................................. 204 
6.4 DISCUSSION ...................................................................... 207 
j !_ -




As shown previously, a striking feature of autoimmune diabetes and 
thyroiditis induced by the Tx-X procedure was the high degree of 
variability in the incidence levels of these diseases seen between 
successive groups of animals (see chapter 3.0, Figure 3.7). Why should 
there have been such variability given that the PVG strain is highly inbred 
and all animals should therefore have been genetically identical? 
Although random rearrangement of T cell receptor elements could have 
accounted for a small degree of individual variability, it is unlikely that this 
could have accounted for such striking differences in the incidence of 
disease between successive groups. Thus, identification of this non­
genetically determined factor(s) capable of influencing the course of 
disease to such a profound degree could provide a major step towards 
unravelling the complex aetiology of this and other autoimmune 
syndromes. 
For some time the role of environmental factors in the pathogenesis of 
autoimmune disease has been debated (see chapter 2.4.3). Although 
environmental factors may take a number of forms and may influence the 
animal via many pathways, it is probable that the greatest opportunity for 
diversity is that exerted by the variability of antigenic challenge via the 
gastrointestinal (GI) tract. The mucosa! surfaces of the GI tract are 
constantly encountering substances capable of modifying or stimulating 
the immune system, and as a result mucosal immunity must involve a 
closely regulated system that allows selective reactivity to pathogenic 
material while remaining tolerant to the vast array of non-harmful or 
essential molecules. 
- I ! I -
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The lymphoid tissues of the GI tract include organized structures (Payer's 
patches) consisting of large lymphoid follicles and associated epithelium 
that constitute the major antigen processing system, in association with 
many isolated lymphoid follicles dispersed throughout the submucosae 
(Keren, 1992). The lymphoid follicles of the gut contain a large number of 
B lymphocytes that are precursors for plasma cells generating lgA, and 
this is the primary immunoglobulin isotype found within the intestinal 
lumen (Biewenga et al., 1993). Nevertheless, both lgG and lgM­
containing plasma cells are present in the gut, and there is some evidence 
to suggest that the production of either lgA or lgG and lgM may provide a 
means by which the mucosal immune system is activated towards a 
positive (immunizing) or suppressive (tolerizing) response to an antigen 
(Strober et al., 1981 ). In addition, CD4+ and cos+ T lymphocytes are 
also present throughout the GI tract, located primarily interepithelially or 
within the lamina propria (Keren, 1992), and these undoubtedly play a key 
regulatory role, although precisely how remains uncertain at this stage. 
The ability to manipulate the immune system via the gastrointestinal route 
has been well documented. Early studies by Vaz et al. showed that mice 
given a single dose of ovalbumin (OVA) were immunologically tolerant to 
OVA, producing low levels of lgG and lgE anti-OVA antibodies after 
subsequent immunization with the antigen (Vaz et al., 1978). Other 
studies have shown that animals may also be immunized to OVA by the 
oral route, depending on the dosage regime and the age of the animal 
(Faria et al., 1993). In addition, T and B cells have been shown to be 
important in regulating tolerance to orally encountered OVA (Peng et al., 
1989). 
. I ! . 
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For animal models of autoimmune disease where the autoantigen has 
been defined, oral administration of antigen has been shown to be 
protective. Probably the most extensively studied model in this respect is 
experimental allergic encephalomyelitis (EAE) induced in Lewis-strain rats 
by immunization with myelin basic protein (MBP). Higgins and Weiner 
demonstrated that the oral administration of MBP suppressed the 
development of EAE (both clinically and histologically) and also the in vitro
proliferative responses of T cells to MBP and production of anti-MBP 
antibodies (Higgins and Weiner, 1988). 
Studies on EAE are of particular interest as recently trials have begun to 
assess the efficacy of oral administration of MBP for the treatment of 
multiple sclerosis (Weiner et al., 1993). These studies of course assume 
that the mechanism of oral tolerance is operating effectively in MS 
patients. Clearly, if this is not the case, then the administration of MBP 
could lead to enhanced immune stimulation and perhaps more serious 
disease. 
Oral administration of autoantigen has also been used to suppress the 
onset of disease in other models of autoimmunity, including S-antigen in 
experimental autoimmune uveitis (Thurau et al., 1991) and type-II collagen 
in collagen-induced arthritis (Thompson and Staines, 1985; Nagler­
Anderson et al., 1986). For IDDM, there has been one report of the 
suppression of diabetes onset in NOD mice by oral administration of 
insulin over a one year period from 5 weeks of age (Zhang et al., 1991) 
and in streptozotocin (STZ)-induced diabetes by the oral administration of 
islet tissue before and during STZ treatment (Kolb et al., 1991 ). 
. I 
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Despite the large number of studies of oral tolerance, its mechanism is still 
unclear. For soluble proteins such as OVA and MBP, suppressor T cells 
have been implicated, as shown by the ability to adoptively transfer 
suppression by lymphocytes or to abrogate tolerance by 
immunosuppressive agents such as cyclophosphamide (Richman et al., 
1978; Lider et al., 1989). For MBP, others have proposed that antigen 
feeding induces clonal anergy rather than suppressor cells {Whitacre et 
al., 1991 ), while in other systems, suppressor 8 cells have been 
implicated (Asherson et al., 1977) and in some cases serum factors have 
been reported to transfer tolerance, implicating a role for antibody or 
immune-complexes in tolerance induction (Andre et al., 1975). 
For Tx-X-induced autoimmune disease, evidence of a role for 
gastrointestinally-derived antigens in the pathogenesis of disease has 
already been provided in this study by the inability to induce IDDM in 
conventionally-reared animals, presumably differing from SPF animals in 
their gastrointestinal bacterial load (see section 3.3.2(ii)), and in a previous 
study by the ability to augment the susceptibility of SPF animals to 
thyroiditis by feeding gastrointestinal contents derived from conventional 
animals (Penhale and Young, 1988). Thus, it appears that intestinally­
derived factors have the potential to profoundly modify the susceptibility of 
Tx-X rats to autoimmune disease, acting either to enhance or decrease 
susceptibility, possibly as a result of abnormalities in immune tolerance 
towards gastrointestinally-derived antigens in these animals. 
The following chapter describes a set of preliminary studies undertaken to 
assess the immune status of Tx-X animals to antigens processed via the 
gastrointestinal route. Thus, the influence of feeding a soluble protein 
antigen (OVA) on the subsequent immune response to systemic antigenic 
! ! -
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challenge was assessed, both in terms of cell-mediated and humoral 
immune responses. 
6.2 MATERIALS AND METHODS 
6.2.1 Induction of Oral Tolerance 
A schematic representation of the protocol used for inducing oral tolerance 
to ovalbumin (OVA) in Tx-X rats is shown in Figure 6.1. Tx-X rats for OVA 
feeding were chosen on the basis of normal blood glucose levels and 
normal glucose tolerance 8 weeks after final irradiation. Age-matched, 
normal female PVG rats were used as controls. Fed animals were given 
four 100mg doses of OVA (Fluka Chemicals, Buchs, Switzerland) in 0.5ml 
of bicarbonate buffer (PBS containing 0.15M NaHCO3, pH 7.4) at 2 day 
intervals. Doses were given directly into the stomach under ether 
anaesthesia using a blunted 23 gauge needle and plastic tubing. Three 
days following the final feed, all animals were immunized with 200µg of 
OVA in Complete Freund 1s Adjuvant injected into the right hind foot pad. 
Blood samples were taken at 0, 9, 15, 22 and 29 days following feeding, 
and the animals killed 36 days following the first OVA feed. 
6.2.2 Assessment of Immunological Tolerance 
i) Delayed-type Hypersensitivity (DTH)
Prior to killing, all animals were tested for DTH responses to OVA by ear 
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Figure 6.1. Protocol for the induction and assessment of oral tolerance to OVA 
in Tx-X rats. Tx-X or normal PVG rats were fed four 100mg doses of OVA 60 
days after final irradiation, then immunized with 200µg of OVA three days later. 
Bleeds were taken at various times during the experiment and analyzed for 
anti-OVA antibody, and DTH and in vitro proliferative responses to OVA 
assessed three weeks after the first feed. 




into one ear of each rat and an equivalent volume of saline injected into 
the other ear as a control. After 24 hours the thickness of each ear was 
measured using a micrometer by an operator unaware of the treatment 
status of the individual animal. Results were expressed as the difference 
in thickness (mm) between the OVA and saline-treated ear (� ear 
thickness). 
ii) /n Vitro Lymphocyte Proliferation Assays
In vitro lymphocyte proliferation assays were performed essentially as 
described in section 5.3.2. Briefly, lymphoid cells were harvested from 
either the spleen or the popliteal lymph node draining the site of 
immunization, and single-cell suspensions prepared. Triplicate wells were 
seeded with 2x105 cells in the presence or absence of 1 0µg/ml OVA for 
48 hours, followed by an 18 hour incubation with 3H-thymidine at 
1.0µCi/well. Proliferative responses were expressed as a stimulation 
index (SI) calculated as previously described (see section 5.3.2). 
iii) Humeral Immunity to OVA
lgG, lgM and lgA isotype antibody production to OVA was analyzed by 
ELISA using 96-well microtitre plates sensitized overnight with 5µg/ml of 
OVA in ELISA coating buffer (see section 4.2.2) for the detection of lgM 
and lgG antibody isotypes, or a 1 0µg/ml solution for lgA (100µ1/well). 
After washing 3 times with PSST, the plates were blocked for 1 hour at 
room temperature with 100µ1 of PSST, followed by incubation with 100µ1 
of serum prepared at the time points indicated in Figure 6.1. Sera were 
diluted 1/2000 in PSST for detection of lgG, or 1/50 for lgM and lgA. After 
an incubation period of overnight at 4°C for lgA, or 2 hours at room 
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temperature for lgG and lgM, bound antibodies were detected using 
alkaline phosphatase-conjugated, goat anti-rat lgG (Nordic Immunology, 
Tilburg, The Netherlands) specific for each isotype (lgG, lgM or lgA) 
diluted 1/2000 in PSST. After 2 hours at room temperature, optical 
density (OD) was measured as described in section 4.2.2. 
6.3 RESULTS 
6.3.1 Cell-mediated Immunity 
To assess the influence of oral feeding of OVA on the subsequent cell­
mediated immune response to systemic OVA challenge, in vivo (DTH) 
and in vitro (lymphocyte proliferation) assays were performed 30 days 
after the final OVA feed using saline-fed Tx-X or normal animals as 
controls. 
i) DTH Responses
The DTH responses of Tx-X and normal animals to OVA are shown in 
Figure 6.2. Despite the severe lymphopaenic state of Tx-X rats, these 
animals were still capable of mounting a DTH response to OVA equivalent 
to that of normal animals. In the case of Tx-X rats however, prior feeding 
of OVA was capable of suppressing the DTH response when compared 
with saline-treated Tx-X controls (P<0.03). Feeding of OVA to normal 
animals also suppressed the DTH response to OVA when compared to 
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Figure 6.2. 0TH responses of OVA-fed and control, Tx-X and normal, PVG rats to 
OVA. OVA or saline-fed animals (n=5 for all groups) were established as 
described in Figure 6.1 and 0TH responses assessed 30 days after feeding by 
injecting 20µg of OVA intradermally into one ear and an equivalent volume of 
saline into the other. After 24 hours the difference in thickness (�) between the 
OVA and saline treated ears was determined by micrometer. 




ii} /n Vitro Proliferative Responses
Similar to DTH responses, the in vitro proliferative responses of Tx-X rat 
lymphocytes to OVA were also suppressed when compared to controls as 
a result of feeding the antigen prior to immunization (Figure 6.3). This 
tolerizing effect was seen for cells isolated from both the spleen and to a 
greater extent from the lymph node draining the site of immunization, 
however this did not reach statistical significance. 
6.3.2 Humeral Immunity 
To determine the ability to induce humeral tolerance to OVA in Tx-X rats, 
serum samples taken at various time points during the experiment were 
analysed for titres of lgG, lgM and lgA antibody isotypes to OVA (Figure 
6.4) For lgG, both OVA-fed Tx-X (P <0.005) and normal rats (P <0.001) 
showed significantly suppressed antibody responses to OVA by day 29 
compared with saline-fed controls. Interestingly, control Tx-X rats 
generated equivalent titres of lgG anti-OVA antibodies as saline-fed 
normal rats. This indicates that, at least for lgG production, Tx-X rats 
were capable of being orally tolerized to the same degree as normal 
animals. In addition, the ability of saline-fed Tx-X controls to mount a 
substantial lgG response to a T-dependent antigen such as OVA indicates 
that the observed suppression of lgG response to systemic OVA induced 
by prior OVA feeding was not simply due to the inability of Tx-X animals to 
mount a sufficient humoral response to the antigen. 
lgM responses were similar for all groups except at day 9, when OVA-fed 
normal rats showed significantly raised lgM titres compared with other 
groups (P <0.01 ). This probably represented a primary lgM response 
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Figure 6.3. Proliferative responses to OVA of spleen and lymph node cells from Tx­
X and normal PVG rats. Spleen and lymph node cells were isolated from OVA- or 
saline-fed Tx-X and normal rats 27 days after OVA immunization (n=5 or * n=3). 
After culturing for 48 hours in the presence of 1 0µg/ml OVA, cell proliferation was 
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Time from final OVA feed (days) 
---0- Normal PVG / Saline-fed 
--0--- Tx-X I Saline-fed 
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Figure 6.4. Anti-OVA antibody responses of OVA-fed Tx-X and normal PVG 
rats. Titres of anti-OVA lgG, · 1gM and lgA antibody isotypes were determined by 
ELISA using serum samples taken at various time points after OVA feeding and 
measuring optical density at 405nm (00405nm), Rats were immunized with 
200µg of OVA on day 9 post-feeding (arrowed). 
P < * 0.005, t 0.0001 and II 0.003 compared with saline-fed controls. 
§ P <0.01 compared with OVA-fed Tx-X value.
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towards OVA encountered orally, as the bleed at this time point was taken 
prior to the OVA immunization. That these animals had begun to respond 
to oral OVA was also evident by the raised levels of lgM in the 11time 011
bleeds, both in normal and Tx-X OVA-fed animals. By day 15, however, 
the lgM antibody titre of this group had dropped to levels similar to the 
other 3 groups. 
For serum anti-OVA lgA, although low titres were observed, all groups 
showed increasing levels prior to systemic OVA challenge at day 9 (Figure 
6.9). OVA-fed Tx-X animals did not then respond to systemic challenge 
and by day 29 showed significantly suppressed responses compared with 
all other groups (P <0.01 ). OVA-fed normal PVG rats, however, showed 
enhanced lgA response after systemic challenge, perhaps indicating a 
priming effect. In contrast, saline-fed animals (both normal and Tx-X) 
tended to show steadily increasing in lgA levels throughout the 
experiment. 
6.4 DISCUSSION 
The above studies were undertaken to investigate the ability of Tx-X rats 
to tolerate antigens encountered via the oral route. As previous studies 
have shown, the induction of autoimmunity in Tx-X rats is able to be 
modulated as a result of manipulation of the gastrointestinal tract. Thus it 
was of particular interest to determine whether modulation of the immune 
system by Tx-X could lead to an enhanced positive (immunizing) or 
suppressive (tolerizing) immune response to intestinal antigens. 
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For cell-mediated immunity to orally-encountered OVA, four 100mg doses 
of OVA prior to parenteral OVA challenge were capable of inducing a state 
of immunological unresponsiveness in Tx-X rats. This was demonstrated 
in vivo as assessed by a reduced DTH response in OVA-fed Tx-X 
animals compared with saline treated controls (Figure 6.2) and also in
vitro as assessed by lymphocyte proliferation to OVA (Figure 6.3). In the 
latter case, a greater degree of tolerance was seen with cells isolated from 
the lymph node draining the site of immunization when compared with 
cells from the spleen. This may have reflected the poor proliferative 
responses of spleen cells from Tx-X rats in vitro as a result of increased 
suppressive factors within these cultures (see section 5.4), or may have 
been due to an increased immunoregulatory function of cells from this site. 
For humoral responses, oral administration of OVA was able to suppress 
lgG responses to systemic OVA in both Tx-X and normal animals by day 
29 of the experiment (Figure 6.4). Of particular note in this case was the 
ability of saline-fed Tx-X rats to generate high titres of lgG antibody to 
OVA, indicating that although profoundly lymphopaenic, Tx-X rats were 
still capable of initiating strong humoral responses to T-dependent 
antigens. For lgM, no significant differences in antibody titre were 
observed except at day 9, where OVA-fed normal rats showed 
significantly raised lgM levels (Figure 6.4). As the serum samples at this 
point were taken before systemic OVA challenge, this probably 
represented a primary lgM response to orally-derived OVA, which was 
less evident in Tx-X animals. By day 29 however, no differences were 
observed in lgM titres between normal and Tx-X rats. 
Being the primary regulatory immunoglobulin of the GI tract, the isotype of 
potentially the greatest interest was lgA. For serum lgA, a heterogeneous 
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response was observed to OVA between groups (Figure 6.4). 
Nevertheless, there was a tendency towards OVA-fed normal animals 
showing an enhanced, or primed, response to systemic OVA after feeding, 
while OVA-fed Tx-X animals showed significantly suppressed lgA levels 
by day 29 (P <0.01 ). As seen for lgG, Tx-X animals were capable of 
generating an lgA response equivalent to that of normal animals, 
indicating that there was no deficiency in lgA production in Tx-X animals. 
From these results, however, it was evident that lgA was present in the 
serum at very low concentrations. Future studies of salivary or intestinal 
lgA levels, where antibody titres will be presumably increased, may further 
highlight the differences between treatment groups. 
An isotype-specific antibody response has also been seen in other 
systems after feeding of antigen. For example, Fuller et al. have shown 
that oral administration of MBP to Lewis rats prior to MBP immunization 
suppressed serum lgG and lgA responses, while salivary lgA levels were 
increased (Fuller et al., 1990). These workers suggested that antigen­
feeding influenced 8-cell development by inhibiting T-cell derived 
lymphokines involved in 8-cell maturation and immunoglobulin class 
switching, such as IL-4, 5 and 6. This hypothesis was supported by the 
recent studies of Hoyne et al., who demonstrated that OVA orally-tolerized 
mice show a modified lymphokine production, including undetectable 
levels of IL-4 (Hoyne et al., 1993). 
Of interest in the present study was the inability to induce cell-mediated 
tolerance to OVA in normal PVG rats, as indicated by normal DTH and 
proliferative responses of OVA-fed when compared with saline-fed rats. A 
number of factors have been shown to the influence the induction of 
tolerance in rodents, including the age of the animal and the dose and 
! I -
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timing of the antigen feed. For example, in adult mice, a single dose of 
OVA is capable of inducing systemic tolerance to the antigen, both 
humeral and cell-mediated (Ferguson et al., 1988). In rats however, oral 
tolerance to OVA was only found to be inducible in young animals 
receiving much larger doses of OVA (Wold et al., 1988). In contrast, new­
born mice have been shown to be less sensitive to the induction of oral 
tolerance (Strobel and Ferguson, 1984). Faria et al. also showed that 
strains of mice susceptible to the induction of oral tolerance at 8 weeks of 
age become refractory at 24 weeks of age (Faria et al., 1993). This same 
group also demonstrated that the outcome of feeding antigen, that is, 
tolerance or immunization, is affected by the dose and timing of feeding. 
There have also been reports of intestinal microflora influencing the ability 
to induce oral tolerance, as germ-free mice remained tolerant to OVA after 
feeding for a shorter period than conventional animals, suggesting that the 
intestinal flora may act as regulatory factor in intestinal immune responses 
(Moreau and Corthier, 1988). In this respect, it would be of interest to 
compare the ability to orally-tolerize conventionally-derived and SPF­
derived Tx-X rats, especially considering that the former are refractory to 
the induction of IDDM by Tx-X (see section 3.3.2). 
In the present study, the age of the rats used, the dose of OVA 
administered and the time of feeding may all have influenced the observed 
outcome in relation to oral tolerance to OVA in both Tx-X and normal rats. 
This has been supported by a previous study where Tx-X rats were fed 
from 1 to 4 doses of OVA (100mg per dose) soon after final irradiation 
(P Deplazes, P Stumbles and J Penhale, unpublished observations). This 
was in contrast to the present study, where rats were fed 8 weeks after 
final irradiation. In this earlier study, Tx-X animals fed high doses of OVA 
I .
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(4 feeds) exhibited both enhanced humoral and cell-mediated responses 
to OVA when compared to those receiving low doses, indicating an 
immunizing or priming effect and thus contrasting with the present study. 
In addition, 4 doses of OVA induced a tolerizing of cell-mediated immunity 
to OVA in age-matched normal control animals, but this was not observed 
for the humoral (lgG) response, and this also contrasts with the results of 
the present study. 
In conclusion, this study has shown that Tx-X rats are capable of being 
orally tolerized to systemic antigen challenge, both at the cell-mediated 
level and in an isotype-specific manner at the humeral level (lgG but not 
lgM), by this particular feeding protocol. Tx-X rats appeared to be more 
susceptible to orally-induced tolerance to OVA than normal animals of the 
same age, suggesting an abnormality in the regulation of intestinal 
immunity in these rats. This was supported by a previous study in younger 
Tx-X rats that demonstrated a priming, rather than a tolerizing, response 
to systemic challenge with OVA after prior antigen-feeding. In both the 
present and this previous study however, it was possible to demonstrate 
that the immune response of Tx-X rats to antigens encountered via the 
oral route differed from that of normal animals and it is conceivable that a 
defect in tolerance to intestinally-derived antigens may influence the 
pathogenesis of autoimmunity in Tx-X animals. Further studies are 
required to establish this phenomenon, however, and to determine the role 
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These studies have described the clinical, histopathological and 
immunological features of a recently-identified diabetic syndrome induced 
in an inbred rat strain using a combination of thymectomy and irradiation 
(Tx-X), and have shown that the syndrome can consistently be induced in 
animals not normally prone to the spontaneous development of this 
disease. 
The key clinical and histopathological features of the Tx-X syndrome, 
including the rapid onset of hyperglycaemia, the absolute dependency on 
insulin therapy and the presence of severe islet pathology in affected rats 
(Chapter 3.0), showed strong similarities to the IDDM syndrome of man. 
Furthermore, the Tx-X-induced syndrome was similar to the diabetic 
syndromes of both the BB rat and NOD mouse in many respects, further 
highlighting the value of this model for the study of diabetes initiation and 
pathogenesis (Table 7.1 ). Tx-X rats, however, differed from the human 
and NOD mouse conditions (but similar_to BB rats) in that these rats had a 
severe lymphopaenia induced by the manipulation procedure. 
The ability to induce disease by a non-specific manipulation of the immune 
system strongly suggests an immune-mediated origin for this syndrome. 
Furthermore, the ability to induce disease in an animal strain not normally 
prone to this disease implies that this procedure is in some way 
unmasking the autoreactive potential of a population of autoaggressive 
cells that are under regulation in the normal animal, a hypothesis 
previously postulated for thyroiditis induced by the same procedure 
(Penhale et al., 1973), but equally relevant to the pathogenesis of 
diabetes. Support for this effector/regulator imbalance hypothesis was 
provided in the present study by the ability to restore the immuno-
i !_ --
213 
Table 7.1. Comparison of the Tx-X, human, BB rat and NOD mouse diabetic 
syndromes. 
Tx-X Human BB Rat NOD Mouse 
Age of Onset 7-56 days after Any age * 50 - 120 days 70 - 210 days 
finalX 
Incidence 35-40% �0.2% 80-90% t 70-80% t
Sex Susceptibility Male>Female Male � Female Male > Female Female >> Male 
Hyperglycaemia +++ +++ +++ +++ 
lnsulinopaenia +++ +++ +++ ++ 
Ketoacidosis +++ +++ +++ +++ 
lnsulitis +++ + +++ +++ 
Islet Atrophy Detectable Detectable Detectable Detectable 
ICA Detectable Detectable Not Detectable Detectable 
ICSA ? Detectable Detectable Detectable 
IAA Detectable Detectable Detectable? Detectable 
64kDa Antibodies Detectable Detectable Detectable Detectable 
Lymphopaenia +++ ± +++ ± 
co4+ Tcells Decreased II Decreased Decreased Normal-Increased 
cos+ Tcells Decreased 11 Increased Decreased Normal-Increased 
CD4:CD8 ratio Abnormal? Abnormal? Abnormal Normal 
la Expression Increased Increased Increased Increased 
Anti-B cell CTL ? Present Present Present 
Thyroiditis Present Present Present Present 
* Most common before 20 years of age
t Varies according to subline or colony
II As determined by Fewell and Mason, 1993
! I_ -
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regulatory capacity of Tx-X animals by transfusion of lymphocytes isolated 
from unmanipulated, syngeneic donors (Table 5.1). 
Further support for this hypothesis has also recently been provided by the 
studies of Fawell and Mason, who have identified the regulatory cell of 
normal animals capable of preventing the expression of Tx-X-induced 
diabetes to be a CD4 + T cell of the phenotype CD45RCl0w TCRaB+ RT6+ 
Thy-1- OX4o- (Fowell and Mason, 1993). Cells of this phenotype have 
been shown to generate low levels of IFNy but significant levels of IL-2 
and mRNA for IL-4, IL-10 and TGFB1 (Fawell et al., 1991 and D. Fawell, 
personal communication), thus suggesting them to be of a Th2-like 
phenotype. In addition, studies in the BB rat have also shown that injection 
of a CD4+ RT6+ T cell can prevent the onset of disease in this animal 
(Mordes et al., 1987). 
Evidence for the activation of autoaggressive effector cells by the Tx-X 
procedure was provided in this study by the ability to transfer islet lesions 
to normal, unmanipulated syngeneic recipient rats using ConA-activated 
lymphoid cells isolated from diabetic donors (Table 5.2). Although this 
study was not designed to determine the characteristics of the 
autoreactive cells involved, several studies in other animal models have 
suggested that both CD4 + and cos+ T cells are required. In the NOD 
mouse, in vitro depletion of either CD4 + or cos+ T cells inhibits disease 
transfer (Bendelac et al., 1987; Christianson et al., 1993), while in vivo
depletion of either of these cell types inhibits disease (Wang et al., 1987; 
Charlton et al., 1988). In the BB rat, CD4 + T cells alone appear capable 
of transferring the disease (Metroz-Dayer et al., 1990), however in vivo
depletion of cos+ T cells inhibits the disease onset (Like et al., 1986). 
Similarly, for the Tx-X model, in vivo depletion of cos+ T cells completely 
\ .. · 
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inhibited the disease, while transfusion of cos+ T cells from normal 
donors restored disease susceptibility of cos+ T cell-depleted Tx-X rats 
(Fewell and Mason, 1993). 
That the B cell damage observed in Tx-X animals was cell-mediated was 
also supported by the detection of insulitis in a large proportion of Tx-X
animals, whether diabetic or otherwise (Table 3.2). Although this lesion 
had given way to islet atrophy in acutely diabetic animals, a significant 
proportion of •post-diabetic stage• Tx-X rats (that is, rats unlikely to ever to 
develop clinical disease) showed insulitis at necropsy. This indicates that 
a 1sub-clinical1 form of the disease also occurred in some Tx-X animals, 
although how these animals managed to control this immune attack on the 
B cells and maintain normal carbohydrate metabolism remains to be 
determined. 
Taken together, these data are supportive of the conclusion that islet B 
cells of Tx-X rats are destroyed by a cellular immune response, possibly 
mediated by a cytolytic cos+ T-cell (Fowell and Mason, 1993). 
Furthermore, the ability to suppress the onset of disease in Tx-X animals 
by reconstitution with normal lymphocytes, particularly those of the C04+, 
C045RCl0w phenotype (Fowell et al., 1991 ), suggests that the B -cell 
cytolytic coa+ T-cells are capable of being regulated by a sub-population 
of C04+ T-cells which are being selectively depleted by the Tx-X
procedure. 
Of particular interest was the identification of increased numbers of 
activated macrophages in Tx-X rats (see section 5.4). The central role of 
macrophages in regulating the immune response, particularly with regard 
to antigen processing and presentation, is well documented. The recent 
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identification of nitric oxide (NO) as a potent immunoregulatory molecule, 
combined with the observation that NO synthesis is upregulated in 
activated macrophages (see section 5.4), provides a mechanism whereby 
activated macrophages could play a central role in the regulation/initiation 
of Tx-X-induced autoimmunity. 
Considering all of the above observations regarding the regulation of 
cellular immunity and the interaction of T cell subsets, it is possible to 
propose a theoretical model for the interaction of activated macrophages 
and T cell subsets in the initiation and mediation of islet cell destruction in 
Tx-X rats (Figure 7.1 ). According to this model, the effector/regulator 
imbalance induced by Tx-X leads to, amongst other dysfunctions, 
increased macrophage activation. In addition, it is possible that the Tx-X
procedure also alters tolerance to gastrointestinal antigens (addressed 
later in this chapter) and these may provide extra stimuli for macrophage 
activation. The consequences of this increased macrophage activity could 
be two-fold. First, in the microenvironment of the islet, NO synthesis and 
IL-1 B production by resident activated macrophages leads to initiation of 
NO synthesis by B cells and thus their initial damage (Corbett et al, 1992). 
Antigens released by the damaged B cell are then processed and 
presented by both local and recruited antigen presenting cells, initiating 
and/or perpetuating a B -cell specific, cell mediated immune response. 
Secondly, on a more systemic level, the production of NO by activated 
macrophages in peripheral lymphoid tissue could favour the activation of a 
CD4+, Th1-type T cell by suppressing Th2-type CD4+ regulatory T cells, 
which in turn upregulates IFNy production by Th1 CD4+ T cells, leading to 
further activation of macrophage NO synthesis (Albina et al., 1991 ). IFNy 
itself would also act to suppress the activity of Th2 T cells (Fawell et al., 
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Figure 7.1. Hypothetical role for activated macrophages in the induction 
and regulation of autoimmunity in Tx-X animals. See text tor details. 





differential effect of this molecule on Th1 and Th2 cells is suggested by 
the fact that NO production is enhanced by IFNy (a Th1 cytokine), implying 
that cells producing this cytokine remain functional and are not 
suppressed by NO. In addition, IL-4 (a Th2 cytokine) is known to inhibit 
IFNy-induced NO synthesis (Appelberg et al., 1992; AI-Ramadi et al., 
1992), suggesting that cells producing this cytokine are likely to be 
suppressed in an environment of increased macrophage activation. 
Activated Th 1 T- cells may then either participate in B cell destruction 
directly and/or provide cognate help for the activation of B -cell specific 
coa+ cytotoxic T cells. 
While this model is one of several that could be suggested, and 
represents an over-simplification of what may be happening in vivo, it 
does incorporate a number of in vitro and in vivo findings to date, both in 
the Tx-X and other models of IDDM. Further support for this model would 
be provided by in vivo macrophage inhibition studies, perhaps by silica 
treatment which interestingly has been shown to inhibit diabetes in both 
the BB rat (Oschilewski et al., 1985; Amano and Yoon, 1990) and NOD 
mouse (Charlton et al., 1988). Note also that this model supposes that 
rather than a single B -cell antigen, a number of antigens may act as 
targeting molecules for the B -cell specific autoimmune response, a 
situation that seems to be supported by the available experimental data 
(see section 2.4.2). 
In addition to these cellular studies, further evidence for an autoimmune 
aetiology for diabetes induced by the Tx-X procedure was provided by 
humoral studies identifying autoantibodies to islet cell components by a 
number of techniques (Chapter 4.0). Generally however, these antibodies 
were present at low titres and were difficult to detect. Nevertheless, the 
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identification of ICA by immunofluorescence and antibodies to islet cell 
components and a 64kDa islet cell protein by immunoblotting and 
immunoprecipitation respectively add further support to the similarities 
between this model and the human syndrome. In addition, the concurrent 
development of autoantibodies to thyroid components, and the cellular 
infiltration of thyroid glands in Tx-X rats provides support for an 
autoimmune pathogenesis for diabetes and thyroiditis in these animals. 
The difficulty in detecting islet-specific autoantibodies, both in the Tx-X
and other experimental autoimmune diabetes syndromes, questions the 
significance of these autoantibodies in the disease pathogenesis, although 
this indirectly provides further support for the activity of a Th1-like cell 
mediated immune response in Tx-X animals, of which reduced help for 
antibody production is a characteristic feature (Fowell et al., 1991 ). 
Autoantibodies do, however, provide a tool for the identification of 
potential autoantigens, the value of which was highlighted by the difficulty 
in detecting T cell reactivity to islet cell and soluble proteins in Tx-X rats 
(section 5.3). Thus, the Tx-X model should prove useful for the 
identification of potential diabetic autoantigens and their subsequent in
vivo analysis. 
Although autoimmunity arising from an effector/regulator cell imbalance is 
a likely pathogenic mechanism for disease induction in Tx-X rats, it is clear 
from the data that other factors are involved in the aetiology of 
autoimmune disease in these animals. Thus, diabetes expression is a 
strain-related phenomenon, with PVG strain rats being particularly 
susceptible, but also with some indication that incidence may be 
influenced to an extent by the RT1 u haplotype of the MHC (Table 3.4).
This MHC haplotype is unquestionably linked to disease susceptibility in 
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the BB rat, and there is strong evidence to suggest that susceptibility to 
IDDM in both humans and NOD mice is also under strict genetic control 
(see Chapter 2.0). 
The influence of gender on the expression of diabetes in Tx-X rats was 
less clear, although there was a tendency towards an increased disease 
expression in males (see Table 3.3 and Figure 3.10). A gender difference 
appears to be more pronounced in RT1 u congenic rats, however, where 
Tx-X leads to a 100 percent incidence of diabetes in males and around 70 
percent in females (Fawell et al., 1991 ). A similar situation exists for both 
humans and the BB rat, where males are marginally more susceptible 
{Table 7.1 ). Interestingly, in the NOD mouse females are significantly 
more susceptible, and a similar observation has been made for the 
expression of thyroiditis in Tx-X rats, where steroid hormones have been 
shown to have a profound influence on susceptibility to this disease 
(Ansar Ahmed and Penhale, 1982; Ansar Ahmed et al., 1983). 
Of particular interest was the observation that the environmental status of 
the animal could influence the induction of disease by Tx-X. Thus, 
conventionally reared animals were significantly less susceptible to Tx-X­
induced diabetes than their SPF-derived counterparts , both in terms of 
acute diabetes and islet lesions (see Table 3.3). It therefore appeared 
that a protective environmental agent, presumably of gastrointestinal 
origin, was present in conventional animals capable of suppressing the 
induction of diabetes. As none of the common rat viral pathogens could be 
detected in either SPF or conventional animals, it is reasonable to assume 
that this effect is due to differences ( either qualitative or quantitative) in 
their intestinal bacterial flora. That intestinally-derived antigens are 
capable of modulating the expression of disease in Tx-X animals has 
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reconstitution of SPF animals with intestinal contents from conventional 
rats resulted in an enhanced disease expression (Penhale and Young, 
1988). Thus, it is clear that environmental agents, probably 
gastrointestinally derived, are capable of modulating autoimmune disease 
induction in Tx-X rats. 
One significant question raised by these observations is whether the 
process of thymectomy and irradiation alters the ability of such treated 
animals to remain immunologically tolerant to intestinal antigens. A loss 
or disruption of tolerance to orally presented antigens could provide a 
mechanism whereby intestinally-derived bacterial antigens could influence 
the expression of autoimmune disease in these animals. To test the 
hypothesis that Tx-X animals may have an abnormal tolerance to orally 
encountered antigen, Tx-X rats were fed a soluble protein antigen (OVA) 
and their immune response towards this antigen examined (Chapter 6.0). 
Although this set of experiments indicated that Tx-X rats were capable of 
being tolerized to OVA via the oral route, these animals did behave 
differently to the age-matched, non-Tx-X control rats. Nevertheless, it is 
also very likely that several factors could influence the outcome of this 
type of experiment, such as the age of the animal, the dose and frequency 
of antigen feeding, supported by previous studies in younger rats where a 
priming or a tolerizing affect could be observed in Tx-X animals depending 
on the dose of antigen fed (see Chapter 6.0). 
In light of the ability of intestinal factors to modulate disease expression in 
Tx-X animals, and the possible disruption of the ability of these animals to 
tolerate orally-derived antigens, it is possible to speculate on a mechanism 
whereby increased leakage of potentially autostimulatory factors from the 
gut, coupled with disregulated immunoregulation towards these factors, 
j I .. ·1 \ .. · : !_ 
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may be operating in Tx-X animals to provide a trigger for the initiation of 
an autoimmune response. A role for environmental agents in the 
aetiology of a wide range of autoimmune diseases has long been 
postulated, but to date still remains controversial. A mechanism often 
proposed for the ability of environmental, and in particular microbial 
(bacterial or viral), agents to trigger an autoimmune response is that of 
molecular mimicry, a process whereby an epitope of a microbial antigen 
mimics that of a tissue autoantigen, thus leading to the possibility of a 
cross-reactive immune response. 
Molecular mimicry has been suggested as a possible mechanism 
contributing to the aetiology of a number of autoimmune diseases, 
although direct evidence for this phenomenon has been difficult to 
establish {Oldstone, 1989). Nevertheless, there is evidence from other 
models of autoimmune disease, particularly those of arthritis, where 
environmental conditions can alter the course of the disease, while in 
humans, molecular mimicry of antigens of several bacterial strains 
probably leads to the induction of arthritis in susceptible individuals (va� 
Eden, 1991 ). For diabetes, insulin or a related molecule has been 
described in strains of E. coli (Le Roith et al., 1981 ), and a potential B cell 
autoantigen glutamic acid decarboxylase (GAD - see Chapter 2.0) has 
long been known to be an active bacterial enzyme (Strausbauch and 
Fischer, 1970). In support of this, GAD-producing strains of bacteria have 
recently been isolated from the gut of diabetic Tx-X rats (J Koppen, 
personal communication). Similarly, intestinal bacteria are known to have 
peroxidase activity, thus presenting the possibility for cross-reactivity with 
the putative autoantigen of thyroiditis (thyroid peroxidase). Thus, there is 
enormous potential for immunological cross reaction between gut-derived 
bacterial proteins and tissue antigens, although the extent to which 





molecular mimicry can influence the course of autoimmunity in Tx-X rats 
remains to be determined. 
In conclusion, this study has shown that-a diabetic syndrome closely 
resembling human IDDM of man can be induced in rats not normally 
prone to this disease by a combination of thymectomy and irradiation (Tx­
X). The evidence presented in this study strongly supports the conclusion 
that the specific destruction of B cells observed in this syndrome is of 
autoimmune origin, resulting from a regulator/effector cell imbalance in 
these animals that activates a population of latent autoaggressive cells 
that in the normal animal are under strict control. How these cells escape 
early deletion in the thymus remains an intriguing question. The fact that 
other strains examined in this study were not nearly so susceptible to 
diabetes induction suggests that PVG rats may have a primary defect in 
this deletion process. 
In addition, evidence has been provided demonstrating that genetic and 
environmental factors are both capable of influencing the aetiology of Tx­
X-induced autoimmunity, a situation mirroring that of the human disease. 
The suitability of this model for the study of IDDM pathogenesis was 
further highlighted by the ability to manipulate the Tx-X syndrome towards 
inducement or inhibition, while the lack of the genetic constraints observed 
in other animal models of IDDM should provide additional opportunities for 
the study of the role of cell mediated immune mechanisms in this disease. 
Finally, the close similarities between this syndrome and the clinical 
disease of humans provides further evidence for an immune-mediated 
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